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Apesar da evolução do conhecimento sobre aos tumores mamários da cadela 
nas últimas décadas, a definição do prognóstico e de protocolos de tratamento 
representam ainda desafios atuais, tanto para patologistas como para clínicos. 
Neste sentido, a avaliação de fatores prognósticos em tumores mamários 
malignos da cadela (TMMC) assume grande importância clínica. Nesta Tese 
estudou-se a relação entre a sobrevivência dos animais e o grau histológico, 
incluindo uma avaliação detalhada dos parâmetros constituintes do grau 
(formação tubular, pleomorfismo nuclear e contagem de figuras de mitose). 
Neste âmbito, foram também testadas novas abordagens quantitativas para 
avaliação de potenciais características morfológicas de prognóstico nos TMMC. 
Paralelamente estimou-se, pela primeira vez, a reprodutibilidade do método de 
determinação do grau histológico em TMMC.  
Para a realização destes estudos foram selecionados casos de TMMC 
espontâneos, a partir de uma série de cadelas seguidas durante um período de 
dois anos após a cirurgia. 
Nestes animais, o grau histológico de Nottingham (originalmente concebido 
para carcinomas mamários da mulher) tinha valor prognóstico em análise 
estatística univariada. Globalmente, a determinação do grau apresentava 
moderada reprodutibilidade entre observadores, sendo o pleomorfismo nuclear 
o parâmetro menos reprodutível. Ainda assim, este foi o único parâmetro com 
relação estatisticamente significativa e independente com a sobrevivência. Já 
os restantes parâmetros do grau, formação tubular e contagem de figuras de 
mitose, não tinham individualmente valor prognóstico. 
Relativamente a novas abordagens quantitativas aplicáveis aos TMMC, testou-
se a avaliação do pleomorfismo nuclear através da quantificação do “volume 
nuclear médio pesado pelo volume”. Este parâmetro estereológico foi 
significativamente menor em tumores benignos e, permitiu distinguir duas 
classes em termos de pleomorfismo do volume nuclear nos tumores malignos. 
Relativamente à formação tubular, e admitindo que este parâmetro do grau 
poderia estar relacionado com a celularidade tumoral, foi aplicado um método 
estereológico (disector ótico) para determinar a densidade numérica nuclear 
das células tumorais. Este método foi aplicado pela primeira vez no estudo dos 
TMMC e demonstrou que a densidade numérica nuclear era menor nos 
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tumores mais agressivos, correlacionando-se negativamente com o volume 
nuclear médio pesado pelo volume. Estes resultados sugerem que parâmetros 
quantitativos relacionados com o pleomorfismo nuclear e com a celularidade 
poderão ter valor prognóstico nos TMMC e tal deverá ser explorado em 
estudos futuros.  
Quanto às contagens de figuras de mitose, foi testado um método de contagem 
em campos selecionados através de amostragem aleatória e sistemática do 
tecido tumoral, associada à correção das contagens para a quantidade de 
epitélio maligno presente em cada campo. No entanto, a contagem de mitoses 
segundo este método não apresentava vantagens para a definição do 
prognóstico dos TMMC. 
Ainda no seguimento da otimização da determinação do prognóstico na cadela, 
testou-se a utilização de uma fórmula de índice multifatorial de prognóstico, a 
qual integrava o grau histológico, o tamanho tumoral e a evidência de invasão 
vascular e/ou de metástases nos gânglios linfáticos regionais. Esta fórmula foi 
adaptada do índice de prognóstico de Nottingham, utilizado na Medicina 
Humana, e demonstrou uma boa capacidade discriminativa dos tumores mais 
agressivos, parecendo constituir uma ferramenta útil para a definição do 
prognóstico nos TMMC. Estudos prospetivos são necessários para validar o 
uso deste índice de prognóstico nos TMMC.  
Com o objetivo de estabelecer novos parâmetros morfológicos com potencial 
valor prognóstico para os TMMC, foram avaliadas diversas variáveis 
morfológicas em preparações histológicas de rotina. A presença de invasão 
vascular, percentagem de necrose, de diferenciação escamosa e de formas 
nucleares anormais, assim como a presença de nucléolos grandes e atípicos, 
emergiram como fatores de prognóstico. De acordo com os nossos dados 
preliminares, o contributo de cada fator poderá ser calculado e integrado numa 
fórmula de um índice de graduação prognóstica específico para os TMMC.  
Reconhecendo que as características morfológicas dos tumores podem ter 
subjacentes um espetro de alterações genéticas, procedeu-se à caracterização 
genómica de uma série de TMMC através do método da hibridização 
comparativa genómica em arrays. Os perfis genómicos dos TMMC 
apresentavam uma grande variedade de alterações cromossómicas, incluindo 
ganhos, deleções e perdas em diferentes cromossomas, em especial nos 
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cromossomas 9, 22, 27, 34 e X. Na série analisada foram incluídos tumores 
múltiplos síncronos da mesma cadela, no sentido de determinar a sua relação 
clonal. Ainda que face à reduzida amostragem os resultados possam ser 
considerados preliminares, estes já apontam para que as lesões síncronas 
possam constituir entidades neoplásicas independentes do ponto de vista 
genético.  
Em termos gerais, demonstrou-se nos estudos desta Tese que parâmetros 
morfológicos quantitativos podem ser incluídos na avaliação do prognóstico dos 
TMMC e que uma maior utilidade clínica do grau histológico poderá passar por 
refinamentos no método e nos componentes a avaliar. Complementarmente à 
abordagem morfológica verificou-se que a heterogeneidade clinico-histológica 
reconhecida dos TMMC poderá refletir uma grande variabilidade em termos de 
bases genéticas dos tumores. Deste modo, a relação das alterações 
genómicas com o espetro clínico da doença deverá ser alvo de novos estudos 









The body of evidence regarding the biology of canine mammary tumors has 
increased over the decades, however the clinical management of female dogs 
affected by the disease is still challenging for both clinicians and pathologists. It 
is well recognized that searching of new prognostic factors is of uttermost 
clinical importance. Herein, a comprehensive evaluation of the prognostic value 
of the histological grade and its parameters (tubule formation, nuclear 
pleomorphism and mitotic count) in malignant canine mammary tumors (CMT) 
was performed. Moreover, quantitative methods were introduced to evaluate the 
potential prognostic utility of morphological parameters. Additionally, the 
repoduciblity of the histological grading method was evaluated, for the first time, 
in CMT. For these purposes, spontaneous malignant CMT, surgically removed 
and belonged to a series of female dogs followed over two years, were 
selected.  
When applied to malignant CMT, the human Nottingham grading method 
presented prognostic value in univariable analysis and a moderate 
reproducibility, being nuclear pleomorphism the least reproducible parameter. 
Nuclear pleomorphism classification showed a significant and independent 
association with survival, while tubule formation and mitotic count scores did not 
provide prognostic information. 
As to the quantification strategies, a stereological estimator of the nuclear size 
pleomorphism named volume-weighted mean nuclear volume was significantly 
lower in benign tumors, and it allowed the identification of two classes of 
nuclear size pleomorphism in malignant cases. Considering that tubule 
formation could be related with the level of tumor cellularity, a stereological 
method (optical disector) was applied to estimate the nuclear numerical density, 
a cellularity-related parameter. This method was used for the first time in the 
study of malignant CMT and rendered interesting results: the nuclear numerical 
density was lower in cases that progressed and this parameter was negatively 
correlated with the volume-weighted mean nuclear volume. Accordingly, 
quantitative estimations of nuclear pleomorphism and cellularity-related 




As regarding to mitotic count, a new counting method was investigated. Mitotic 
figures were counted in systematic random sampling fields, considering the 
whole tumoral section and correcting for the area of the malignant epithelium 
present in each field. However, this approach did not improve the prognostic 
value of the mitotic counts.  
Seeking for improvements in prognostic definition of malignant CMT, a 
multifactorial index formula, which included the histological grade, the tumor 
size, and presence of vascular invasion and/or regional lymph node 
metastases, was tested. The formula was adapted from the human Nottingham 
Prognostic Index (NPI) and demonstrated a good predicting capacity of a 
clinical aggressive tumoral behavior. The adaptation of the NPI to CMT seemed 
to be a valuable tool for prognosis definition, pending this evidence for 
validation in prospective studies.  
Aiming to find new potential grading parameters in malignant CMT, different 
morphological characteristics were evaluated in routine slides. The presence of 
vascular invasion, percentage of necrosis, squamous differentiation, atypical 
nucleoli and abnormal nuclear forms appeared as suitable prognosticators in 
malignant CMT. All these features could be easily assessed during 
histopathological examination and, according to our preliminary evidences the 
value of each parameter could be computed and integrated in a canine-specific 
prognostic index formula. 
Considering that the tumoral morphological features could be underpinned by 
the genetic changes, we also evaluated the genomic aberrations in malignant 
CMT using array comparative genomic hybridization. The genomic profiles of 
malignant CMT revealed a wide range of genomic aberrations affecting different 
chromosomes, with gains, losses and deletions. Chromosomes 9, 22, 27, 34 
and X were more frequently affected. By analyzing a small set of synchronous 
multiple tumors of the same female dog, preliminary evidence pointed to a 
clonal genetic independence of the lesions. 
Overall, the studies of this Thesis showed that quantitative methodologies could 
be valuable for prognosis definition in malignant CMT and that the clinical utility 
of the histological grade could be improved if adjustments regarding the method 
and the parameters were considered. Moreover, the works suggested that the 
clinicopathological variability of malignant CMT seemed to be closely related to 
 XIII 
 
genetic heterogeneity, and supported that influences of genomic aberrations in 
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1.1 The canine mammary gland and its tumors 
The canine mammary gland is a unique organ, undergoing extensive 
remodeling and differentiation during the entire reproductive life of female dogs 
(Santos et al., 2010a). In each estrous cycle, waves of epithelial and 
mesenchymal proliferation, ductal branching and alveoligenesis are followed by 
intense regressive changes. All these are strictly coordinated with hormonal 
levels of estrogen and progesterone (Rehm et al., 2007; Santos et al., 2010a). 
Unfortunately, these profound physiological and morphological activities of 
canine mammary gland are linked to a high risk of neoplastic transformation. In 
fact, mammary neoplasia is the most common form of cancer in intact female 
dogs (Sorenmo, 2003). According to the large European cancer registries 
databases, the incidence ratio of mammary gland tumors varies from 111 per 
10,000 to 200 per 100,000 dog-years of risk, with the median age of first 
diagnosis being around seven years old (Dobson et al., 2002; Egenvall et al., 
2005). In general, the development of mammary tumors in dogs less than five 
years old is rare and, in most cases, only benign tumors are diagnosed at that 
age (Kurzman and Gillbertson, 1986). There are differences between breeds 
regarding the risk for developing mammary tumors, suggesting a genetic 
influence in the canine mammary tumorigenesis (Sorenmo, 2003; Egenvall et 
al., 2005; Sorenmo et al., 2011). However, nowadays there is little evidence that 
canine mammary tumors (CMT) have a specific inheritance or are associated 
with germ line mutations (Nieto et al., 2003; Rivera and von Euler, 2011); this 
contrasts with human breast cancer cases (van der Groep et al., 2011). Rivera 
et al (2009) reported that BRCA1 and BRCA2 germ line mutations were 
associated with an increased risk for developing CMT in particular breeds of 
dogs, but larger studies about their importance and role in the risk of disease 
are still missing (Rivera and von Euler, 2011). In this vein, the majority of CMT 
appear to correspond to sporadic cases (Nieto et al., 2003). 
The pioneer work of Schneider et al. (1969) demonstrated a chief role of sex 
hormones in the neoplastic process and, nowadays, this is consensual (Gobello 
and Corrada, 2001; Lana et al., 2007; Smith, 2014). Therefore, it is not 
surprising that an increasing emphasis has been given to the expression of 
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estrogen and progesterone receptors in benign and malignant CMT (e.g., de las 
Mulas et al., 2005; Mainenti et al., 2014; Peña et al., 2014). In the dog, the 
mammary expression of growth hormone (regulated by the progesterone) and 
growth hormone receptor (which are important for the normal cyclic epithelial 
changes), is altered in tumors and apparently, this endocrine pathway could 
also contribute to the tumorigenesis (van Garderen and Schalken, 2002). 
The heterogeneity, at clinical and at morphological level is, eventually, the most 
idiosyncratic characteristic of CMT (Sorenmo et al., 2011). There is no typical 
clinical presentation for CMT  animals of different ages can present as 
asymptomatic or symptomatic, with a single or multiple nodules, small or large, 
slow or rapidly growing tumors (Perez-Alenza et al., 2000; Hellmén, 2005). 
Moreover, the coexisting mammary nodules have frequently different 
histopathological classification (Sorenmo et al., 2009). The presence of multiple 
palpable nodules variably sized in the mammary glands with a synchronous or 
metachronous development is more common in female dogs than in other 
mammals (Sorenmo et al., 2009).  
In a microscopical perspective, CMT are also highly heterogeneous. This is 
somehow reflected by the increased number of classification systems published 
so far and by the existence of some level of disagreement between those 
classifications (Hampe and Misdorp, 1974; Monlux et al., 1977; Moulton et al., 
1990; Benjamin et al., 1999; Misdorp et al., 1999; Misdorp, 2002; Goldschmidt 
et al., 2011). In recent years, the official classification of the World Health 
Organization (WHO) has been widely adopted by the veterinary diagnostic 
pathology community and this is highly recommended for the sake of 
parallelism between studies (Sleeckx et al., 2011; Matos et al., 2012). CMT can 
be composed of luminal epithelial cells only (simple tumors), or associated with 
myoepithelial cells (complex tumors) and with mesenchymal cells, like cartilage 
or bone tissue (mixed tumors) (Misdorp et al., 1999; Misdorp, 2002). The 
frequent biphasic appearance of the tumors is a unique feature of CMT (Rasotto 
et al., 2014). In veterinary pathology myoepithelial cells (either resting or 
proliferating) could be part of an invasive carcinoma (Sánchez-Céspedes et al., 
2011; Peña et al., 2014). In contrast, in human pathology, the presence of a 
myoepithelial cell layer (assessed by immunohistochemistry) assists in the 
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differential diagnosis between benign and malignant tumors (e.g., intraductal 
papilloma versus papillary carcinoma and for distinguishing invasive from in situ 
carcinomas) (MacGrogan et al., 2012; O’Maley et al., 2012; Pinder et al., 2012). 
A special attention has been given to the histogenesis of mixed CMT with the 
great majority of studies using imunohistochemical methods and aiming to 
clarify the origin of the mesenchymal metaplastic components, such as cartilage 
or bone (Gärtner et al., 1999; Tateyama et al., 2001; Ramalho et al., 2006). 
Despite some debate on the origin of these tissue within the mixed CMT still 
prevails, the recent literature appears to reinforce the putative role of 
myoepithelial cells in the mesenchymal metaplastic differentiation (Goldshmidt 
et al., 2011; Rasotto et al., 2014).  
About 30% of excised tumors are malignant (Misdorp, 2002). These malignant 
CMT can spread to distant organs and cause the death of the animal. 
Metastases affect mainly the lungs, liver and spleen, in a decreased order of 
frequency (Clemente et al., 2010a). The inflammatory carcinoma is a highly 
aggressive tumor that presents a slightly different metastatic pattern, since it 
has a predilection for the genitourinary system (Clemente et al., 2010a).  
 
1.2 Canine mammary tumors – malignancy and prognosis 
The prevalence of metastases-associated death after two years of follow-up 
ranges from 20 to 44% (Hellmén et al., 1993; Peña et al., 1998; 
Karayannopoulou et al., 2005; Sassi et al., 2010; Peña et al., 2013). The 
prediction of the metastatic capacity of malignant tumors is the unresolved chief 
question in CMT and a limitative factor for implementing new therapeutic 
options. The remarkable clinicopathologic heterogeneity of malignant CMT 
probably accounts for the limited available therapeutic options (Goldshmidt et 
al., 2011; Klopfleisch et al., 2011, Sorenmo et al., 2011).  
Traditionally, surgery is considered the gold standard therapy for CMT 
(Sorenmo, 2003; Sorenmo et al., 2011). However, the extension and type of the 
surgical procedure has been debated for long among veterinarians (Lana et al., 
2007). In general, it is recommended to perform a radical mastectomy (all chain 
mastectomy), instead of multiple nodulectomies or local mastectomies, 
especially in animals bearing multiple tumors (Sleeckx et al., 2011). Proponents 
 4 
 
of radical mastectomy argue that this approach is faster and reduces the risk of 
new tumors, thus avoiding the need of a second surgery (Stratmann et al., 
2008). Recently, is has been stressed that the focus should be placed in the 
completeness of surgical margins, as this factor is associated with an improved 
survival of dogs with malignant tumors (Tran et al., 2014). 
The prognosis of malignant CMT still remains a challenge to both pathologists 
and clinicians. In recent years, relevant literature has been published 
addressing consensual recommendations in veterinary oncology, some of them 
specifically referring to CMT (Webster et al., 2011; Matos et al., 2012; Nguyen 
et al., 2013). According to those guidelines, prognostic studies should 
completely describe the selection of the sample and the methodology of the 
assessments. The pathological evaluation of possible prognostic markers 
should be done by at least two observers and, whenever possible, multivariable 
analysis should be performed as this statistical evaluation eliminates possible 
confounders (Webster et al., 2011). Unfortunately, these procedures were not 
always followed in CMT studies; the high variability in study designs is 
nowadays evident, jeopardizing a straightforward identification of robust 
prognostic factors in CMT (Matos et al., 2012). The search for prognostic 
factors in CMT is already beyond the traditional clinicopathologic parameters 
(Dagli, 2008). Undoubtedly, this represents a promise way to reach new 
therapeutic targets, but at the same time, it is important to keep in mind that 
histopathological evaluations are simple and cost-effective methods for 
assessing prognosis, as occurs in human breast cancer (Pinder et al., 1995; 
Rakha et al., 2010). Fortunately, the amount of evidence collected for some 
clinicopathologic factors is large and their prognostic role is already well 
established in CMT (Sorenmo et al., 2011; Sleeckx et al., 2011). Probably, the 
two most important prognostic factors are tumor size and lymph node 
metastases (Sleeckx et al., 2011). Both are associated with distant metastases 
for the WHO staging of the disease, also known as the tumor-node-metastasis 
(TNM) system (Rutteman et al., 2001).  
Tumor size is defined as the largest diameter determined either by clinicians or 
pathologists (Peña et al., 1998; de las Mulas et al., 2005; Sorenmo et al., 2011) 
and there is a general agreement that it has prognostic significance (Sorenmo 
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et al., 2011). Some studies suggested that a single cut-off of 3 cm, rather than 
the two cut-offs of the WHO staging (3 and 5 cm), is more suitable for 
prognostic purposes (Kurzman and Gilbertson, 1986; Philibert et al., 2003; 
Santos et al., 2013). However, Chang et al. (2005) using a multivariable 
analysis found that dogs with tumors larger than 5 cm had a significant worse 
prognosis. Despite some discrepancies regarding the threshold, several studies 
supported the importance of tumor size in prognosis definition and its inclusion 
in the stage of the disease (Ferreira et al., 2009; Sorenmo et al., 2011).  
The presence of regional lymph node metastases is also relevant for staging 
the disease. However, the number of positive nodes, which is of utmost 
importance in human breast cancer stage (Senkus et al., 2013), is usually 
disregarded in CMT (Rutteman et al., 2001). Lymph node assessment in female 
dogs is primarily performed by physical examination (Sorenmo et al., 2011), 
which constitutes another difference from breast cancer patients. These latter 
are usually submitted to diagnostic imaging of regional lymph nodes (usually by 
ultrasonography) and, in most centers of developed countries, a sentinel lymph 
node procedure during the surgery is also performed (Senkus et al., 2013). 
Even if this is the state of the art in women’s breast cancer, such procedures 
are not routinely performed by veterinarians (Webster et al., 2011). In female 
dogs bearing mammary nodules, the draining lymph nodes are carefully 
evaluated during the pre-surgery physical examination, and subjected to 
cytological evaluation when enlarged (Sorenmo et al., 2011). The histological 
examination of regional lymph nodes is performed when inguinal nodes are 
included as part of the mastectomy specimen or when the cytology is positive 
for metastases. This justifies that even prospective cohorts included cases 
without histological examination of the regional lymph nodes (Santos et al., 
2013; Peña et al., 2013). However, several authors confirmed that the 
histological evidence of metastases in regional lymph nodes (at the time of the 
diagnosis) is a significant prognostic factor (reviewed by Sorenmo et al., 2011). 
Another important issue related to regional lymph node assessment in 
malignant CMT is the use of immunohistochemistry as an auxiliary method to 
detect occult metastases. The TNM staging system for human breast 
carcinomas indicates that the presence of isolated metastatic cells or clusters 
with less than 0.2 mm (or 200 cells) in a lymph node, should not be included in 
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the count of affected lymph nodes (Senkus et al., 2013). In female dogs, Matos 
et al. (2006a) used immunohistochemistry with antibodies against cytokeratins 
and detected micrometastasis in 9% of regional lymph nodes. The clinical 
relevance of this finding has never been completely appraised. However, it 
should be, at least, considered as a sign of aggressiveness of the tumor (Matos 
et al., 2006a), and consequently, alert the clinician for the need of more rigorous 
follow-up of those animals. Another important issue related to regional lymph 
node, corresponds to differences in lymph drainage in healthy and in neoplastic 
mammary gland (Pereira et al., 2003; Patsikas et al., 2006). Conventionally, it is 
assumed that the first two pairs drain to axillary nodes, the two last pairs drain 
to inguinal lymph nodes, while the lymph of the third pair could simultaneously 
be collected by both lymph stations (Pereira et al., 2003). However, it has been 
reported that new anastomoses between lymphatic vessels of the different 
mammary pairs can develop and other lymph nodes (as sternal, medial iliac or 
popliteal) can be involved when the mammary gland is affected by a neoplastic 
disease (Pereira et al., 2003; Patsikas et al., 2006). In this vein, all the evidence 
substantiates that the entire lymph nodes stations should be carefully evaluated 
during the physical examination and additional procedures should be performed 
if abnormalities are detected (Matos et al., 2006a; Sorenmo et al., 2011).  
 
1.3 Histological grade in canine mammary tumors  
Traditionally, the grading of malignant CMT has followed the human 
counterparts, as also occurred with the histological classification (Hampe and 
Misdorp, 1974). The comparative canine versus human approach was a goal 
when the classification of domestic tumors was designed under the auspice of 
the WHO (Beveridge and Sonin, 1974). In that first official classification, Hampe 
and Misdorp (1974) opened the window for using the level of tubular 
differentiation in the canine mammary malignancy grading system, as occurred 
in human pathology. Two years later, Misdorp and Hart (1976) proposed a 
grading method based on the existing human grading systems, i.e., Patey and 
Scarff (1928) and Bloom and Richardson (1957) (as detailed in the section 1.4 
of this chapter). It was proposed that all types of CMT should be graded 
according to the level of differentiation (tubule formation) and the degree of 
cellular anaplasia (which included irregular cell size, shape and staining of cells, 
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nuclei and number of mitoses). In that system, only the sarcomas were not 
included (Misdorp and Hart, 1976). Even if a higher grade of malignancy was 
associated with a worse prognosis, none of the individual grading parameters 
showed a statistical association with outcome (Misdorp and Hart, 1979). 
Interestingly, the authors stated that higher grade, higher level of differentiation 
and anaplasia were more common in simple carcinomas than in complex 
carcinomas. Regarding the mitotic counts, there was no significant difference 
between complex and simple carcinomas (Misdorp and Hart, 1979).  
In 1983, Gilbertson et al. proposed a different staging and grading system for 
CMT, which was based on the stromal and vascular invasion, as well as in 
nuclear differentiation degree. The method also followed the human grading 
system developed by Black et al. (1955). It included the assessment of the 
degree of invasion (stromal and vascular / lymph node invasion), as well as the 
degree of nuclear differentiation (Table 1). Regarding this latter parameter, the 
numerical grade increased with the increasing degrees of differentiation 
(Gilbertson et al., 1983; Kurzman and Gilbertson, 1986). Significant differences 
were found between stages 0, I and II regarding disease-free interval (DFI); 
animals with stage II had a particularly high recurrence rate (Kurzman and 
Gilbertson, 1986). In contrast, dogs with nuclear grade 1 (atypical and poorly 
differentiated tumors) had more than fourfold increased risk of recurrence in the 
two years post-surgery and this effect was most apparent in the stage I of the 
disease (Kurzman and Gilbertson, 1986).  
The Gilbertson system was adopted by other research groups (e.g., 
Karayannopoulou et al., 2001), however, whilst in some studies only the degree 
of invasion was used (Papparella et al., 2002; Sarli et al., 2002), in others an 
emphasis was given to nuclear grade (Preziosi et al., 1995).  
Methods similar to that used by Misdorp and Hart (1976) and, clearly influenced 
by the human Bloom and Richardson method (1957) have been adopted by 
French, Italian, Spanish and Portuguese research groups (e.g., Lagadic and 
Estrada, 1990; Peleteiro, 1994; Restucci et al., 2000; de las Mulas et al., 2005: 
Sánchez-Céspedes et al., 2011). Peña et al. (1998) used a grading system 
based on human Bloom and Richardson method, in association with the 
vascular invasion included in the histological staging of Gilbertson et al. (1983). 
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In that study the presence of vascular invasion was used as an exclusive 
diagnostic feature of poorly differentiated tumors.  
In the reference book “Tumors in Domestic Animals” edited by Meuten, Misdorp 
(2002) completely adopted the numerical human method of Bloom and 
Richardson (1957), which included three grading parameters: tubule formation, 
nuclear pleomorphism and mitoses / hyperchromatic nuclei per high-power field. 
Each of these was scored from 1 to 3, and the combined sum of the scores 
(from 3 to 9) defined the grade: scores 3 to 5, 6 to 7 and 8 to 9 defined grade I, 
II and III, respectively (Table 2). 
 
Table 1 – Classification system of the histological stage and grade according to 
Gilberston et al. (1983) criteria. 
Score   Histological stage – degree of invasion  
0 
I 




Vascular / lymphatic invasion and/or metastases to lymph nodes 
Systemic / distant metastases 
Score   Nuclear grade – degree of nuclear differentiation 
1 “Atypical” / poorly differentiated 
2 “Intermediate” / moderately differentiated 
3 “Typical” / well differentiated 
 
Despite some controversy still exists, the grading system most used over the 
last decade has been the standard method of the human breast cancer, the so-
called Elston and Ellis method or Nottingham method (e.g., Karayannopoulou et 
al., 2001; Nieto et al., 2003; Karayannopoulou et al., 2005; Clemente et al., 
2010b; Carvalho et al., 2011; Santos et al., 2011; Kim et al., 2013). This human 
method was based on a large cohort of patients treated and followed at the 
Nottingham Hospital, United Kingdom (as detailed in the section 1.4 this 
chapter). The method presented high similarity with that of Bloom and 
Richardson, but the criteria defined for each parameter were more objective 
(Elston and Ellis, 1991). In brief, tubule formation became assessed semi-
quantitatively (categorized in 1-3 according to the percentage of epithelium 
arranged in luminal structures). Nuclear pleomorphism score was established in 
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comparison with the normal surrounding parenchyma, and finally, the mitotic 
count was categorized according to the number of mitoses and the field 
diameter of the microscope (Elston and Ellis, 1991) (Table 3).    
 
Table 2 – Histological grading system according to Misdorp (2002) criteria. 
 
 Score  
Parameter    1 2 3 













Mitotic figures / 
hyperchromatic nuclei 
(per high-power field) 
Occasional 2-3 > 2-3 
Sum of scores 3 - 5 6 - 7 8 - 9 
Grade I II III 
 
 
Table 3 – Nottingham histological grade method (Elston and Ellis, 1991). 
 
 Score  
Parameter    1 2 3 
Tubule formation  > 75% 10-75% <10% 
Nuclear pleomorphism* absent moderate marked 
Mitotic count** <9 9-17 >17 
Sum of scores 3 - 5 6 - 7 8 - 9 
Grade I II III 
* compared to normal surrounding parenchyma; ** counted in 10 high-power fields; cut-offs 
depending on microscopic field diameter of the microscope; in this case, it was 0.55 mm. 
 
It is noteworthy that the Nottingham method has been adopted by several 
research groups dedicated to the study of CMT and from different parts of the 
world (Table 4). However, it is nowadays recognized that the use of human 
grading methods requires adjustment efforts in the veterinary field (Goldschmidt 
et al., 2011; Matos et al., 2012; Mills et al., 2015). In literature, only one 
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retrospective study compared the Misdorp (adapted from the human Bloom and 
Richardson’s method) and Nottingham method adapted to CMT (Rasotto et al., 
2012). According to that study, the latter method was better for predicting the 
metastatic capacity of CMT, because a considerable proportion of tumors 
allocated to grade I (i.e., well differentiated) by the Misdorp method presented 
vascular / lymph node invasion. The more rigorous mitotic count and the 
exclusion of hyperchromatic nuclei in the Nottingham method were described as 
main advantages (Rasotto et al., 2012).   
Recently, Peña et al. (2013) proposed changes to the Nottingham method, 
including specific scores in particular subtypes of malignant CMT (e.g., in 
malignant myoepithelioma tubule formation should be scored 2) and the 
assessment of nuclear pleomorphism and mitotic counts in all the malignant cell 
types (and not exclusively in the luminal epithelium). These topics are still a 
matter of debate, and four main drawbacks can be pointed to this new method. 
In first place, considering that myoepithelial cells are unable to be organized in 
tubular structures without luminal epithelial cells, the above mentioned 
recommendation is arguable. Additionally, the actual contribution of each 
malignant component for the assessment of nuclear pleomorphism is not clear 
in this new proposed grading method. Moreover, the authors did not suggest a 
grading method to carcinosarcomas and, lastly, they did not perform a 
comparative analysis between their modified method and the original 
Nottingham’s method regarding their ability to predict survival in CMT. Such a 
comparative approach would be warranted for the sake of the validation of the 
proposed modifications. 
Nowadays, the prognostic significance of the histological grade in malignant 
CMT is still under study (Peña et al., 1998; Nieto et al., 2000; Peña et al., 2013; 
Santos et al., 2013; Mainenti et al., 2014). Karayannopoulou et al. (2005) used 
the original Nottingham grading method for different types of carcinomas and 
concluded that the tumor grade was directly related with prognosis, with the 
single exception of simple carcinomas, where no differences were 
demonstrated between grades II and III. Furthermore, undifferentiated tumors 
(grade III) presented a 21-fold increased risk of death as compared to the other 
two grades combined (Karayannopoulou et al., 2005). In that same year, de las 
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Mulas et al. (2005) confirmed the independent prognostic value of histological 
grade (performed using the human Bloom and Richardson’s method as basis), 
regarding the DFI. However, this was observed when grade I plus grade II 
tumors were compared with grade III (de las Mulas et al., 2005). Additionaly, 
another study demonstrated a non-independent worse prognostic of grade III 
tumors, for tumor-related death and survival time, when compared with jointed 
grades I and II (Santos et al., 2013). Such grouping of grades (I and II versus 
III) in the statistical analysis of prognosis raises the issue of the actual existence 
a three-tier grading system in CMT and adds doubts on the validity of the 
grading method in this species. Recently, two studies demonstrated that the 
Nottingham method with modifications proposed by Peña et al. (2013) provided 
independent prognostic information (Peña et al., 2013; Mainenti et al., 2014). 
Still, it has been stressed that in order to be universally accepted and adopted 
in CMT, any grading method should be validated in various prospective cohorts 
(Goldschmidt et al., 2011; Matos et al., 2012). Until the present day, there have 
been relatively few efforts in that direction.  
In human pathology, the criticism regarding histological grade resides mainly in 
the: 1) lack of reproducibility of grade and its parameters; 2) great proportion of 
tumors allocated to less discriminative grade II; and 3) problems associated with 
grading special types of carcinomas (Dalton et al., 1994; Volpi et al., 2004; 
Meyer et al., 2005; Rakha et al., 2008a). Regarding the first issue, the 
interobserver reproducibility is, to the best of our knowledge, completely 
unknown in CMT. In the majority of reports the number of grading observers 
was not provided (Table 4), while in others it was stated that two observers 
classified and graded the tumors but the statistic agreement values were not 
provided (Restucci et al., 2000; Karayannopoulou et al., 2005; Rasotto et al., 
2012). Notably, the overlooking of reproducibility of histological grade in CMT is 
contradictory, at some extent, with the most recent guidelines in veterinary 
oncology, which clearly state that the measurement of interobserver variability is 
critical to validate any prognostic marker, before it can be translated to a clinical 
setting (Webster et al., 2011). Moreover, the significance and distribution of the 
three parameters of the histological grade, as well as their individual influence 
on survival outcome has never been scrutinized in CMT. As far as we know, 
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only the classic studies by Misdorp and Hart (1976, 1979), performed an 
evaluation of the prognostic value of each grading parameter. 
Concerning the distribution of tumors by the three grades, the disproportionate 
high number of cases graded II, as occurred in some human cohorts, seems not 
to be a major problem in CMT (Table 4). Considering the more than twenty 
studies published over the last two decades and the different grading methods 
(Table 4), grade II comprised 33% of cases, whereas grade I and III 
corresponded to 36% and 31%, respectively. Still, the proportion of each grade 
in the studies would depend on several factors, including intrinsic biological 
characteristics of the tumors, sampling schemes used to select the case series 
or pre-analytical parameters, such as tissue fixation and preparation (Rakha et 
al., 2010). It should be noted that in some CMT cohorts the distribution of cases 
by the three grades was not provided (e.g., Clemente et al., 2010b; Mainenti et 
al., 2014), and the selection/inclusion criteria were not always completely 
described. 
In their original publication, Elston and Ellis (1991) stressed that the 
assessment of histological grade is not restricted to ductal carcinomas and 
special types should also be graded. Nevertheless, the usefulness of 
histological grade in some subtypes of tumors such as lobular and medullary 
carcinomas is still controversial (Sinha et al., 2000; Adams et al., 2009; Rakha 
et al., 2010). Regarding lobular carcinomas, it has been argued that two of the 
three grading parameters present little variation (tubule formation is typically 
scored 3 and mitotic count scored 1) and thus, grading is mainly derived from 
differences in the nuclear pleomorphism, which is the least reproducible grading 
feature (Adams et al., 2009). In some studies there were no differences 
regarding survival between grade I and II lobular carcinomas and very few 
tumors were graded III (Sinha et al., 2000). More recently, the research group of 
the Nottingham University Hospital confirmed, in a large cohort (with more than 
500 patients), that grade was an independent prognostic factor in lobular 
carcinoma and that a difference in survival was observed between all the three 
grades (Rakha et al., 2008a). Accordingly, the routine assessment of 
histological grade using the Nottingham criteria in lobular carcinomas is 
currently recommended (Rakha et al., 2008a; 2010). With medullary 
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carcinomas the scenario is quite different and this subtype of carcinoma might 
appear to be an exception regarding the importance of histological grade 
(Elston and Ellis, 1998; Rakha et al., 2010). This type of carcinoma is usually 
graded III, but their prognosis is more favorable than this grade would imply 
(Jacquemier et al., 2012). In this vein, some authors believe that this data 
warrants further confirmation (Rakha et al., 2010).  
In CMT the Nottingham method has been performed in different subtypes of 
malignant tumors, including complex and mixed carcinomas with myoepithelial 
and mesenchymal elements. Those elements, including the resting or 
proliferative myoepithelium, typically present slightly or no atypia (Peña et al., 
2014) and so, the grade is mainly based in the luminal epithelial cells 
characteristics (Mainenti et al., 2014). That approach is in accordance with 
previous evidence that the malignant luminal epithelium is the main responsible 
for the progression of disease to local recurrence or systemic metastases 
(Monlux et al., 1977; Gilbertson et al., 1983; Kurzman and Gilbertson, 1986; 







Table 4 – Grading methods in CMT studies published over the last two decades. 
Study Cases Obs Method  G I G II G III 
Preziosi et al. (1995) 48 np NG Gilbertson 8 24 16 
Peña et al. (1998) 39 np BR/Misdorp + VI 6 10 13 








Karayannopoulou et al. (2005) 85 2 Nottingham  27 28 30 
de las Mulas et al. (2005) 155 2 BR/Misdorp 77 49 29 
Matos et al. (2006b) 77 np Nottingham  16 34 27 
Restucci et al. (2007) 25 2 Misdorp np np np 
Gama et al. (2008) 102 np Nottingham  14 33 45 
de Oliveira et al. (2009) 32 2 Nottingham  6 15 11 
Madrazo et al. (2009) 63 np Misdorp 39 20 4 
Clemente et al. (2010b)1 41 np Nottingham  np np np 
Gama et al. (2010) 102 np Nottingham  17 34 51 
Santos et al. (2010b) 64 2 Nottingham  13 28 23 
Sánchez-Céspedes et al. (2011) 63 np BR/Misdorp 32 23 8 
Yoshimura et al. 2011 42 np Nottingham  11 12 19 








Manuali et al. (2012) 50 np Nottingham  33 14 3 
Kim et al. (2012) 37 np Nottingham 8 11 18 
Santos et al. (2011) 94 2 Nottingham  21 43 30 
Peña et al. (2013) 65 np Mod Nottingham 29 19 17 
Kim et al. (2013) 47 np Nottingham  11 14 22 
Andreasen et al. (2014)2 31 np Misdorp/Nottingham  25 4 2 
Guil-Luna et al. (2014) 46 np BR  22 17 7 
Guimarães et al. (2014)2 43 np Misdorp/Nottingham 17 13 13 
Im et al. (2014) 340 np Nottingham  222 74 44 
Mainenti et al. (2014) 79 2 Mod Nottingham  47 12 20 
Yoshimura et al. (2014)3 72 np Mod Nottingham 2 27 
 
43 
Legend: Obs – observers; G – grade; np – not 
provided; NG – nuclear grade; BR – Bloom 
and Richardson’s method; Mod - modified; VI 
– vascular invasion. 
 
1inflammatory carcinomas included. 
2inot clear if the authors used the Misdorp or 
Nottingham criteria. 
4only simple solid carcinomas. 
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1.4 Histological grade in human breast cancer – history of a constant 
renewed interest  
Greenough is credited for applying grading systems to breast cancer for the first 
time (Greenough, 1925). In his pioneering work, six morphological features 
were considered (Table 5). This study showed that the classification of tumors 
in three grades of malignancy was important regarding prognosis. Notably, this 
author also introduced the notion of reproducibility of grading (Greenough, 
1925). 
Three years later, Patey and Scarff (1928) stated that the study of the relation 
between histological grade and prognosis could not be done without accounting 
for the clinical stage of the disease. Curiously, these authors used only three of 
the six morphological features of Greenough (Table 5). They confirmed the 
relation between the histological grade and clinical course in different stages of 
the disease (Patey and Scarff, 1928). 
During the war years, Bloom and Richardson revitalized the grading method of 
Patey and Scarff (Bloom and Richardson, 1957). In their study of more than 
1,500 patients, three grading parameters were considered but, for the first time, 
these were scored from 1 to 3, being the final combined score used to assign 
the overall tumor grade (Table 5). The grade computed by this method was 
correlated with 5, 10 and 15 years of survival. Despite this evidence, the 
authors advised that the histological grade should be used in association with 
other factors, like the axillary node status, for the guidance of prognosis (Bloom 
and Richardson, 1957).   
In that same period, Black et al. (1955) developed a grading system based only 
in the nuclear features of cells. The regularity of nuclear limits, the chromatin 
pattern, the presence of nucleoli and mitotic figures were considered to allocate 
a tumor to grades 0 to 4 (Black et al., 1955). In this study there was a clear 
linear relation between nuclear grade and survival (Black et al., 1955). The 
same research group provided evidence in subsequent studies that nuclear 
grade system had prognostic value (e.g., Black et al., 1975). Even so, other 
groups failed to observe a relation between the nuclear grade and the breast 
cancer survival (e.g., Kister et al., 1969). Later on, in 1968, the WHO adopted 
the Bloom and Richardson method (Roberti, 1997). Despite this, some authors 
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used elements of the two methods simultaneously (Fisher et al., 1975). In the 
Bloom and Richardson method, the number of cases allocated to the less 
discriminative (grade II) category was very high, despite the good correlation 
between grade and survival.  
Le Doussal et al. (1989) evaluated the prognostic value of each of the grading 
parameter of the Bloom and Richardson method and concluded that nuclear 
pleomorphism and mitotic counts were the highest predictors for all survival 
measures. Based on that evidence, these authors modified the grading system 
by defining 5 grading categories (according to the combined score of the 
nuclear pleomorphism and mitotic count). This approach allowed the 
stratification of cases firstly allocated to grade II in two groups with different risk 
of developing metastases (le Doussal et al., 1989). 
Three decades after the development of the Bloom and Richardson grading 
method, Parham et al. (1992) demonstrated that the mitotic count was the most 
significant grading parameter. Based on that evidence and in previous studies 
showing that a significant association between survival and necrosis existed 
(e.g., Fisher et al., 1978), the authors proposed a grading system incorporating 
necrosis and mitotic counts (Parham et al., 1992). With this system the tumors 
were divided in 4 grades and, according to the authors, this allowed a better 
stratification of patients. Nevertheless, none of these previous methods had 
significant followers (Elston and Ellis, 1998). 
Elston and Ellis are widely renowned because of their refinement of the criteria 
of the Bloom and Richardson grading method. These authors used a cohort of 
almost 2,000 patients treated in Nottingham (and because of that the revised 
grade system was later named Nottingham grade method) and answered to the 
criticism of the lower reproducibility of the previous Bloom and Richardson’s 
grade. The novelty of the Nottingham method was that (Elston and Ellis, 1991; 
1998): 
1) tubule formation was assessed in a semi-quantitative fashion: score 1 
was attributed to tumors with more than 75% of luminal structures, score 
2 to tumors with 10 and 75% of tubular gland formation and score 3 to 
those with less than 10% of tubular structures. These cut-offs were not 
 17 
 
arbitrary, but based on a previous study which showed that they allowed 
the best separation in survival curves. 
2) for nuclear pleomorphism assessment the normal cells of the 
surrounding mammary tissue served as reference. 
3) for mitotic counts, a score was given according to the field area of high-
power lens used and only unequivocal mitotic figures were counted, 
excluding apoptotic and hyperchromatic nuclei.  
 
Nottingham grading system became the international gold standard for grading 
breast cancer (Ellis et al., 2012) and its prognostic value was confirmed by 
several prospective cohorts around the world (Elston et al., 1999; Frkovis-
Grazio and Bracko, 2002; Volpi et al., 2004; Rakha et al., 2008a; 2008b; Chen 
et al., 2011). 
Nottingham histological grade has been included in a prognostic index, the so-
called the Nottingham Prognostic Index, NPI (Blamey, 1996; Lee and Ellis, 
2008). This index allows a stratification of breast cancer patients (Rampaul et 
al., 2001) and incorporates three independent prognostic factors: tumoral size, 
lymph node stage and histological grade (Haybittle et a.l, 1982; Blamey, 1996). 
The NPI was built according to the coefficients (β values) obtained in Cox 
multivariable regression analysis (Haybittle et al., 1982; Blamey, 1996):  
 
NPI = [tumoral size (cm) x 0.2] + histological grade (1, 2 or 3) + lymph node 
stage (1, 2 or 3). 
 
Regarding tumor size, it corresponded to the greatest diameter determined by 
the pathologist during the macroscopic examination of fresh specimens or 
during the microscopic examination in very small invasive carcinomas (Elston et 
al., 1999). The histological grade was 1, 2 or 3, corresponding to grades I, II 
and III, respectively. As to the lymph node stage, it was also a three-tier system: 
in stage 1, no evidence of lymph node involvement existed, whilst in stage 2 up 
to 3 axillary nodes had metastases and, finally, in stage 3 more than 4 nodes 




Even if the first histological grading method for human breast cancer was 
described over 90 years ago (Table 5), the interest of the scientific community 
for this topic remains renewed. Moreover, the prognostic significance of 
Nottingham histological grade has been constantly reappraised (e.g., Rakha et 
al., 2008b). More recently, Thomas et al. (2009a) analyzed the prognostic 
significance of Elston and Ellis grade and its parameters and, based on their 
statistical results, they proposed a simplified binary scoring system. 
Accordingly, only two scores of each parameter would exist and their final 
combined score would range from 3 to 6, being score 3 allocated to grade I, 
score 4 and 5 to grade II and score 6 to grade III tumors (Thomas et al., 2009a). 
The authors claimed that their simplified system presented a prognostic value 
similar to the Nottingham method, with the great advantage that it would be 
more reproducible, because pathological assessments tend to vary less when 
variables are dichotomized (i.e., high versus low) (Thomas et al., 2009a). In the 
last few years, Nottingham histological grade applicability was extended to 
needle core biopsies (Kwork et al., 2010; O’Shea et al., 2011). These biopsies 
are used for the preoperative diagnosis of a breast lesion but the mitotic count 
in these specimens tended to be underestimated compared to those obtained in 
the surgical excised specimens (Kwork et al., 2010; O’Shea et al., 2011). 
Modifications of the thresholds for scoring mitotic count and the use of 
immunohistochemical proliferative markers have been proposed as methods for 
improving accuracy of Nottingham histological grade in core biopsies (Kwork et 
al., 2010; O’Shea et al., 2011). 
Meanwhile, the interest in the histological grade has been renewed by the 
advent of new techniques, such as tissue microarrays. Different morphological 
parameters have been tested in tissue microarray sections of human breast 
carcinomas aiming to develop a microarray grade highly correlated to the 
standard Nottingham method performed in the entire tumor (Dalton and Page, 
2012). From the authors perspective the development of a grade suitable for 
very small samples of tumors, would represent a step forward in the 
investigation of human breast cancer (Dalton and Page, 2012). 
For this revision of the literature a major conclusion can be draw: human 
pathologists are highly committed to grading breast cancer and improving their 
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performance when assigning a grade to a tumor, with the ultimate goal of 
providing reliable prognostic data for the better management of their patient. 
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Table 5 – Historical milestones of human breast cancer grading systems. 
Year Author Number of parameters Comments 
1925 Greenough 
 
6 Tubule formation 
Secretor activity 
Cell and nuclear size 





1928 Patey & Scarff 
 
3 Tubule formation 






grades of malignancy 




Five nuclear grades, in 
which 0 was the most 
malignant, and 4 the less 
malignant 
1957 Bloom & 
Richardson 
3 Tubule formation 
Nuclear pleomorphism 
Mitotic count 
Each parameter scored 1 
to 3. Their sum defines 
grade I (3-5), II (6-7) and III 
(8-9) 
1989 Doussal et al. 2 Nuclear pleomorphism 
Mitotic count 
Five grades. This 
modification included 2 
parameters of Bloom & 
Richardson 
1991 Elston & Ellis 
(Nottingham 
method) 
3 Tubule formation (score 
1:<10%; 2: 10-75%; 3: 
>75%) 
Nuclear pleomorphism 
(comparing to normal cells) 
Mitotic count (cut-offs 
defined by microscope field 
diameter) 
Each parameter scored 1 
to 3. Their sum defines 
grade, as in Bloom & 
Richardson 






1.5 Quantitative methods for objectivizing grade 
The introduction of quantitative measurements of grading parameters, which 
are continuous variables, has the advantage of better reflecting the biological 
continuum of tumor progression and could obviate the need of a subjective 
categorization (Ladekarl, 1998). Nowadays, three modalities of quantitative 
methods are available for histopathologists: morphometry, image analysis and 
stereology. Morphometry corresponds to the analysis of microscopic images 
using a caliper micrometer or a digital tool to perform direct measurements 
(Marcos et al., 2012). Regarding image analysis, it includes the capture of 
digital images of tissues, and afterwards a software analyzes the pixels of 
images, converting them into counts of tissue structures or cells (Marcos et al., 
2012). In contrast, stereology is a science that samples objects (such are 
histological sections) and these samples are used to estimate tridimensional 
(3D) characteristics of objects (Gunderson et al., 2013). Geometrical probes are 
used, which consist of test systems composed by points, lines or boxes (test 
volumes). These are superimposed to the tissue sections in order to perform 
counts that, when included in a mathematic equation, allow the recovery of the 
3D information of tissues (Gunderson et al., 1988).   
Stereological methods are intimately associated with a correct sampling (i.e., 
truly representative) of tissues and they are unique in providing objective and 
unbiased estimations of different morphological features, such as numbers or 
sizes of cells or nuclei (Marcos et al., 2012). In order to use these methods, 
tissue handling, processing and sectioning should be kept within reasonably 
standardized limits (Sørensen, 1992). Nevertheless, the possibility of bias 
related to tissue handling, when stereology is applied to routine diagnostic 
material, should not cloud the advantages of stereology over traditional two-
dimensional (2D) techniques (Kamp et al., 2009). These latter are highly 
influenced by the shape, orientation and size of the particles being counted 
(Kamp et al., 2009).  
In the 80’s and 90’s of the 20th century, studies focusing on measuring and 
counting morphological features of human breast cancer became more 
frequent. Haumeder is credited for confirming that the nuclear and nucleolar 
area of malignant breast cells were larger than that of the non-malignant tissue 
(reviewed by Meijer et al., 1997). After this milestone, both morphometrical and 
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stereological approaches have been used for studying human breast 
carcinomas, producing different estimators direct or indirectly related to the 
grading parameters (Table 6). 
 
Table 6 – Two-dimensional and three-dimensional quantitative estimators used in 
human breast carcinomas (adapted from Ladekarl, 2004). 
Feature 2D parameter 3D parameter  
Tubule formation / 
cellularity-related 
parameters  
Nuclear profile numerical 
density 
Percentage of neoplastic 
epithelium  
Fraction of fields with 
malignant tubules 
Cellularity index 
Nuclear numerical density [NV 
(nuclei, tumor)] 
Nuclear volume density [VV 
(nuclei, tumor)] 
 
Nuclear size Mean nuclear profile area 
 
Number-weighted mean 
nuclear volume (ν	N) 
Volume-weighted mean 
nuclear volume (ν	V) 
Mitotic activity Mitotic profile density  
Mitotic profile frequency  
Mitotic density [NV (mitoses, 
tumor)] 
Mitotic frequency [NN (mitoses, 
nuclei)] 
Volume corrected mitotic index 
(M/V index) 
 
The percentage of malignant cells within breast carcinomas was investigated by 
Parham et al. (1988). Using routine slides, which incorporated the center and 
the periphery of tumors the percentage of neoplastic epithelium was determined 
in 30 consecutive fields by using a grid of points. The percentage of tumor cells 
showed a wide variation between cases, and those with higher proportion of 
neoplastic cells in relation to stroma had a better prognosis (Parham et al., 
1988). However, no association between the percentage of tumor area and 
histological grade was observed (Parham et al., 1988).  
A cellularity index was computed by van der Linden et al. (1986), this time using 
as few as five fields and counting only epithelial cells that did not contact with 
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the lines of a test system composed by squares (each with a defined area). This 
index tended to be lower in tumors that recurred (van der Linden et al., 1986).  
Tubular formation is one of the grading parameters of breast cancer that has 
been addressed quantitatively, but using a different strategy. The tumor was 
screened at the medium magnification and all the fields showing at least one 
unambiguous tubular malignant structure were considered positive (Kronqvist et 
al., 1999). The ratio between number of positive fields and the total fields in the 
tumor was called fraction of fields with malignant tubules and used to measure 
tubule formation. Additionally, cut-offs for these quantitative features were 
defined in order to score tumors (Kronqvist et al., 1999; 2000; 2002).  
In human breast cancer, two cellularity-related parameters were established 
using stereological methodology (Ladekarl and Sørensen, 1993a; 1993b; 
Artacha-Pérula and Roldán-Villalobos, 1997; Ladekarl et al., 1997): 1) the 
nuclear numerical density [NV (nuclei, tumor)], which means the number of 
neoplastic nuclei per volume of tumor; 2) the nuclear volume density [VV (nuclei, 
tumor)], also known as the volume fraction of nuclei, that is the fraction of the 
total volume occupied by neoplastic nuclei. For estimating the first parameter 
thick sections are used and scanned, following the optical disector methodology 
(Fig. 1A). A nuclear volume density is estimated in thin sections by the point 
counting method, in which points hitting nuclear profiles and the reference 
space are counted (this latter corresponding to the tumor present in sections) 
(Howard and Reed, 2005). 
Probably, the mitotic activity has been the grading parameter with more 
quantification studies. In order to cope with the variation of cellularity between 
tumors, mitotic counts have been corrected to the percentage of neoplastic 
epithelium present in each analyzed field. This methodology, which was 
introduced in human pathology by Haapasalo et al. (1989), included the 
simultaneous counting of mitotic figures and estimation of the percentage of the 
volume of neoplastic tissue by a point counting procedure in each field; this 
generated the so-called volume corrected mitotic index (M/V index) (Haapasalo 
et al., 1989). The M/V index has been reported to be a powerful factor for 
predicting survival in human breast carcinomas (Lipponen et al., 1991; 
Aaltomaa et al., 1991; 1992; Jannink et al., 1995; Kronqvist et al., 1998). Other 
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morphometric approaches have been used to count mitoses in human breast 
cancer, namely the mitotic profile density (i.e., number of mitotic profiles per 
tissue area) and frequency (i.e., number of mitotic profiles per 1000 nuclear 
profiles). For these 2D estimators, and for increasing the efficiency of the 
procedure, counting frames with different areas were superimposed to the fields 
of vision (Ladekarl and Sørensen, 1993a; 1993b).  
In stereology, the mitotic density (i.e., the number of mitotic figures per unit of 
volume) was already estimated in thick histological sections of human breast 
cancer by the optical disector (Ladekarl et al., 1997). By that procedure, the 3D 
mitotic frequency was computed (2.8 mitotic figures per 1000 nuclei in ductal 
carcinomas, with higher in lymph node positive cases). This figure was quite 
similar to that estimated by a simpler 2D morphometrical method in thin 
sections (mitotic profile frequency of 2.1 per 1000 nuclei), and thus, it remains 
questionable whether the use of a more technical demanding technique, such 
as the optical disector, does have a real clinical utility (Ladekarl, 1995; 2004). 
Mitotic counts included in grading systems of CMT have been expressed as 
number of mitotic figures per each high-power field or per 10 high-power fields 
selected in the most proliferative area of a lesion (Misdorp, 2002; 
Karayannopoulou et al., 2005; Goldschmidt et al., 2011). Still, a research group 
has used a different approach: by using image analysis, Sarli et al. (1999; 2002) 
estimated the number of mitotic figures per 1000 neoplastic cells. Briefly, the 
total area of the nuclei of the neoplastic cells in 10 high-power fields was 
estimated and divided by the mean nuclear area (determined in 10 nuclei) in 
order to estimate the number of nuclear profiles. Despite the interesting 
approach, this mitotic index seemed not useful for prognostic purposes (Sarli et 
al., 1999; 2002).  
As to mitotic counts, nuclear morphologic features of human breast cancer have 
been evaluated by morphometrical and stereological methods. In 1993, 
Ladekarl and Sørensen published a study focusing on the assessment of 
various quantitative nuclear parameters in in situ and invasive ductal and 
lobular breast carcinomas, in which morphometrical and stereological methods 
were applied. Regarding the former, the mean nuclear profile area and the 
nuclear profile numerical density (i.e., number of nuclear profiles per tissue 
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area) were estimated (Ladekarl and Sørensen, 1993a). As previously 
mentioned, for these 2D estimates, counting frames with defined areas were 
used and the procedure fairly corresponded to that recommended in the 
stereological unbiased counting rule (Gundersen, 1977). Regarding to the 
stereological parameters estimated by Ladekarl and Sørensen (1993a) they 
comprised the volume-weighted mean nuclear volume (ν	V). The ν	V was 
estimated by the point sampled intercepts (PSI) method, which uses a test grid 
made of parallel lines bearing a systematic pattern of points (Sørensen, 1992; 
Ladekarl and Sørensen, 1993a; Gunderson et al., 1988). This parameter 
increases as the nuclei enlarges, being further augmented when a substantial 
variation in their size exists (Fig. 1B). It is mostly used in histopathology, since it 
grades quantitatively the nuclear size pleomorphism, correlating with the 
prognosis of various neoplasias (Sørensen, 1992; Ladekarl, 1998).  
The prognostic value of morphometrical and stereological estimators in human 
breast carcinomas was already evaluated using a multivariable analysis 
(Ladekarl and Sørensen, 1993b; Ladekarl, 1995). The ν	V, the nuclear profile 
density number and the mitotic profile frequency showed independent 
prognostic value. A prognostic index that included the quantitative variables and 
the clinical stage was proposed (Ladekarl and Sørensen, 1993b). The authors 
discussed the limitations of the 2D morphometrical parameters, such as the 
nuclear profile numerical density and the mitotic profile frequency, and 
emphasized the value of the stereological ν	V, not only because of the simplicity 
of the estimation method, but also because of its applicability to routine tumor 
sections (Ladekarl and Sørensen, 1993b; Ladekarl, 1995).  
By the same time, a Spanish group reached to similar conclusions (Roldán-
Villalobos et al., 1996; Artacha-Pérula and Roldán-Villalobos, 1997). By 
studying the ν	V in human ductal carcinomas, these authors defined a cut-off of 
425 µm3 that was significantly associated with short survival (Roldán-Villalobos 
et al., 1996). They also estimated other stereological parameters in breast 
tumors of the 3 histological grades, such as nuclear numerical density [NV 
(nuclei, tumor)], the nuclear volume fraction, and the number-weighted mean 
nuclear volume (ν	N). The latter corresponds to the mean volume of nuclei, 
being determined using the nucleator technique (Fig. 1C) (Gundersen et al., 
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1988). The ν	N does not provide direct information regarding the variability of the 















Fig. 1 – Overview of the estimation of the nuclear mean volumes and numerical 
density. (A) Estimation of nuclei numerical density using the optical disector in thick 
sections. Nuclei are counted as they appear in focus within the disector height (h) and 
within or touching inclusion lines (green) but not the exclusion ones (red). In this 
example, 8 nuclei would be counted. (B) Estimation of the volume-weighted mean 
nuclear volume (ν	V) according to the point sampled intercepts method. The nuclei are 
sampled according to their volume, by overlaying a grid of points at random and, for 
each nucleus hit by a point, the intersection between the line and nuclei is marked (red 
crosses) and distance between both ends of the nuclei measured (yellow line), which is 
used to estimate the ν	V. This procedure uses thin sections. (C) Nucleator method for 
estimating number-weighted mean cell volume (ν	N). After applying the disector to 
sample cells the stereological system generates two lines passing through the 
nucleolus; intersections between the lines and nuclear borders (red crosses) is marker 
and the average distance (yellow lines) used to estimate the ν	N. In this case thick 
sections are needed.  
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According to the results of that group, the NV (nuclei, tumor) tended to be lower 
in poorly differentiated tumors, but no statistical difference was observed 
between tumors of the grade I, II and III. In contrast, the nuclear volume fraction 
increased with the grade, and both the ν	V and the ν	N were significantly higher in 
grade III tumors compared with grade I and grade II tumors. These two nuclear 
volume estimates were positively correlated with each other, were significantly 
associated with survival outcome, and therefore appeared as quantitative and 
useful prognostic factors (Artacha-Pérula and Roldán-Vilalobos, 1997).  
Various tumor parameters can be assessed by quantitative methods, but there 
is a general agreement that variables related to nuclear size and mitotic counts 
have an increased prognostic importance in human breast cancer (Ladekarl, 
1998; Baak et al., 2005; Skaland et al., 2008; Baak et al., 2009). In most cases, 
the 2D and 3D estimators showed significant correlations, which were better for 
the mitotic activity estimators (Ladekarl, 2004). In human breast cancer, 
unbiased 3D quantification techniques have been recommended for estimating 
nuclear size of neoplastic cells, whereas for mitotic activity the 2D techniques 
can be sufficiently accurate for grading purposes (Ladekarl, 2004). 
The interest in quantitative variables in human breast cancer extends to the 
present days. In a recent report nuclear parameters in in situ carcinomas and in 
ductal hyperplasia were studied in digitalized routine sections by computer 
image processing and analysis (Dong et al., 2014). This study demonstrated 
that nuclear quantitative features allowed a differential classification of in situ 
carcinomas and hyperplasia, and, in case of carcinomas, the distinction 
between high and low nuclear grades was possible (Dong et al., 2014). The use 
of quantitative features of cells for the diagnosis and grading of malignancy, 
could act as a second-reader in borderline and dubious cases, being a real-time 
support for the decision-making of pathologists (Dong et al., 2014). 
Despite this promising data based on 2D and 3D quantification in human breast 
cancer, a scarce interest has been devoted to quantitative analysis of cellular 
features in CMT. As far as we know, a 3D quantification (i.e., based on 
stereological methods) has never been performed in CMT. Computer-assisted 
image analysis has been used to estimate 2D/morphometrical nuclear 
characteristics in CMT (Simeonov and Simeonova, 2006; 2007; de Vico et al., 
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2007). Two of those studies were performed in cytological preparations and did 
not include clinicopathological data, other than the histological diagnosis 
(Simeonov and Simeonova, 2006; 2007). Interestingly, the authors reported that 
the mean nuclear diameter, perimeter, and roundness (also known as nuclear 
form factor) were significantly higher in malignant CMT compared to benign 
ones. In a series of CMT, de Vico et al. (2007) estimated the mean nuclear 
area, the mean nuclear form factor and their respective standard deviations. 
The estimates of mean nuclear area were significantly higher in lymph node 
positive cases. Therefore, this parameter appeared as a good morphometrical 
discriminator of metastatic tumors (de Vico et al., 2007). Yet, the utility of 
quantitative and unbiased estimators for improving the reproducibility, accuracy 
and prognostic value of the histological grade in CMT remains to be 
determined.   
 
1.6 Genomic studies: a tool with clinical implications 
Cancer is rooted in inherited or acquired genetic and epigenetic alterations 
(Wang, 2013). The successive accumulation of alterations in the genome 
contributes to the acquisition of several functional and morphological 
characteristics by neoplastic cells, such as sustained proliferative activity or 
invasion (Hanahan and Weinberg, 2011). In the perspective of cancer 
development, the most relevant genetic changes (numeric or structural) or 
epigenetic alterations (such as DNA methylation and histone modifications) are 
those affecting oncogenes, tumor suppressor genes, or the DNA repair system, 
also named as caretaker of the genome (Hanahan and Weinberg, 2011). 
Significant efforts have been focused in the comprehensive characterization of 
genetic underpinnings of the major human tumor types (Wang, 2013). In human 
breast cancer the knowledge of chromosome changes associated with the 
carcinogenesis have significantly improved over the last 30 years (Steinarsdottir 
et al., 2011). The study of DNA changes progressed along with the 
development of techniques (Costa et al., 2008). Early studies used flow 
cytometry to detect genomic changes, without chromosome specificity and 
karyotyping methodology, which required living cells (Dressler et al., 1988; 
Heim et al., 1997; Teixeira et al., 2002; Costa et al., 2008). The standard 
chromosome banding analysis is a good method for an initial screening for 
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karyotype abnormalities (Teixeira, 2002). However, major drawbacks exist, 
namely: its low resolution, which limits the detection of highly complex 
karyotypes, and its requirement of living cells, either from fresh tumoral 
specimens or obtained from short-term culture of tumor cells (Teixeira et al., 
2001; Tan and Reis-Filho, 2008).  
The dependence of short-term culture was considered a potential pitfall for the 
use of conventional cytogenetic analyses in the study of solid tumors, including 
breast cancer (Teixeira et al., 2001). The next logical methodological step was 
to use a technique independent on the availability of metaphases from the 
neoplastic cells. This was accomplished by the use of comparative genomic 
hybridization (CGH) (Teixeira et al., 2002). This method allows the detection of 
changes in the copy number of chromosomes, providing a global overview of 
chromosomal gains and losses throughout the whole genome of the tumor 
(Weiss et al., 2003). CGH uses differentially labeled total genomic tumor DNA 
and normal reference DNA (obtained from unrelated healthy individuals) that 
are cohybridized onto normal metaphase chromosome spreads on a glass slide 
(Kallioniemi et al., 1993; Teixeira et al., 2002; van Beers and Nederlof, 2006; 
Costa et al., 2008). The ratio of fluorescence intensities of tumor and normal 
DNA is measured along the chromosome axis, which allows the mapping of 
chromosomal gains and losses (Teixeira et al., 2002; Costa et al., 2008).  
More recently, the resolution of the CGH method was improved by the 
development of array-based CGH technologies (aCGH) (Costa et al., 2008). In 
aCGH, the metaphase was replaced by DNA fragments arrayed on a 
microscope slide, for which the exact chromosomal location is known from the 
genome sequence (Costa et al., 2008). These aCGH platforms could be 
constructed using bacterial artificial chromosome (BAC) clones which provide a 
resolution of about 1 Megabase (Mb), or short 130-600 base pair (bp) single-
stranded molecules (oligonucleotides) with a theoretical resolution of up to 2 
kilobase (kb) (Climent et al., 2007; Tan and Reis-Filho, 2008). Currently, aCGH 
is the method of choice for screening and characterizing copy number variations 
of human solid tumors, allowing, for the first time, the full classification of 
complex karyotypes (Climent et al., 2007; van Beers and Nederlof, 2006). It 
should be stressed that despite its high resolution, aCGH cannot detect ploidy 
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variations and balanced reciprocal aberrations and that aCGH is a relatively 
expensive technique that requires specific equipment and specialized 
interpretation skills (van Beers and Nederlof, 2006).  
In breast cancer, CGH technologies have been applied for: 1) searching for 
genomic regions harboring candidate genes involved in carcinogenesis; 2) 
studying intratumoral heterogeneity; 3) establishing the clonal relation between 
multiple tumors as well as between the tumor and their metastases; and 4) 
identifying DNA copy number changes that could be prognostic or predictive 
markers (Reis-Filho et al., 2005; Climent et al., 2007; Andre et al., 2009). 
CGH studies already revealed that the most common forms of invasive breast 
carcinomas are associated with recurrent unbalanced chromosomes changes, 
namely gains in 1q, 8q, 11q, 16p, 17q and losses of 1p, 13q, 16p and 17p 
(Reis-Filho et al., 2005). Some of those aberrations were associated with poor 
prognosis, such as gains of 3q or 8q, whereas the loss of 16p correlated with 
good prognosis (Reis-Filho et al., 2005; Horlings et al., 2010). The profiling of 
DNA copy number changes was associated with different clinicopathological 
features, including grade (Bergamaschi et al., 2006), estrogen receptor status 
(Loo et al., 2004), gene-expression subtype (Andre et al., 2009), and survival 
(reviewed by Climent et al., 2007).  
CGH methodology also confirmed that some human breast carcinomas are 
composed by different cells, clonally unrelated, thus supporting the existence of 
polyclonality, previously suggested by conventional chromosome banding 
techniques (Teixeira et al., 1994; Heim et al., 1997; Teixeira et al., 2001; Torres 
et al., 2007). This evidence contradicted the almost unanimous conviction that 
carcinomas were monoclonal in their origin (Heim et al., 2001). Moreover, by 
CGH and a robust statistical analysis, it was reported that significant divergent 
clonal evolution occurred in primary breast cancer and their lymph node 
metastases and that, apparently, the metastases developed during the early 
stages of tumorigenesis (Torres et al., 2007). 
Another important issue of breast cancer was explored by classic cytogenetic 
analysis and CGH. Both techniques were used to disclose the clonal 
association between synchronous breast carcinomas (Teixeira et al., 1996; 
1997; 2004). In this regard, the existing evidence supports that ipsilateral 
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lesions are clonally related, and could represent a process of intra-mammary 
spreading of a single breast cancer, while most synchronous bilateral breast 
cancer cases seemed to correspond to independent tumors rather than 
metastatic events (Agelopoulous et al., 2003; Teixeira et al., 2004; Hwang et al., 
2004). Accordingly, CGH offered the unprecedented possibility to confirm if 
multiple breast carcinomas really represented multiple primary entities, which 
certainly would have an obvious clinical applicability, being helpful for 
delineating appropriate therapies (Teixeira et al., 2004; Bendifallah et al., 2010).   
In veterinary pathology, the issue of clinical and morphological heterogeneity, 
as well as multiplicity of CMT, is much more important than in humans. 
However, unlike breast cancer, CMT are poorly characterized regarding cancer-
associated genomic aberrations. Understanding the fundamental biology of 
CMT is crucial, not only for improving the management of the disease, but also 
to further support the dog as a potential model for studying human breast 
cancer (Rowell et al., 2011). Classic chromosome banding studies of CMT are 
rare (Mellink et al., 1989; Mayr et al., 1990; 1993). The presence of bi-armed 
chromosomes (putatively due to isochromosome formation) and the loss of X 
were already reported. In one study, the fluorescence in situ hybridization 
(FISH) technique was performed in cells lines derived from malignant CMT and 
reported abnormalities comprised the chromosomes 8 or 11, 13 or 15, 37, 38 
and X; the changes included the loss and formation of isochromosomes, as well 
as centric fusion (Tap et al., 1998).  
It should be noted that conventional cytogenetic analyses in dogs are 
technically demanding, because the normal diploid number of dogs is very large 
(39 pairs of chromosomes, as opposed to the 23 pairs of humans) and the 
canine chromosomes (except the X and Y chromosomes) are acrocentric, 
similar in size, shape and banding pattern (Reimann-Berg et al., 2012). 
Therefore, the genomic studies of canine cancers have greatly benefited from 
the introduction and development of metaphase and aCGH (Thomas et al., 
2007; 2008). Genome integrated canine BAC arrays for CGH analyses were 
developed with clones spaced at 10Mb and 1Mb (Thomas et al., 2007; 2008). 
These authors developed a comprehensive genome-wide set of single locus 
probe FISH reagent for the canine genome (Thomas et al., 2008). In 
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combination, these tools already begun to make an huge impact on the 
understanding of cancer-associated genomic changes in a variety of cancers, 
including hematopoietic malignancies (Breen and Modiano, 2008; Thomas et 
al., 2011), intracranial malignancies (Thomas et al., 2009b) and sarcomas 
(Thomas et al., 2009c; Angstadt et al., 2011; Hedan et al., 2011). More recently, 
the resolution for canine aCGH has been extended using an oligonucleotide 
platform comprising 180,000 60-mer features, which are currently under use 
(Breen and Thomas, 2012). These genetic resources offer new opportunities to 
investigate the type and nature of recurrent chromosomal abnormalities of CMT. 
These tools may also contribute to further understand the genetic process 
involved in CMT, by identifying regions of canine genome with carcinogenesis 
associated genes, as has been demonstrated in other tumors of dogs (Breen 
and Thomas, 2012; Thomas et al., 2014). Interestingly, in some of those 
studies, interspecies genetic overlap between canine and human tumors were 
reported (Rowell et al., 2011; Breen and Thomas, 2012).  
Until the present, only two studies reported genomic alterations in malignant 
CMT using modern genomic-wide methodology (Beck et al., 2013; Liu et al., 
2014). In those studies a total of 17 animals with CMT were included  a figure 
that drastically differs from the number of breast cancer cases studied so far. In 
the work by Beck et al. (2013) five CMT of different subtypes (simple 
carcinomas, complex carcinomas and carcinosarcoma) were submitted to 
whole-genome sequencing, aiming to detect copy number and structural 
aberrations. In all but one case, the authors described genomic aberrations, 
affecting several known cancer associated genes, such as c-MYC and KIT 
(Beck et al., 2013). A recurrent deletion of chromosome 27 was observed in the 
analyzed series. Moreover, similarities to human breast cancer and specific 
canine alterations were also reported (Beck et al., 2013). Last year, Liu et al. 
(2014) performed aCGH and whole-genome sequencing in 12 cases of CMT. 
According to the authors, simple carcinomas were associated with extensive 
genetic aberrations while complex carcinomas presented no major copy number 
alterations, but were associated with several histone modifications. Based on 
their findings, the authors hypothesized that complex carcinomas could arise 
from epigenetic changes, rather than genomic aberrations (Liu et al., 2014).  
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A generalized optimism exists regarding the clinical applicability of the genetic 
characterization of human cancer, even if the translation of the data from the 
bench to the clinical setting will take several years (Caldas, 2011). In veterinary 
oncology, and specifically in CMT, there is a long road ahead. However efforts 
should be pursued to increase the knowledge on genetic changes and 
mechanisms involved in CMT development. There are a couple of issues with 
direct clinical implications that deserve further studies. Firstly, the genetic 
characterization of the malignant CMT will be crucial to support the stratification 
of cases with different prognosis. Secondly, understanding the genetic 
connection between the different neoplastic mammary nodules will provide 
evidence-based options regarding the surgical and eventual adjuvant therapy in 




2. Aims  
Pathologists and clinicians are still challenged for an accurate prognosis 
definition in each case of malignant CMT. From the pathologist’s perspective, a 
reliable and reproducible grading method is essential. Considering this, we 
aimed to: 
• perform a comprehensive evaluation of the prognostic value of histological 
grade in malignant CMT, considering the individual role of each grading 
parameter (tubule formation, nuclear pleomorphism and mitotic count) and 
their association with survival;  
• test quantification strategies, using stereology and morphometrical 
approaches that could contribute to a more objective assessment of the 
grading parameters;  
• study the level of interobserver reproducibility of the histological grade and 
their parameters in a series of malignant CMT;  
• evaluate the feasibility of a prognostic formula for malignant CMT, namely 
by adapted human Nottingham Prognostic Index, which incorporates the 
histological grade. 
 
Keeping in mind that the grading method for malignant CMT has been adapted 
from human breast cancer grading systems, we also intended to:   
• investigate potentially new grading parameters, easily assessed during the 
histopathological examination of malignant CMT in order to contribute to 
the future development of a canine-specific histological grading method. 
 
Both clinicians and pathologists agree that the genetic basis of CMT remains 
poorly understood; this clearly contrasts with the human breast cancer. 
Particularly, in the case of multiple tumors, it is unknown if they share the 
genetic background or represent truly independent tumors. Considering this, we 
aimed to:  
• study genetic alterations in malignant CMT and assess the clonal relation 
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Canine mammary neoplasia is highly heterogeneous in morphological 
appearance and in biological behavior. The successful clinical management of 
this disease should rely on robust prognostic factors. Histological grade, 
determined by the human Nottingham histological grade method (NHG), has 
been considered one of such factors. Despite the adoption of this method, it is 
unknown if interobserver agreement exists regarding the assessment of its 
parameters in canine mammary carcinomas. In this study, the agreement 
between two observers regarding the NHG nuclear pleomorphism scoring was 
evaluated in 89 canine mammary carcinomas. In each case, the histological 
evidence of vascular invasion and/or regional lymph node metastases, regarded 
as early signs of tumor aggressiveness, was recorded. In 48 animals two years 
follow-up data was available. Nuclear pleomorphism was also quantitatively 
assessed by a stereological method, which allowed for an unbiased estimation 
of nuclear size and its variability, by determining the volume-weighted mean 
nuclear volume (ν	V). Differences in the ν	V estimations of the normal 
parenchyma, benign and malignant tumors were comparatively evaluated. In 
malignant tumors the stereological estimations of nuclear pleomorphism were 
compared with the histological score of nuclear pleomorphism included in the 
NHG. Additionally, the prognostic significance of clinicopathological features in 
carcinomas included the nuclear score and the ν	V was evaluated. A modest 
agreement between the two observers in the histological score of nuclear 
pleomorphism was obtained. The value of ν	V significantly increased from 
normal parenchyma, to benign and to malignant tumors. Carcinomas scored as 
1 and 2 presented similar ν	V and only tumors scored 3 presented significantly 
higher estimates. The ν	V was not associated with vascular invasion and/or 
lymph node metastases, but was higher in tumors that progressed during 
follow-up. In multivariable analysis, only tumor size stood up as an independent 
factor regarding evidence of aggressiveness and an optimal cut-off of 2.9 cm 
was defined. According to these results, we propose that the ν	V could be 
included in the toolbox for assisting in the diagnosis and grading of canine 







Mammary gland tumors are the most frequent neoplasia in female dogs, 
particularly in countries where spaying is not performed routinely early in life 
(Sorenmo, 2003). Approximately half of the affected dogs have malignant 
disease, based on the histopathological examination (Lana et al., 2007). 
Metastases to distant organs are the most common cause of morbidity and 
mortality associated with malignant canine mammary tumors (CMT) (Clemente 
et al., 2010; Lana et al., 2007). It is now clear that CMT is a complex disease 
characterized by a heterogeneous clinical and biological behavior. This 
probably contributes to the limited therapeutic options that are currently 
available (Goldschmidt et al., 2011; Klopfleisch et al., 2011, Sorenmo et al., 
2011). Searching for new prognostic parameters is of utmost importance and 
this has been addressed by several studies (e.g., Philibert et al., 2003; Chang 
et al., 2005; Santos et al., 2013).  
Histological grade is well established as an important prognostic factor in 
human breast cancer (Rakha et al., 2010). In veterinary pathology, different 
grading systems have been used and claimed to have prognostic value, but 
such variety of methods represents a drawback for establishing grade as 
prognostic factor (Matos et al., 2012). One of the most frequently used methods 
for histological grading of malignant CMT is the NHG, originally developed for 
human breast cancer (Elston and Ellis, 1991). Karayannopoulou et al. (2005) 
provided some evidence that this method had advantages when compared to 
previous methods for prognostic purposes in dogs. The NHG is based on the 
semi-quantitative assessment of three morphological features: tubule formation, 
mitotic counts and nuclear pleomorphism. The latter should mainly be evaluated 
by comparing the nuclear size and its variation with normal mammary epithelial 
cells (Elston and Ellis, 1998). Nuclear pleomorphism is considered a hallmark of 
malignant transformation, increasing in parallel to the absence of cell 
differentiation (Sørensen, 1992; Ladekarl, 2004). However, it has been claimed 
that karyomegaly often leads to overdiagnosis of malignancy in CMT (Matos et 
al., 2012; Peña et al., 2013). Still, objective and unbiased estimations of nuclear 
size and nuclear pleomorphism were never compared in benign and malignant 
CMT, and their role in prognosis is largely unknown.  
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Nowadays, it is recognized that the histological grading system of malignant 
CMT deserves further investigation (Goldschmidt et al., 2011; Matos et al., 
2012). Irrespective of the method, grading is usually based on a subjective, 
experience-dependent judgment by the pathologist and on qualitative or semi-
quantitative evaluations of morphologic and cytological features (Sørensen, 
1992; Artacha-Pérula and Roldán-Vilalobos, 1997). Not only the observer, but 
also the selection of the tumor areas to assess grade can significantly influence 
the scoring of parameters. This is especially relevant for CMT, which are 
intrinsically very heterogeneous (Klopfleisch et al., 2011). The subjective nature 
of morphological evaluation is associated with a high risk of inter- and 
intraobserver variations that can hamper the reproducibility and accuracy of the 
biological information, jeopardizing a comparative analysis between studies 
(Artacha-Pérula and Roldán-Vilalobos, 1997). A simple way to overcome such 
subjectivity is to use unbiased quantitative parameters for scoring neoplasms, 
namely by applying appropriate stereological methods (Ladekarl, 1995). This 
has been performed in various human tumors, including breast cancer 
(Sørensen, 1992; Ladekarl and Sørensen, 1993; Ladekarl, 1995; Steiner et al., 
1994; Artacha-Pérula and Roldán-Vilalobos, 1997; Ladekarl, 1998; Yörükoglu et 
al., 1998; Soda et al., 1999; Fujikawa et al., 2000). The design-based 
stereological estimates are precise, shape-independent, and allow an objective 
evaluation of several cytological features, including nuclear pleomorphism 
(Ladekarl, 1998). However, to the best of our knowledge, stereological methods 
were never applied for studying CMT.  
The point sampled intercepts (PSI) method is considered the easiest way to 
objectively quantify the nuclear size and its pleomorphism (Gundersen and 
Jensen, 1985; Ladekarl, 1998). The PSI generates estimations of the volume-
weighted mean nuclear volume, ν	V (Sørensen, 1992). The ν	V is not an intuitive 
parameter: it involves sampling the nuclei in proportion to their individual 
volumes; cells with bigger nucleus are more likely to be sampled and, thus 
contributing more to the estimate (Gundersen et al., 2013). The ν	V increases as 
the nucleus enlarges, being further augmented when a substantial variation in 
its size exists. Therefore this parameter combines information on nuclear size 
and its variability (Sørensen, 1992; Ladekarl, 2004). This parameter is mostly 
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used in histopathology and it has been emphasized that the ν	V estimates 
provide relevant information for diagnosis and grading of human breast tumors 
(Ladekarl and Sørensen, 1993; Ladekarl, 1995; Roldán-Vilalobos et al., 1996; 
Artacha-Pérula and Roldán-Vilalobos, 1997). 
The aims of this study were to: 1) assess the nuclear pleomorphism of CMT and 
normal mammary parenchyma using stereological tools, namely the PSI 
method; 2) compare the stereological estimation of nuclear pleomorphism in 
normal parenchyma, benign and malignant CMT; 3) compare the stereological 
estimations with the histological score of nuclear pleomorphism in malignant 
tumors; 4) verify the prognostic significance of the nuclear pleomorphism 
estimations, by using univariable and multivariable analyses.  
 
2.2 Material and methods 
2.2.1 Clinical cases and histological analysis 
Pathology archives from ICBAS, University of Porto were accessed to select 
retrospectively 122 spontaneous CMT (33 benign and 89 malignant) that had 
been surgically removed. The selection of cases was blinded to clinical data. 
Six normal mammary gland cases (one case per each estrous phase, i.e., 
proestrous, estrous, early diestrous, late diestrous, early anestrous and late 
anestrous), previously included in a study (Santos et al., 2010) were also 
selected. For animals bearing mammary tumors, owners gave informed consent 
for the surgery with curative intents, after declining postoperative adjuvant 
therapy. Histological evaluations were performed in all the slides containing the 
largest cross section of the tumor. The histological diagnosis was performed by 
two observers (MS and PDP) using the criteria of the World Health Organization 
classification (Misdorp et al., 1999). In malignant CMT the following 
clinicopathological parameters were recorded: the largest diameter accurately 
measured with a caliper, before surgery by the clinician (AdM or AS); the 
presence of peritumoral vascular invasion (defined as the presence of tumor 
emboli within endothelial-lining spaces without distinguishing between lymphatic 
and blood vessels) and regional lymph node metastases [lymph nodes were 
evaluated in routine slides and after immunolabelling with pancytokeratin 
AE1/AE3 and cytokeratin 14, as previously described by Matos et al. (2006)]; 
 58 
 
the histological scoring of nuclear pleomorphism according to the NHG criteria 
(Elston and Ellis, 1991; Karayannopoulou et al., 2005), considering only luminal 
epithelial cells. Two observers (MS and PDP) assigned the nuclear grading 
score independently in order to determine the interobserver agreement. 
Subsequently, in cases with discrepant scores, a consensus was obtained by 
reviewing the slides using a multi-head microscope. Briefly, nuclei were scored 
as 1 if no visible increase in size and shape variability was detected, comparing 
to normal surrounding mammary epithelial cells; scored as 2 when moderate 
variation in size and shape existed (nuclei were generally larger than the normal 
ones); scored as 3 when a marked increased variation in size and shape was 
present, with very large and bizarre forms observed in at least one quarter of 
the tumor area (Fig. 1) (Elston and Ellis, 1991). 
 
2.2.2 Stereological analysis 
A systematic random sampling approach for the selection of the fields was used 
in each slide, meaning that the first field of sampling was randomly selected and 
thereafter fields were sampled systematically by adjusting the distance between 
individual fields of vision roughly proportional to the overall area of the tissue of 
interest; all the parenchyma (in normal mammary glands) and all the tumor area 
(in CMT cases) present in the slides was considered. The stereological analysis 
was performed with a workstation comprising a microscope (BX-50 Olympus, 
Japan) equipped with a 100x oil immersion objective (Olympus Uplan), a CCD 
video camera (Sony, Japan) connected to a PC monitor, and a motorized stage 
(Prior, United Kingdom) for stepwise displacements in x-y directions; the 
workstation was controlled by the software CAST-Grid (Version 1.5, Olympus, 
Denmark). The ν	V was estimated by the PSI method (Gundersen and Jensen, 
1985). This parameter quantifies the nuclear size and pleomorphism, estimated 
with a test-system made of parallel lines bearing a systematic pattern of points 
(Fig. 2). Only the nuclear profiles of epithelial cells hit by one of these points 
were sampled. On these profiles, the line segments overlying the nucleus were 
measured (from boundary to boundary) (Fig. 2); this resulted in a length (l) that 
was used to estimate the ν	V as follows (Gundersen and Jensen, 1985): 
3




Fig. 1 – Histological normal surrounding mammary tissue (A, C, E) and tumor cells (B, 
D, F) in three cases of canine mammary carcinomas. Nuclear pleomorphism scoring 
followed the criteria of the Nottingham histological grade method: score 1 (image B) 
presents no increased size and shape variability comparing to normal epithelial cells 
(image A); score 2 (image D) has moderate variation and larger nuclei than normal 
ones (image C); whereas score 3 (image F) shows marked increased variation in size 
and shape, with very large nuclei and prominent nucleoli comparing with normal 
adjacent parenchyma (image E). Hematoxylin-eosin, Bar 20 µm. 
 
Estimates of the ν	V are volume-weighted, because the nuclear profiles are point 
sampled with a chance proportional to their volume. It is assumed herein that, 
globally, the nuclei do not display a preferred three-dimensional orientation, i.e., 
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that the nuclei are isotropically oriented; our qualitative observations do support 
the presumption. For estimating the ν	V, a total nuclear profiles of 92 (39, SD, 
standard deviation), 115 (43) and 166 (69) was measured, on average, in each 
slide of normal mammary parenchyma, benign and malignant tumor cases, 
respectively. The coefficient of variation (CV = SD/mean) was also computed, 
as well as the coefficient of error (CE), estimated according to the formula: 
 
CE = 100 · CV ÷ √n 
In which, n stands for the cases included in each group.  
 
 
Fig. 2 – Estimation of the volume-weighted mean nuclear volume (ν	V) with the point 
sampled intercepts method. A test system made of parallel lines bearing a systematic 
pattern of points is generated by the software. Nuclei in focus that are hit by one of the 
points are selected. In these nuclei, the distance between the intersections of the 
nuclear boundaries with the lines (marked with red crosses) was measured. 
Hematoxylin-eosin, Bar 13 µm. 
 
2.2.3 Follow-up and survival study 
Follow-up data were collected over two years following the protocol detailed in 
Santos et al. (2011). Briefly, each female dog was evaluated prior to surgery, 3 
weeks after the procedure and every 3 months thereafter. Each evaluation 
included a complete physical examination, thoracic radiographs (3 views) and 
an abdominal ultrasound. Any clinical signs or lesions that could be related to 
tumor progression, either in the scheduled evaluations or in between them was 
thoroughly investigated (e.g., fine-needle aspiration, ultrasound-guided biopsy, 
and skeletal radiography). A complete necropsy was performed when the 
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animals died spontaneously or were euthanized in search for evidences of 
subclinical local recurrence or metastatic disease. Overall survival (OS) was 
calculated from the date of surgery to the date of animal death/euthanasia due 
to tumor metastasis. Disease-free interval (DFI) was calculated from the date of 
surgery to the date of detection of tumor progression, i.e., confirmed local 
recurrence and/or metastases. In the survival study, cases were censored if: 1) 
animals died due to causes unrelated to tumor; 2) were lost to follow-up; 3) 
were alive and free of distant metastases 24 months after surgery. 
 
2.2.4 Statistical analysis  
Cohen’s Kappa statistic was used to assess the interobserver agreement for the 
histological scoring of nuclear pleomorphism. Additionally, an asymptotic 
marginal homogeneity test was used, to evaluate if statistical differences 
between the observers existed.  
One-way ANOVA followed by Tukey multicomparison test were used to check 
for differences in ν	V of normal mammary parenchyma, benign and malignant 
tumors. The same approach was performed for investigating differences in the 
stereological estimation in each nuclear pleomorphism consensual score. ROC 
curves analyses were used to determine if tumor size and ν	V values could 
discriminate malignant tumors with or without evidence of vascular invasion 
and/or lymph node metastases. In malignant tumors, the association between 
clinico-pathological parameters (tumor size, histological type, nuclear 
pleomorphism consensual score, and ν	V) and the evidence of vascular invasion 
and/or lymph node metastases was assessed by logistic regression models. 
Pearson Chi-square or Fisher test (when the assumptions for the Pearson Chi-
square were not fulfilled) were used to assess which categorical variables 
should enter in the multivariable logistic model, while independent t-test was 
used for continuous variables. It is opportune to mention that in addition to the 
histological type, malignant tumors were grouped for statistical purposes, into 
two categories: 1) solid and anaplastic types; 2) tubulopapillary and complex 
types (one case of squamous cell carcinoma was excluded). This was 
performed according to previous evidence that solid and anaplastic tumors 
show increased metastatic activity (Misdorp et al., 1999; Rasotto et al., 2012; 
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Peña et al., 2013). As different categories of tumor size have been described in 
the literature, this parameter was analyzed in three different ways: 1) as a 
continuous variable; 2) grouped according to the WHO criteria (< 3cm; 3-5cm; > 
5cm); 3) categorized as suggested by Santos et al. (2011) (< 3cm; ≥ 3cm).  
A survival analysis of DFI and OS was performed to determine if differences 
existed between the group with and without evidence of vascular 
invasion/lymph node metastases. The Kaplan-Meier plots were used to show 
differences between these groups. Finally, a log-rank test (Mantel-Cox) was 
applied to analyze the significance of the differences between groups. The 
same approach was used for the results of the ROC analysis if significant. The 
association of nuclear pleomorphism consensual score and ν	V with survival 
data was also evaluated by univariable analyses. The counts of malignant 
tumors with progression (recurrence and/or metastases and death) and 
malignant tumors without events during the entire follow-up period were used 
for those univariable analyses. In all the tests a P value lower than 0.05 was 
considered significant. The statistical analyses were performed in the program 
IBM SPSS Statistics, version 22 (IBM, New York, USA). 
 
2.3 Results 
The 122 CMT analyzed included 17 complex adenomas, 10 simple adenomas 
and 6 benign mixed tumors, 42 complex carcinomas, 23 solid carcinomas, 21 
tubulopapillary carcinomas and 3 other carcinoma types (one squamous cell 
and two anaplastic carcinomas). In 26% of the malignant tumors there was 
histological evidence of vascular invasion and/or lymph node metastases at the 
time of the diagnosis. For survival analysis only cases presented as one 
malignant tumor per animal (n of animals = 40) and cases of multiple malignant 
tumors per animal with no evidence of disease progression (recurrence and/or 
metastases) during the follow-up period (n of animals = 8; n of tumors = 18) 
were considered. During the follow-up period 10 animals progressed (recurred 
and/or metastasized), 26 were disease-free at the end of the follow-up period, 
and the remaining cases were censored. 
When scoring the nuclear pleomorphism in malignant tumors, the two observers 
disagreed in 30/89 cases (34%), with higher agreement in the score 3 
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comparing to scores 1 and 2 (Table 1). The Kappa value was 0.46 (P < 0.001), 
thus corresponding a low-moderate agreement (Vieira and Garrett, 2005). 
Asymptotic marginal homogeneity test was performed to check if there was a 
significant difference between the observers and none gave systematically 
lower or higher values than the other (P = 0.16).  
In each subtype of carcinomas (except for those named “other carcinomas”) 
score 2 was given to 50-60% of the cases. In solid and tubulopapillary 
carcinomas, score 3 represented 30-40% of the cases, while in complex 
carcinomas only 19% of cases were score 3. In the latter, 29% had score 1 in 
nuclear pleomorphism (Table 2). It is noteworthy that no association was 
detected between nuclear pleomorphism scores and histological subtypes (P = 
0.26).  
Regarding the histological subtype, no significant association with evidence of 
vascular invasion and/or lymph node metastases was detected. However, when 
the tumors where grouped into two histological type categories (solid plus 
anaplastic and tubulopapillary plus complex), it was noticed that the latter 
presented a low risk of vascular invasion and/or lymph node metastases 
comparing to the other category (P = 0.01) (Table 3). 
 
Table 1 – Results and concordance of the nuclear scoring in 89 canine mammary 
carcinomas by two observers. 
 Nuclear grade observer A 
Total 1 2 3 
Nuclear grade 
observer B 
1 8 4 0 12 
2 10 29 9 48 
3 1 6 22 29 








Table 2 – Nuclear grading scores, mean (standard deviation) of volume-weighted 
mean nuclear volume (ν	V) and frequency of vascular invasion and/or lymph node 
metastases in each carcinoma subtype (‘others’ include 1 squamous cell and 2 











In general, the stereological analysis was simple: the PSI method lasted 10 to 
15 minutes per slide. The mean (SD, standard deviation) ν	V was 128 µm3 (64 
µm3) in normal mammary gland, 179 µm3 (31 µm3) in benign tumors and 
291µm3 (75 µm3) in malignant tumors (Fig. 3). In the latter group, the mean 
(SD) ν	V was 267 µm3 (50 µm3), 265 µm3 (50 µm3) and 357 µm3 (92 µm3) in 
tumors with nuclear scores 1, 2 and 3, respectively. Regarding normal 
parenchyma, a wide range of values of ν	V  was obtained (CV = 0.50); the higher 
value was estimated in early diestrous and the lower one in proestrous. The 
mean values of the stereological estimations were significantly different in 
normal parenchyma, benign and malignant tumors (Tukey test, P < 0.001 in all 
comparisons). 
The CE of the estimates was 19% for normal parenchyma, 3% for the benign 
tumors and 3% for the group of malignant tumors. When the latter ones were 
grouped by the nuclear pleomorphism score, the CE was 5%, 7% and 5% for 



















1 2 2 12 0 
2 12 12 22 2 
3 9 7 8 1 
ν	V (µm3) 311(98) 295(82) 282(49) 248(116) 
Invasion / 
metastases 
11 5 7 0 
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Table 3 – Results of the univariable models and the final multivariable model using 
vascular invasion and/or lymph node metastases as the dependent variable in 89 
canine mammary carcinomas.  
Legend: OR – odds ratio; CI – confidence interval; TP – tubulopapillary; ν	V – volume-weighted 
mean nuclear volume; Ref – referent. 
 
Independent variables 
Univariable analysis Multivariable analysis 
OR 95% CI P   OR 95% CI P  
Histological subtype       
All categories: 
      
TP Ref  
 
   
Solid 2.94 0.80 - 10.74 0.103    
Complex 0.64 0.17 - 2.32 0.498    
Others 0 0 - >100 0.991    
Two categories: 
      
Solid and anaplastic Ref  
 
   
TP and complex  0.28 0.10 - 0.77 0.014 0.31 0.09 - 1.07 0.065 
Tumor size        
Continuum (cm)* 1.50 1.21 - 1.87 <0.001 1.63 1.26 - 2.10 <0.001 
WHO categories 
      
< 3 cm Ref      
3 - 5 cm 8.67 2.24 - 33.53 0.002    
> 5 cm 12.43 3.47 - 44.43 <0.001    
Santos et al., 2011 categories 
      
< 3 cm Ref      
≥ 3 cm 9.58 3.20 - 28.72 <0.001    
Nuclear pleomorphism        
Score 3 Ref  
 
   
Score 2 0.42 0.15 - 1.20 0.101    
Score 1 0 >0.001 - 0 0.991    
Two categories 
      
Score 1 and 2 Ref  
 
   
Score 3 3.42 1.26 - 9.29 0.017 2.57 0.76 - 8.63 0.126 




Fig. 3 – Box plot with median, first and third quartile values and the distribution of the 
volume-weighted mean nuclear volume (ν	V) values in normal mammary parenchyma, 
benign and malignant canine mammary tumors. Only slight overlaps existed between 
ν	V values of each group. Outliers are indicated by the different marks.  
 
The ANOVA comparison between nuclear pleomorphism scores and ν	V 
revealed significant differences between score 1 versus 3 (P < 0.001) and 2 
versus 3 (P < 0.001). Tumors scored as 1 and 2 did not differ significantly 
regarding their ν	V. The histogram of ν	V values in malignant tumors showed a 
larger proportion of values around 300 µm3, mainly including tumors with 
nuclear scores 1 and 2; a much smaller peak appeared to exist after 400 µm3, 
corresponding to tumors that scored 3 in nuclear pleomorphism (Fig. 4).  
 







Fig. 4 – Histogram of the volume-
weighted mean nuclear volume (ν	V) 
values of the 89 canine mammary 
carcinomas. The higher peak of the 
values is around 300 µm3. 
 
 
In univariable analysis, the ν	V was not associated with histological evidence of 
vascular invasion and/or lymph node metastases. Therefore, in descriptive ROC 
analyses the discriminating power of the ν	V estimations between malignant 
tumors with and without histological evidence of vascular invasion and/or lymph 
node metastases was very low (AUC statistics 0.55, 95% confidence interval 
0.41–0.70). According to the ROC findings, no optimal cut-off value of nuclear 
ν	V could be defined for differentiating tumors with and without vascular invasion 
and/or lymph node metastases. The ν	V cut-off of 420 µm3 provided 96% 
specificity but only 22% sensitivity. However, when the ν	V values of the tumors 
that progressed (recurred and/or metastasized) were compared to those that 
did not progress during the follow-up, it was noticed that the mean ν	V in the 
former was significantly higher [393 µm3 (74 µm3) versus 270 µm3 (68 µm3); P < 
0.001].  
The nuclear pleomorphism score categories (score 1 plus score 2 versus score 
3) was associated with evidence of vascular invasion and/or lymph node 
metastases (P = 0.02) and with tumor progression during the follow-up (P < 
0.001). In fact, only tumors scored as 2 or 3 showed histological evidence of 
vascular invasion and/or lymph node metastases and progression (in the latter, 
9 out 10 were scored 3, with only one case being nuclear score 2). In 
multivariable analysis, histological type categories and nuclear pleomorphism 
score failed to retain their association with evidence of vascular invasion and/or 
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lymph node metastases. Tumor size was the only factor with statistical 
significance as independent predictor of vascular invasion and/or lymph node 
metastases (Table 3). In the descriptive ROC analysis, the discriminative power 
of tumor size was high (AUC statistics 0.80, range 0.70-0.91) (Fig. 5). According 
to the ROC findings, the optimal cut-off tumor size value that would distinguish 
tumors with and without vascular invasion and/or lymph node metastases at the 














Fig. 5 – Receiver operating curve (ROC) curve for tumor size values in 89 canine 
mammary carcinomas. The area under the curve (AUC) is 0.80 which indicates that 
tumor size has high discriminatory power between tumors with and without evidence of 
vascular invasion and/or lymph node metastases at the time of the diagnosis. An 
optimal cut-off of 2.9 cm with 74% sensitivity and 77% specificity was defined.  
 
Regarding the survival study, the mean DFI (14.2 ± 2.7 months) and OS (15.2 ± 
2.6 months) of the dogs bearing tumors with histological evidence of vascular 
invasion and/or lymph node metastases were significantly shorter than the DFI 
(22.4 ± 0.9 months) and OS (23.2 ± 0.5 months) of the cases without such 
evidence (Fig. 6). The tumors were also grouped by the tumor size cut-off value 
previously determined by the ROC curve in order to perform a survival analysis 
(Fig. 4). Tumors ≥ 2.9 cm in their maximum diameter were associated with 




Fig. 6 – Kaplan-Meier disease-free interval (DFI) and overall survival (OS) curves 
comparing cases with histological evidence of vascular invasion and/or lymph node 
metastases (dashed line) and cases without that evidence (continuous line) in 40 
female dogs presenting a single mammary carcinoma. Vertical marks represent 
censored cases in each group. Histological evidence of vascular invasion and/or lymph 
node metastases was significantly associated with lower DFI and OS (P = 0.004 and P 
= 0.001, respectively). 
 
Fig. 7 – Kaplan-Meier disease-free interval (DFI) and overall survival (OS) plots. 
Tumors were grouped on the basis of optimal cut-off size value determined by ROC 
curve analysis: size < 2.9 cm (continuous line) and size ≥ 2.9 cm (dashed line). Vertical 
marks represent censored cases in each group. Size ≥ 2.9 cm was associated with 
shorter DFI (P = 0.04) and OS (P = 0.02).  
 
2.4 Discussion  
In this study a comprehensive evaluation of the nuclear pleomorphism of CMT 
and its prognostic value was performed. The malignant tumors were divided 
according to the presence or absence of vascular invasion and/or lymph node 
metastases at the time of histological diagnosis, as previously described by 
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Rasotto et al. (2012). This could be viewed as one of the earliest morphological 
signs of tumor aggressive behavior and we propose that its recognition is 
essential for the development of effective post-operative metastatic disease 
prevention strategies, like chemo- or radiotherapy. This assumption was 
supported by the survival analysis of this series, where tumors with histological 
evidence of vascular invasion and/or lymph node metastases had poorer 
survival after surgery, thus corroborating previous studies (Hellmén et al., 1993; 
Sarli et al., 2002; Philibert et al., 2003; Chang et al., 2005).  
The interobserver variability in scoring nuclear pleomorphism using the NHG 
criteria had not, to the best of our knowledge, been previously studied in CMT.  
In some of the most recent reports focusing on the use of the NHG method for 
mammary tumors of dogs, the concordance between the observers was not 
reported (Karayannopoulou et al., 2005; Clemente et al., 2010; Peña et al., 
2013). In this study, there was a modest agreement between the two observers 
regarding nuclear pleomorphism scoring. At a first glance, this fact could be a 
reason for concern since it anticipates a probable low reproducibility of 
histological grading in CMT. As already mentioned, malignant CMT are highly 
heterogeneous tumors and an inherent subjectivity associated with the selection 
of the highly malignant areas is likely to occur (Ladekarl, 1998; Misdorp, 2002; 
Kamaki et al., 2006; Rakha et al., 2010). Moreover, according to our 
stereological findings, tumors with nuclear scores 1 and 2 had objectively 
comparable ν	V. Therefore, a lack of concordance between observers in these 
nuclear scores, as observed in this study, is more prone to occur. It is 
noteworthy in human breast cancer, one study concluded that the ν	V 
estimations were not correlated with the nuclear scores of histological grade 
(Ladekarl, 1995), and other study established that the estimations in grade I and 
grade II were similar (Artacha-Pérula and Roldán-Vilalobos, 1997).   
The stereological assessment of nuclear pleomorphism by the PSI method uses 
a systematic random sampling, which is not only highly efficient but also 
obviates the subjectivity associated with the selection of the apparently more 
aggressive tumor areas (Ladekarl, 1998). To the best of our knowledge, nuclear 
pleomorphism in CMT has never been quantified by unbiased stereological 
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techniques. According to this statistical analysis, malignant tumors presented a 
significant higher nuclear pleomorphism compared to benign tumors.   
The unbiased assessment of nuclear pleomorphism seems not to be related to 
the histological evidence of vascular invasion and/or lymph node metastases in 
malignant CMT. However, ν	V was significantly higher in tumors that recurred 
and/or metastasized during the two years follow-up period. This opens the 
possibility that this parameter may be regarded as a survival predictor, in 
accordance with the human scenario, in which it has been correlated with 
outcome of patients affected by breast carcinoma (Artacha-Pérula and Roldán-
Vilalobos, 1997; Laderkarl, 1998).  
It is consensual that canine mammary neoplasms are morphologically distinct 
from those of women. Yet, the NHG was straightforwardly adapted to the dog, 
taking for granted that the evaluation of the parameters should be the same as 
used in human pathology (Matos et al., 2012), and the three scores of nuclear 
pleomorphism were considered, without any validation studies. It is worth 
mentioning that the present study showed that tumors scored 1 or 2 in nuclear 
pleomorphism presented similar mean nuclear volumes and that there was a 
low interobserver concordance in nuclear score 1 and 2. Moreover, nuclear 
score 3 was associated with a higher probability of vascular invasion and/or 
lymph node metastases, and poor survival. Therefore, only two nuclear grading 
scores appear to exist in malignant CMTs: low grade and high grade, 
corresponding mostly to NHG nuclear scores 1 and 2 and to nuclear score 3, 
respectively.  
There is a general agreement that the tumor size of canine malignant mammary 
tumors has a prognostic significance (Philibert et al., 2003; Chang et al., 2005; 
Sorenmo et al., 2011). Our multivariable analysis results confirmed that tumor 
size represents an independent prognostic factor regarding the capacity of 
tumor vascular invasion and metastasize. Keeping in mind that different tumor 
size categories have been proposed and used (Misdorp, 2002; Santos et al., 
2011; Peña et al., 2013), a ROC curve analysis was performed in order to 
define the tumor size threshold value with the highest sensitivity and specificity 
to predict aggressive tumor behavior. Our results highlighted that tumors with or 
bigger than 2.9 cm in their largest diameter were more associated with vascular 
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system invasion and/or metastases to the regional lymph nodes. The 
established cut-off of 2.9 cm supports that the tumor size categories (under and 
over 3 cm), defined by Sorenmo (2003) and used by Santos et al. (2011), are 
suitable for CMT and should be routinely applied, for better reproducibility of 
future studies. Moreover, it indirectly supports the model proposed by Sorenmo 
et al. (2009) that correlates the development of a malignant phenotype with 
increased tumor size. According to our findings, tumor size does matters and 
clinicians should consider more radical surgical procedures and meticulous 
periodical follow-up evaluations of animals affected by malignant tumors larger 
than 3 cm, with a special regard to the surgical removal of regional lymph 
nodes.  
Unlike tumor size, nuclear pleomorphism was unable to show independent 
prognostic value when included in the multivariable model. This analysis 
obviates possible confounding factors when assessing prognostic factors, 
justifying the fact that some parameters, although related to prognosis in 
univariable analysis, lose their value in multivariable models (Peña et al., 2013; 
Santos et al., 2013). We think that the role of nuclear pleomorphism as a 
prognostic factor deserves to be studied in larger series by multivariable 
survival analysis. 
To the best of our knowledge, this was the first time that a stereological tool was 
used to compare the nuclear pleomorphism in benign and malignant CMT. The 
results pointed to significant differences in the ν	V from either tumor. This finding 
corroborated previous morphometric studies performed in cytological and 
histological preparations, which demonstrated that the nuclear area and 
perimeter were significantly higher in malignant CMT (Simeonov and 
Simeonova, 2006; 2007). We consider that the estimates of ν	V could assist in 
the differential diagnosis of benign and malignant tumors, being particularly 
important for tumors presenting borderline malignancy. As to the normal 
parenchyma, the mean value of ν	V was significantly lower that those from 
tumors, however a high variation during the estrous cycle seemed to occur. The 
value of ν	V of the normal parenchyma during early diestrous was within the 
range of values seen in maligant tumors. Early diestrous mammary parenchyma 
is characterized by profilerative cells, presenting euchromatic and large nuclei, 
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with moderate size variability  this could justify the high values of the ν	V 
estimated
 
in this phase (Santos et al., 2010). Thus, the variation of the ν	V of 
normal parenchyma during
 
the estrous cycle, as an objective estimation of 
nuclear volume variability, deserves attention from future studies. In malignant 
CMT, the seterological estimation of nuclear pleomorphism did not clearly 
discriminated tumors of the 3 different NHG nuclear scores. Some evidence that 
higher tumoral ν	V could predict a poor animal outcome was also provided by 
the present study. However, the analyzed sample with follow-up data, 
particularly the number of cases with tumor related events, was relatively small, 
hampering further statistical analysis (e.g., a ROC curve analysis of the ν	V 
values in tumors that progressed and tumors that did not progressed during the 
follow-up period). In addition, the role of this stereological evaluation of nuclear 
volume in other subtypes of canine mammary malignant tumors, like 
carcinosarcomas, remains to be determined.    
In this study, evidence that the nuclear pleomorphism evaluation in CMT by the 
NHG criteria is highly prone to interobserver variability was provided. As an 
immediate recommendation, the authors propose that this parameter should be 
evaluated simultaneously by, at least, two observers, that should be able to 
produce a consensus nuclear grading score. Meanwhile, prospective studies of 
larger series and rigorous follow-up data are needed to validate the possibility 
that only two nuclear pleomorphism scores should be considered in malignant 
CMT. We hypothesize that the ν	V, as an unbiased stereological that elegantly 
combines the estimation of nuclear size and its variability, can provide an 
objective threshold, allowing the differential diagnosis between benign and 
malignant CMT, as well as the distinction between low and high nuclear grade 
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INTEROBSERVER REPRODUCIBILITY OF HISTOLOGICAL GRADE IN 




















Histological grading of canine mammary carcinomas (CMC) has been 
performed using the human Nottingham histological grade method as basis. 
Evidence exists that the histological grade could be a prognostic factor in CMC; 
however, no data are available concerning interobserver variability in grading. In 
this study we analyzed the interobserver reproducibility between three 
observers when assigning individual parameter scores and grade to 46 CMC. 
The influence of tumor size and vascular invasion and/or lymph node 
metastases on the odds of grading disagreement was also evaluated. The 
mean kappa values were 0.71, 0.51, 0.69 and 0.70 for tubule formation, nuclear 
pleomorphism, mitotic counts and grade, respectively. There was moderate to 
good agreement in scoring parameters and tumor grading, with nuclear 
pleomorphism being the least reproducible. These findings are similar to those 
of human studies. The odds of grading disagreement increased with tumor size, 
but decreased with the presence of vascular invasion and/or lymph node 
metastases. Individual scoring differences were attenuated by reaching a 






The Nottingham histological grade (NHG), the standard method in human 
breast pathology, has been apllied (with or without modification) for grading 
canine mammary carcinomas (CMC) (Karayannopoulou et al., 2005; Peña et 
al., 2013). The NHG is composed of the sum of scores assigned to three 
morphological features (tubule formation, nuclear pleomorphism and mitotic 
count), each taking a value of one to three points (Elston and Ellis, 1991). A 
total score ≤ 5 points, 6-7 points, and 8-9 points denotes grade I, II, III 
carcinomas, respectively (Elston and Ellis, 1991). 
Nowadays, the histological grade is widely used in CMC, but there are no 
studies focusing on the reproducibility of grading. This scenario contrasts 
markedly with human pathology, where the reproducibility of grading methods, 
including the NHG, has been debated for years (Stenkvist et al., 1979; Frierson 
et al., 1995; Robbins et al., 1995; Dalton et al., 2000; Meyer et al., 2005). 
Furthermore, the measurement of interobserver variability in veterinary 
oncology is considered critical to validate prognostic markers (Webster et al., 
2011). 
In human studies, the agreement between observers has been estimated in 
three different ways: percentage of equal judgments, Cohen’s kappa (κ) 
statistics and Spearman correlation coefficient (Stenkvist et al., 1979; Longacre 
et al., 2006). Each of these statistical methods has limitations and pitfalls; 
reporting all three may provide a better reproducibility assessment (Stenkvist et 
al., 1979). The agreement percentage is intrinsically dependent on the number 
and frequency of the classifying categories (Stenkvist et al., 1979). The κ 
statistic implies the assumption that categories have the same width and the so-
called κ paradox may occur, namely when the frequencies of categories are 
clearly unbalanced (Sim and Wright, 2005). In those cases, the proportion of 
agreement may be high but the κ value could be low and an interpretation 
based solely on the κ value would lead to erroneous conclusions (Sim and 
Wright, 2005). Still, some controversy exists regarding the best κ value 
(weighted or unweighted) to be used in breast cancer grade reproducibility 
studies (Chowdhury et al., 2007). The unweighted κ value (κu) considers all 
types of disagreements as equal, independently of their magnitude (Sim and 
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Wright, 2005). In contrast, the weighted κ value (κw) emphasizes large 
differences between ratings in ordinal scales (Sim and Wright, 2005). It should 
be noted that recent guidelines in veterinary oncology recommend the use of κw 
statistics (Webster et al., 2011).  
The aim of this study was to determine the interobserver agreement in grading 
simple CMC and in scoring each grading parameter, using the NHG. 
Additionally, the influence of clinicopathological parameters (tumor size, 
vascular invasion and/or lymph node and tumor progression) on the odds of 
grading disagreement was estimated. 
 
3.2 Material and methods 
3.2.1 Cases and histological analysis 
Pathology archives from the ICBAS, University of Porto were accessed to 
retrospectively select 46 spontaneous simple CMC that had been surgically 
removed. The selection of cases and their histological study were blinded to 
clinical data. For 30 cases follow-up data were collected over two years 
following the protocol detailed in Santos et al. (2013). Owners gave informed 
consent for both surgery and follow-up. 
The histological diagnosis was reviewed by two observers to confirm that all 
cases fulfilled the criteria for simple carcinomas (composed of luminal epithelial 
cells) (Misdorp et al., 1999). For each case, tumor size (i.e., largest diameter) 
and histological evidence of vascular invasion (defined as the presence of 
tumor emboli within endothelial-lined spaces and without distinguishing bteween 
lymphatic and blood vessels) and/or regional lymph node metastases were 
recorded. All the slides resulting from the largest cross section were used for 
grading. Three observers from the same institution (MS, a veterinary pathologist 
with 10 years of experience; PDP, a veterinary pathologist with 15 years of 
experience, both with special interest in canine mammary pathology; and CL, a 
medical pathologist and Professor of human pathology with more than 40 years 
of experience) graded all the tumors independently, using the NHG (Elston and 
Ellis, 1991; Karayannopoulou et al., 2005). Briefly, tubule formation was scored 
as 1, 2 or 3 when more than 75%, 10-75% or less than 10% of neoplastic cells, 
respectively, were arranged in structures exhibiting an obvious lumen. Nuclear 
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pleomorphism was scored as follows: score 1 denoted a slight increase in 
variability of nuclear size and shape, compared to normal surrounding epithelial 
cells; score 2 denoted moderate variation in nuclear size and shape; score 3 
denoted marked variation in nuclear size and shape, with very large and bizarre 
forms. Mitotic figures were counted in 10 high-power fields and scored using the 
cut-offs defined by the field diameter of the microscope (field diameter of 
0.55mm; field area of 0.238 mm2; score 1 ≤ 8 mitotic figures, score 2 = 9-17 
mitotic figures; score 3 ≥ 18 mitotic figures), thus assuring equivalence with 
assessments made by Elston and Ellis (Elston and Ellis, 1998; 
Karayannopoulou et al., 2005). The selection of the high-power field for mitotic 
counts was performed independently by each observer in the most mitotically 
active parts of the tumor (Elston and Ellis, 1991).  
Cases with scoring discrepancies between the veterinary pathologists were 
reviewed using a multi-head microscope, in order to obtain a consensus. The 
consensus grade (observer 1 and 2) and its components were also compared 
with the grade assigned by the medical pathologist (observer 3).  
 
3.2.2 Statistical analysis 
The interobserver variability was measured by estimating the percentage of 
equal assessments. The κu and κw statistics were used to assess the paired 
interobserver agreement for histological grading and for parameter scoring. A 
value of κ greater than 0.8 is considered to indicate almost perfect agreement, 
whereas 0.6 < κ ≤ 0.8 and 0.4 < κ ≤ 0.6 values indicate good and moderate 
agreements, respectively. In contrast, κ < 0.4 is considered a poor agreement 
(Vieira and Garret, 2005). The interobserver variability in total score assigned 
(values 3 to 9) was also estimated as a correlation coefficient (Spearman rank 
correlation coefficient). For these tests a P < 0.05 was considered significant. 
Logistic regression was used to assess the influence of clinicopathological 
parameters on the odds of grading disagreement. For this analysis, a P < 0.1 
was considered significant. All analyses were performed using R free software 






In this series of 46 simple CMC, mean (standard deviation) tumor size was 3.3 
cm (3.1cm). At the time of diagnosis, 33% (15/46) of the tumors showed 
vascular invasion and/or lymph node metastases. During the follow-up period, 
27% (8/30) of dogs developed progression-related events (i.e. recurrences or 
distant metastases). Grade I tumors were relatively uncommon, representing 
11% to 20% of cases depending on the observer (Table 1).  
 
Table 1 – Individual and consensual (observers 1 and 2) grading of 46 canine 








Overall, there was an agreement percentage for tumor grading of 52%. For 
tubule formation, nuclear pleomorphism and mitotic counts the agreement was 
61%, 50% and 54%, respectively. The agreement of the sum of scores was 
24%. The interobserver variability, measured as the percentage of concordance 
and κ values in paired comparisons, is illustrated in Table 2. The tumor grade 
κw varied from 0.59 to 0.80 (mean κw of all pairwise comparisons was 0.70). For 
tubule formation, nuclear pleomorphism and mitotic counts, the mean κw of all 
pairwise comparisons was 0.71, 0.51, and 0.69, respectively. Higher agreement 
values were obtained for some of the paired comparisons: a) consensus and 
observer 3 (medical pathologist) for tubule formation, nuclear pleomorphism 
and mitotic count; and b) observer 2 versus observer 3 for overall tumor grade 
(Table 2). In general, the highest agreement between observers was seen for 
evaluation of tubule formation, closely followed by the mitotic count (Table 2). 
The agreement for nuclear pleomorphism in all pairwise comparisons was 
moderate. In all instances, the Spearman correlation coefficient for the overall 
score was higher than 0.70 (P < 0.001). 
 
 
Obs 1 Obs 2 Consensus    
Obs 1+2 
Obs 3 
Grade 1 5 9 6 8 
Grade 2 20 19 21 17 
Grade 3 21 18 19 21 
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Table 2 – Percentage of concordance and kappa statistics values between observers 
in grading parameters scores and in histological grading. 
 

















































































Legend: brackets meaning 95% confidence intervals; C – percentage of concordance; κu – 
kappa unweighted; κw – kappa weighted; Obs – observer; cons – consensus; TF – tubule 
formation; NP – nuclear pleomorphism; M – mitotic count. 
 
Cases with complete agreement between the three observers for tumor grade 
are illustrated in Fig. 1. When disagreement existed, the pathologists always 
clustered their opinions around two adjacent grades and the difference in score 
of each parameter and the sum of scores were ±1, in the majority of cases. As 
the disagreement usually corresponded to adjacent scores the κw was invariably 







Fig. 1 – Canine mammary simple carcinomas presenting overall grade agreement 
between the three observers. A and B – grade I; C and D – grade II carcinoma; E and 
F – grade III carcinoma. Hematoxylin-eosin. Bar 200 µm (E),100 µm (A, C), 50 µm (B, 
D, F).  
 
The odds of disagreement when scoring parameters increased with tumor size: 
each centimeter increase in diameter accounted for 1.4 times higher odds of 
disagreement (P = 0.065). In contrast, the odds of disagreement decreased by 








were detected at diagnosis (P = 0.08). The level of disagreement was similar in 
tumors with and without progression during the follow-up period.  
 
3.4 Discussion 
In the last decade, NHG has been used to CMC grading; however, its use 
requires adjustment for veterinary pathology (Matos et al. 2012; Mills et al., 
2015). In this first study about grade reproducibility, we focused on simple CMC 
since they are considered most similar to the common forms of human breast 
carcinoma. This subtype of tumors is suitable for comparing grading 
assessment by veterinary and medical pathologists, which was one goal of this 
study. Moreover, as simple carcinomas are associated with a poorer prognosis 
when compared to complex and mixed carcinomas (Misdorp et al., 1999), it is 
critical, in prognostic terms, to be aware of interobserver reproducibility in 
grading this particular tumor subgroup.  
The reproducibility observed in this study (κw = 0.70 for the overall grade) is in 
close agreement with the human scenario (κ
 
of 0.30-0.70) (Meyer et al., 2005; 
Rakha et al., 2010). Furthermore, the higher reproducibility value in scoring 
tubule formation (0.71), followed by mitotic count (0.69) and finally nuclear 
pleomorphism (0.51) is similar to the majority of human breast studies 
(reviewed by Meyer et al., 2005; Rakha et al., 2010). In grading CMC, 
consensus seems to be least common with scoring of nuclear pleomorphism. In 
human literature, various reasons have been proposed to justify this, including 
the qualitative nature of the scoring method and the heterogeneity of the 
nuclear features within a tumor (Meyer et al., 2005; Longacre et al., 2006; 
Adams et al., 2009). Moreover, we recently demonstrated that CMC that scored 
1 and 2 present similar mean volume–weighted nuclear volumes (Santos et al., 
2014). Additionally, the use of the normal surrounding parenchyma as reference 
may jeopardize the reproducibility of nuclear pleomorphism in CMC, since the 
parenchyma often presents variability in nuclear features, depending on the 
estrous cycle stage (Santos et al., 2010).  
The second poorest agreement was seen for mitotic count, probably due to the 
selection of areas for counting mitotic figures (Meyer et al., 2005; Longacre et 
al., 2006). In large tumors, the high number of slides can be an additional bias, 
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which could explain increased odds of grading disagreement with increasing 
size. To decrease bias, some studies in human breast pathology have assigned 
designated counting areas on the slides of each tumor (Tsuda et al., 2000). In 
our study, there was no attempt to guide observers to any particular slide or 
tumor area. Even if this led to some of the interobserver variation, it represents 
more accurately the procedures of pathologists during their routine diagnostic 
activity (Longacre et al., 2006).  
In this study, the Spearman correlation coefficient for the total combined score 
was relatively high, indicating that when an observer attributed a high score to a 
tumor, it was likely that the other observer would also attribute a high score.  
The levels of agreement in grading parameters showed a tendency to increase 
when consensus between two observers was reached. This suggests that 
efforts to obtain a grading consensus are an effective way to compensate for 
potential individual bias in scoring. In human medicine it has been postulated 
that two or three pathologists should suffice to reach a valid consensus (Dalton 
et al., 2000).    
In conclusion, this is the first study addressing interobserver agreement in 
grading CMC, to the authors’ knowledge. The NHG when applied to simple 
CMC presented a level of reproducibility similar to that reported for human 
breast carcinomas. Future intra- and interdepartmental studies with panels of 
observers and different subtypes of CMC are warranted to fully ascertain the 
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The human Nottingham histological grade (NHG) has been adapted to canine 
mammary malignant tumors (CMT). Nottingham prognostic index (NPI) enables 
the identification of more aggressive human breast cancers. The prognostic 
value of each grading parameters and NPI has never been detailed in malignant 
CMT. The aim of the present study was to assess the prognostic value of NHG, 
its parameters and NPI. Univariable and multivariable analysis were used to 
assess the prognostic value of NHG, its parameters and the NPI adapted to 
malignant CMT in a cohort of fifty nine dogs. Short disease-free interval and 
overall survival were associated with higher NHG, particularly grade III. Only 
nuclear pleomorphism was significantly associated with survival. Veterinary-
adapted NPI exhibited a strong predictive value for disease progression. NHG, 
nuclear pleomorphism and the veterinary-adapted NPI have prognostic value in 
CMT. Nuclear pleomorphism is an independent prognostic factor. Nuclear 







Although the body of evidence in biological markers of canine mammary tumors 
has increased tremendously in the last few years, the individual prognosis and 
clinical management of female dogs affected by the disease are still challenging 
topics, emphasizing both the need for an in-depth evaluation on the existing 
prognostic factors and the search for new ones (Matos et al., 2012). 
In the last decade, the human Nottingham histological grade (NHG) has been 
applied (with or without modifications) to malignant canine mammary tumors 
(CMT) (Karayannopoulou et al., 2005; Gama et al., 2010; Clemente et al., 2010; 
Peña et al., 2013, Santos et al., 2013; Im et al., 2014; Mainenti et al., 2014). 
NHG is based in the assessment of three morphological parameters: tubule 
formation, nuclear pleomorphism and mitotic counts (Elston and Ellis, 1998). 
Each parameter of the NHG is scored 1 to 3 and the total combined score 
defines the grade (Fig. 1). Both tubule formation and mitotic counts are 
evaluated semi-quantitatively using thresholds, but nuclear pleomorphism, 
classified according to the size of the nuclei and their variability, is scored in a 
much more subjective way (Elston and Ellis, 1998; Meyer et al., 2005).  
Despite two recent studies demonstrated that the NHG with modfications 
provided independent prognostic information (Peña et al., 2013; Mainenti et al., 
2014), others only detected an association with survival when grades have 
been grouped  e.g., grade I plus grade II versus grade III (Karayannopoulou 
et al., 2005; Santos et al., 2013)  thus raising the issue of the validity of a 
three-tier classification for malignant CMT grading. Moreover, the individual 
prognostic value of each of the NHG parameters has never been detailed in 
malignant CMT, to the author’s knowledge. 
In fact, it has been stressed that in order to be universally accepted in malignant 
CMT, the prognostic legitimacy of a grading method must be validated in 
various prospective cohorts (Goldschmidt et al., 2011; Matos et al., 2012).  
In human pathology, the NHG is highly correlated to survival and has been 
included in a prognostic index, called the Nottingham Prognostic Index, NPI 
(Blamey, 1996; Lee and Ellis, 2008). This Index allows a stratification of breast 
cancer patients (Rampaul et al., 2001), and incorporates three independent 
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prognostic factors: tumor size, lymph node stage and histological grade 
(Haybittle et al., 1982; Blamey, 1996).  
The tumor size corresponds to the largest diameter, determined by the 
pathologist during the macroscopic examination of fresh specimens or the 
microscopic examination of very small invasive carcinomas (Elston et al., 1999). 
In veterinary medicine, the tumor size, also defined as the largest diameter 
determined either by the clinician or by the pathologist, has been integrated in 
the World Health Organization (WHO) staging of malignant CMT (Peña et al., 
1998; Rutteman et al., 2001; de las Mulas et al., 2005) and there is a general 
agreement that it has prognostic significance (Ferreira et al., 2009; Sorenmo et 
al., 2011). 
The lymph node staging in human breast cancer patients is also a three-tier 
system, depending on the number of metastatic lymph nodes and their location 
(Lee and Ellis, 2008). In veterinary medicine, the presence of regional lymph 
node metastases is also relevant for disease staging, but the number of positive 
nodes is disregarded (Rutteman et al., 2001). Other differences reside in the 
diagnostic imaging of regional lymph nodes and the sentinel lymph node 
examination, which are routinely assessed in women but not routinely 
performed in veterinary medicine (Webster et al., 2011). In dogs, the 
recommended procedures depend on the anatomical location of the primary 
tumor. In all cases, regional lymph nodes should be carefully evaluated during 
the pre-surgical physical examination (Sorenmo et al., 2011); for axillary nodes, 
a cytological evaluation is advised when enlarged and surgery should be 
performed when metastatic disease cannot be excluded (Misdorp, 2002). In 
contrast, the superficial inguinal nodes are usually dissected during the gross 
examination of all the regional caudal or radical unilateral mastectomy 
specimens and routinely submitted for histological examination (Misdorp, 2002; 
Sleeckx et al., 2011; Sorenmo et al., 2011). Several authors have confirmed 
that the histological evidence of metastases in regional lymph nodes at the time 
of diagnosis is a significant prognostic factor (Hellmen et al., 1993; Yamagami 
et al., 1996; Chang et al., 2005). 
The presence of vascular invasion has been also considered as an evidence of 
the metastatic potential of malignant CMT (Rasotto et al., 2012). In human 
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breast cancer, vascular permeation closely correlates with the regional lymph 
node involvement and local recurrence (Elston et al., 1999). According to some 
authors, vascular invasion may be a valuable surrogate for the lymph node 
stage, when nodes were not removed, while others have stressed that vascular 
invasion adds prognostic information to histological grade and tumor size in 
women with node negative breast carcinoma (Elston et al., 1999; Lee et al., 
2006). In malignant CMT, the presence of neoplastic emboli in vessels also has 
an independent role in survival (Sarli et al., 2002), and recently it was reported 
that vascular invasion (associated or not with regional lymph node metastases) 
was associated with short survival times (Santos et al., 2014). Therefore, it is 
reasonable to assume that the assessment of vascular/lymph node invasion at 
the time of diagnosis may be a valuable estimator of the tumor metastatic 
capacity (Rasotto et al., 2012; Rasotto et al., 2014; Santos et al., 2014). 
Whilst no study has ever reported a prognostic index in malignant CMT, it has 
been suggested that a combination of factors could strengthen the prognostic 
information (Peña et al., 1998; Sarli et al., 2002). Moreover, a comprehensive 
evaluation of the individual prognostic value of each NHG grading parameter in 
CMT has never been performed, as far as we know. Therefore, in this study we 
aimed to: 1) evaluate the prognostic value of NHG in a cohort of female dogs 
with malignant CMT; 2) analyze each of the three grading parameters regarding 
their individual prognostic impact; and 3) compute an adaptation of NPI and 
assess its sensitivity and specificity to predict post-surgical disease progression 
in malignant CMT. 
 
4.2 Material and methods 
4.2.1 Selection of cases, histological analysis and follow-up 
A cohort of fifty nine female dogs with spontaneous malignant CMT treated at 
ICBAS-University of Porto was retrospectively selected. Dogs included in this 
study underwent surgery as the only treatment. Owners provided consents for 
surgery with curative intents and 2 years follow-up, as well as for the use of the 
material for research purposes. Of these female dogs, forty nine were selected 
based on the presence of a single malignant tumor (Matos et al., 2012). In the 
subgroup of 10 dogs with multiple malignant tumors, a reference lesion was 
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assigned in accordance to published approaches for synchronous breast 
cancers and CMT (Beckmann et al., 2011; Santos et al., 2011; Schmid et al., 
2011; Santos et al., 2013). In brief, the reference lesion was considered as the 
tumor presenting vascular invasion (primary criterion) or the one with largest 
diameter (secondary criterion). The selection of cases and their histological 
study were blinded to survival outcomes, thus following the recent guidelines in 
veterinary oncology (Webster et al., 2011). Dogs with distant metastases at the 
time of the diagnosis were excluded.  
The histological diagnosis was reviewed by two pathologists (MS and PDP) 
using the criteria of the WHO classification (Misdorp et al., 1999). For each 
case, the tumor size and the histological evidence of vascular invasion (defined 
as the presence of tumor emboli within endothelial-lined spaces irrespective of 
the type and number of invaded vessels) and/or regional lymph node 
metastases [lymph nodes were evaluated in routine slides and after 
immunolabelling with pancytokeratin AE1/AE3 and cytokeratin 14, as previously 
described by Matos et al. (2006a)] at the time of diagnosis were recorded. The 
tumor size was categorized according to WHO criteria (T1 < 3 cm, T2 3-5 cm 
and T3 > 5 cm) and to a previous defined cut-off (< 2.9 cm and ≥ 2.9 cm) 
(Santos et al., 2014). The NHG (Fig. 1) was performed by 2 pathologists and, 
when discrepancies occurred on a particular parameter, a consensus was 
reached. Only epithelial cells were considered for NHG.  
NPI was adapted from (Haybittle et al., 1982), and computed as: NPI = [tumor 
size (cm) x 0.2] + NHG (1, 2 or 3 respectively for I, II and III grades) + evidence 
of vascular invasion and/or regional lymph node metastases (1 or 2, 





Fig. 1 – Nottingham histological grade method: criteria for scoring each grading 
parameter (adapted from Elston and Ellis, 1998). *cells similar to normal surrounding 
parenchyma; ** counted in 10 high power fields (400x), field diameter of the 
microscope = 0.55 mm. 
 
The schedule and the protocol of clinical evaluations before the surgery and 
during the follow-up period were performed as previously described (Santos et 
al., 2013). The disease-free interval (DFI) was calculated from the date of 
surgery to the diagnosis of disease progression (recurrence or metastasis, with 
cytological or histological confirmation). Overall survival (OS) was calculated 
from the date of surgery to the date of animal death/euthanasia due to 
metastasis. Animals that died or were euthanized for unrelated causes and 
those that were lost to follow-up were censored, respectively, at the time of 
death and at the data of their last follow-up examination. Complete necropsies 
were performed, after the owner consent, in all the dogs that died 
spontaneously or were euthanized, and suspected metastatic lesions were 
confirmed by histopathological examination.   
 
4.2.2 Statistical analysis 
The association between histological subtypes and grade was assessed using 
the Fisher test. Disease-specific survivals were determined using Kaplan-Meier 
product-limit estimates, with log-rank (Mantel-Cox) tests used to estimate 
differences in survival fractions according to the NHG (I, II and III) and the score 
of each grading parameter (1, 2 and 3). A similar approach was performed 
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considering the final combined grading scores (3 to 9), used to categorize 
tumors of low grade (final score ≤ 6) and of high grade (final score ≥ 7). 
Regarding mitotic score, we also considered tertile values (or 3-quantiles, i.e., 
the two thresholds that divide the ordered distribution of mitotic counts values 
into three parts) as alternative cut-offs [i.e., scores 1, 2 and 3, respectively for < 
11, 11-23 and > 23 mitotic figures per 10 high-power field (each field with a 
diameter of 0.55 mm)]. Receiver operating characteristic (ROC) curves were 
used to assess the sensitivity and specificity of the veterinary-adapted NPI for 
predicting tumor progression at 12 months post-surgery. Optimal cut-off was 
defined according to the maximization of sensitivity and specificity. Using the 
optimal cut-off, Kaplan-Meier curves were generated and compared using the 
Log-rank test. Cox hazard’s regression model was used to evaluate the 
independent prognostic role of various pathological factors in a multivariable 
analysis. As vascular invasion, tumor size and NHG were components of 
veterinary-adapted NPI, when this index was included in the multivariable 
analysis their components were excluded from the model, in order to avoid 
colinearity. 
In all cases, a P value < 0.05 was considered significant. Statistical analyses 
were performed with R Development Core Team software, version 2.7.1 
(Vienna, Austria) and IBM SPSS Statistics, version 22 (IBM, New York, USA). 
 
4.3 Results 
Fifty nine female dogs aged from 6 to 18 years (mean of 10.9 years) were 
included. Of these, 38 animals presented simple carcinomas (18 
tubulopapillary, 17 solid, 1 anaplastic, 1 squamous cell and 1 mucinous 
carcinoma), 18 had complex carcinomas and 3 had carcinosarcomas. The 
largest diameter of the tumors ranged from 0.5 to 15 cm, being equal or larger 
than 2.9 cm in 26 cases (44%). According to the WHO tumor size system, 35 
were T1, 11 were T2 and 13 were T3. At the time of diagnosis, 17 cases (29%) 
presented vascular/regional lymph node invasion. Post-surgical progression 
was diagnosed in 17 cases (in 14 out 17 the diagnosis of recurrence and/or 
metastases occurred within the first 12 months of the follow-up period). Tumors 
that progressed included different histological subtypes: 7 solid carcinomas, 5 
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complex, 3 tubulopapillary, 1 anaplastic and 1 carcinosarcoma. During the 
follow-up, 14 dogs (24%) died or were euthanized due to progressive disease, 
29 (49%) were alive and free of disease 24 months after the surgery, whilst 16 
dogs (27%) were censored before the end of the follow-up period, being lost to 
follow-up or died from non-malignancy-related causes (in these, the median 
follow-up time was 13 months).  
Animals older than 10.9 years (median age in this series) had increased risk for 
developing recurrence and metastases (P = 0.01). The WHO category of 
tumors T1 < 3 cm was associated with better survival times, but no significant 
difference seemed to exist between the two other size categories regarding DFI 
(Fig. 2).  
 
Fig. 2 – Kaplan-Meier curves of disease-free interval (DFI) and overall survival (OS) of 
cases included in each WHO tumor size category. Female dogs with tumor largest 
diameter < 3 cm had better survival outcomes but no statistical difference seemed to 
exist between the other two categories regarding DFI (log-rank test, P = 0.03 for DFI 
and P = 0.04 for OS). Censoring is indicated by vertical marks. 
 
The cut-off 2.9 cm allowed a stratification of tumors with significant differences 
in survival: size < 2.9 cm had 21 and 22 months of DFI and OS, respectively, 
whereas size ≥ 2.9 cm had 15 and 18 months of DFI and OS (P = 0.009 for DFI 
and P = 0.02 for OS) (Fig. 3). The evidence of vascular invasion and/or regional 
lymph node metastases at the time of diagnosis was associated with shorter 
DFI and OS (P < 0.0001). 
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Regarding the NHG, 14 (24%) tumors were grade I, 22 (37 %) grade II and 23 
(39%) were grade III. A final combined score ≤ 6 (considered as low grade 
tumors) was computed in 22 cases (38%) whilst 37 (62%) cases had a 
combined score ≥ 7 (considered as high grade tumors). The distribution of 
grades in each histological subtype and the scores of NHG parameters are 
presented in Table 1 and 2, respectively. An association between the 
histological subtypes and grade was observed (P = 0.01). Notably, all the solid 
carcinomas and carcinosarcomas were graded II and III. However, no 
significant association existed between histological subtypes and survival, even 
when the simple carcinomas were compared with all the other groups together. 
 
Fig. 3 – Kaplan-Meier plots comparing the disease-free interval (DFI) and overall 
survival (OS) according to tumor largest diameter. Cases with ≥ 2.9 cm were 
associated with poor survival (log-rank test, P = 0.009 for DFI and P = 0.02 for OS). 
















Total I II III 
 TP 6 9 3 18 
Solid  0 4 13 17 
Complex 8 5 5 18 
Carcinosarcoma  0 2 1 3 
Others* 0 2 1 3 
Total 14 22 23 59 
*anaplastic (1), squamous cell (1) and 1 mucinous carcinoma (1) 
 
DFI and OS were significantly related to NHG (P = 0.002 and P = 0.02, 
respectively) (Fig. 4). The mean DFI in grades I, II and III was 23, 21 and 14 
months, respectively, whereas their mean OS was 24, 21 and 17 months. When 
evaluating the DFI, the prognosis strength of a two-tier classification (high and 
low grades determined by the final score) was slightly lower (P = 0.04) than that 
of the original three-tier system of NHG (P = 0.001), and that classification was 
not significantly associated with OS (P = 0.1). When cases graded I and II were 
grouped and compared with those of grade III, the former presented 
significantly longer DFI (P < 0.0001) and OS (P = 0.008) (Fig. 5).  
 
Table 2 – Scoring (and % of distribution) of the each grading parameter of the 
Nottingham histological grading method in 59 malignant canine mammary tumors. 
 Score 
Parameter 1 2 3 
Tubule formation  11 (19%) 29 (49%) 19 (32%) 
Nuclear pleomorphism 5 (9%) 32 (54%) 22 (37%) 




Fig. 4 – Disease-free interval (DFI) and overall survival (OS) of female dogs with grade  
I, grade II and grade III mammary malignant tumors. Significant differences existed 
between the three curves (log-rank test, P = 0.002 for DFI and P = 0.02 for OS). 




Fig. 5 – Kaplan-Meier analyses of disease-free interval (DFI) and overall survival (OS) 
among 59 female dogs with malignant mammary tumors. Animals with tumors graded I 
or II had a significant longer DFI and OS when compared with animals with tumors 
graded III, according to Nottingham histological grading method (log-rank test, P < 
0.0001 for DFI and P = 0.008 for OS). Censoring is indicated by vertical marks. 
 
Among the NHG components, nuclear pleomorphism emerged as a statistical 
significant predictor of the outcome, with longer OS (P = 0.001) and DFI (P < 
0.0001) in animals bearing tumors with nuclear pleomorphism scores of 1 or 2, 
as opposed to score 3 (Fig. 6). Tubule formation and mitotic counts had no 
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prognostic significance, even when scores 1 and 2 were grouped and compared 
to score 3 or when score 1 was compared to scores 2 plus 3. No association 
with outcome was observed when tumors were scored according to the tertile 
values of the mitotic counts.  
 
Fig. 6 – Disease-free interval (DFI) and overall survival (OS) curves of female dogs 
with tumors scored 1 or 2 in nuclear pleomorphism compared to female dogs with 
tumors scored 3 in this parameter. Nuclear pleomorphism was significantly associated 
with survival (log-rank test, P < 0.0001 for DFI and P = 0.001). Censoring is indicated 
by vertical marks. 
 
The mean veterinary-adapted NPI was 4.2 ± 1.4, ranging from 2.1 to 7. 
According to the ROC curve results, the performance of this index to identify 
tumors progressing in the first 12 months post-surgery was moderately accurate 
as the area under the ROC curve (AUC) was 0.80 (95% CI: 0.68 - 0.92) (Fig. 7) 
(Greiner et al., 2000). An optimal veterinary-adapted NPI cut-off value of 4.25 
was defined based on the maximal pair of sensitivity and specificity values 
(sensitivity of 88% and specificity of 67%). High cut-off levels were associated 
with high specificity, with an obvious decrease of sensitivity (for instance, a 
veterinary-adapted NPI cut-off of 5.3 was associated with 91% specificity and 
47% sensitivity). In order to perform a survival analysis, cases were grouped by 
the previously determined veterinary-adapted NPI cut-off value. Cases with a 
veterinary-adapted NPI ≥ 4.25 were associated with poorer outcome (Fig. 8).  
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Taking DFI and OS as dependent variables and selecting a set of independent 
pathological variables including tumor size (either defined as a continuous 
variable or with categories defined by the 2.9 cm cut-off), vascular invasion, 
nuclear pleomorphism (score 1 plus 2 versus score 3), and NHG (I plus II 
versus III)  the multivariable Cox hazard’s regression selected two 
independent covariates, in decreased order of significance: 1) nuclear 
pleomorphism (P < 0.0001 for DFS and P = 0.002 for OS; 2) vascular invasion 
(P = 0.01 for DFS and P = 0.03 for OS). When veterinary-adapted NPI and 
nuclear pleomorphism were used as covariates on the Cox regression model, 














Fig. 7 – Receiver operating characteristic (ROC) curve for tumor progression in 59 
female dogs based on the veterinary-adapted Nottingham prognostic index (NPI). The 
NPI had good discriminative power between tumors that progressed within the first 12 




Fig. 8 – Kaplan-Meier plots of disease-free interval (DFI) and overall survival (OS) 
among 59 female dogs with malignant mammary tumors grouped by the veterinary-
adapted NPI cut-off. NPI ≥ 4.25 was associated with poor survival outcomes (log-rank 




When examining a malignant CMT, the pathologist is expected to provide 
relevant information with prognostic significance. This goal could be achieved 
by tumor grading, since it is known for long that the microscopic appearance of 
tumors and their biological behavior are associated (Greenough, 1925; Elston et 
al., 1999). In the latest years, the NHG (with or without modifications) has been 
applied for malignant CMT grading by several investigators (Karayannopoulou 
et al., 2005, Matos et al., 2006, Clemente et al., 2010, Gama et al., 2010, 
Santos et al., 2011, Rasotto et al., 2012, Manuali et al., 2012, Guimarães et al., 
2014, Im et al., 2014, Mainenti et al., 2014), but data regarding its prognostic 
value is still relatively limited, namely when comparing to the data in human 
breast cancer.  
This study analyzed the relation between the NHG and survival in a cohort of 
animals with malignant CMT and, to the best of our knowledge this is the first 
study where the association between survival and each parameter of the NHG 
was systematically assessed. In our cohort, a high proportion of tumors were 
graded II and III, which is in line with previous studies (Gama et al., 2010; 
Santos et al., 2013). In contrast, other survival studies had a higher proportion 
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of grade I tumors (Karayannopoulou et al., 2005; Peña et al., 2013; Mainenti et 
al., 2014). Since the selection of cases was completely blinded to histological 
features and follow-up data, it is likely that the high proportion of grades II and 
III tumors represents an intrinsic feature of this cohort. At the same time, it 
should be stressed that in our cohort there was an overrepresentation of female 
dogs with a single malignant CMT and, eventually, this could represent a bias of 
selection. This should not affect our results, because solitary and multiple 
tumors have no significant differences in survival (Hellmén et al., 1993; Philibert 
et al., 2003). In fact, the prevalence of tumor progression (29%) and cancer-
associated death (24%) observed in our study are within the published range of 
values (Hellmén et al., 1993; Karayannopoulou et al., 2005; Sassi et al., 2010; 
Peña et al., 2013). 
Herein, the histological type and NHG were significantly associated, 
corroborating previous studies (Karayannopoulou et al., 2005; Peña et al., 
2013; Im et al., 2014). Such association has been justified with the evaluation of 
tubule formation that is typically scored 3 in solid carcinomas  a histological 
type often associated with a worse prognosis (Peña et al., 2013).  
Regarding the NHG, it was associated with disease progression and cancer-
related death, especially when grade I and II tumors were compared to grade 
III; this is also in line with previous findings (Karayannopoulou et al., 2005; 
Santos et al., 2013). However, in this study we assessed for the first time the 
role of each NHG parameter. In this regard, only nuclear pleomorphism stood 
as relevant, with a significant differences in survival between animals bearing 
tumors scored 1 plus 2 and those affected by score 3. Notably, the multivariable 
survival analysis also highlighted the nuclear pleomorphism as an independent 
prognostic factor, in detriment of NHG. This suggested that only two scores of 
nuclear pleomorphism should be considered for an accurate prognostic 
assessment of malignant CMT. The use of a two-tier system for classifying 
nuclear pleomorphism could also solve the modest interobserver agreement 
associated with the use of NHG three scores criteria (Santos et al., 2014). Our 
results also suggested that tubule formation and/or mitotic counts may dilute 
rather than strengthen the prognostic value of the NHG. The absent relation 
between mitotic counts and patient outcomes corroborates previous findings 
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(Sarli et al., 2002; Santos et al., 2013), although it seems to contradict other 
reports, where higher proliferative activities have been associated with poorer 
outcomes (Peña et al., 1998; Nieto et al., 2000; Sarli et al., 2002; Matos et al., 
2006b). However, the latter studies used immunohistochemistry techniques for 
the detection of proliferating markers (e.g., Ki-67 and PCNA) rather than mitotic 
counts. In routinely stained slides it may be difficult to identify mitotic figures, 
particularly in tumors with high apoptotic activity or in those with large areas of 
necrotic tissue (Ladekarl, 1998; Meyer et al., 2005). Furthermore, the mitotic 
count of the NHG is largely dependent on the sampling strategy (selection of 
high power fields by the observer) and the cellularity of the tumor (Ladekarl, 
1998). Considering that the distribution of the mitotic count scores was skewed 
(half of the cases were score 3), we also analyzed this feature with tertiles 
boundaries  following an approach previously used in human and veterinary 
pathology (Frkovis-Grazio and Bracko, 2002; Mills et al., 2015). Nevertheless, 
such analysis also failed to improve the separation of survival plots obtained 
with the original thresholds of NHG. 
Tubule formation is closely related with the differentiation of epithelial cells 
(Misdorp, 2002) and with the histological diagnosis (Peña et al., 2013). To the 
best of our knowledge, no other study ever assessed the association between 
tubule formation and prognosis in malignant CMT. In the veterinary literature, 
only a recent study devoted to feline mammary carcinomas reported a weak 
association between tubule formation and survival (Mills et al., 2015).  
In this cohort of dogs we also assessed the NPI  to the best of our knowledge 
this is the first report of its use in malignant CMT. Notably, this index when 
adapted to malignant CMT exhibited a strong discriminative power for 
identifying cases which progress in the first 12 months after surgery. Therefore, 
it seems to be useful for malignant CMT, and it could also be included in the 
pathologist report. In our case, we introduced some modifications to the original 
NPI: considering that vascular invasion was as an independent prognostic 
factor in our cohort, we surrogated the lymph node stage from the original 
formula, by the histological evidence of vascular invasion and/or regional lymph 
metastases; all the remaining items of veterinary-adapted NPI (size and NHG) 
were maintained. It should be noted that the influence of tumor size on survival 
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is well acknowledged (Sorenmo et al., 2011). Even if we showed the utility of a 
veterinary-adapted NPI, we anticipate that further modifications to the NPI could 
be introduced. According to our multivariable analysis, the inclusion of nuclear 
pleomorphism could increase its prognostic value. At this point, we already 
highlighted the value of this index, but a formula more fitted to malignant CMT 
must be validated, and perhaps upgraded by larger prospective studies.  
In conclusion, this study demonstrated that the NHG is associated with survival 
outcomes in malignant CMT. Regarding its components, nuclear pleomorphism 
was the only parameter associated with survival, retaining its prognostic 
significance in multivariable analysis. We also showed that a veterinary-adapted 
NPI provided valuable data for the prediction of post-surgical disease 
progression. It is suggested that nuclear pleomorphism should be classified as 
two-tier system and its score should be included in routine pathological reports. 
Efforts would be helpful to further validate the use of veterinary-adapted NPI (or 
other similar prognostic indices) in malignant CMT, so that adjuvant therapies 
could be assigned to properly selected cases, similar to the current standards in 
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STEREOLOGICAL ESTIMATION OF A CELLULARITY-RELATED 















Grading of canine mammary carcinomas (CMC) is associated with subjective 
assessments made by the pathologists. Due to its unbiased nature, stereology 
can be used to objectively quantify morphological parameters associated with 
grading and malignancy. However, the use of stereology in CMC has not been 
fully disclosed. The nuclear numerical density [NV (nuclei, tumor)] is a cellularity-
associated parameter that can be estimated by the optical disector. Herein, it 
was estimated in 44 CMC and its association with clinicopathologic factors — 
such as tumor size, histological subtype and grade, vascular/lymph node 
invasion, nuclear pleomorphism and survival — was evaluated. Considering all 
the cases, the mean NV (nuclei, tumor) was 1.6x106 ± 0.5x106 nuclei mm-3. 
Lower values were attained in complex carcinomas, comparing to simple 
carcinomas, in tumors smaller than 5 cm, with low mitotic activity and in those 
with high nuclear pleomorphism. No statistically significant association with 
grade or vascular/lymph node invasion was observed, but tumors with disease 
progression had lower nuclear numerical densities. The NV (nuclei, tumor) and 
the correlated parameters fairly mirror those in human breast cancer, 
suggesting an interesting interspecies agreement. This first estimation of the 
nuclear numerical density in CMC highlights the feasibility of the optical disector 
and their utility for objective morphological assessments in CMC. The 
association between nuclear numerical density and disease progression 































5.1. Introduction  
The level of knowledge in canine mammary carcinomas (CMC) has increased 
considerably in recent years, with breakthroughs in prognosis assessment. 
Several putative prognostic factors have been pointed (Sleeckx et al., 2011), 
but it is still recognized that the definition of prognosis in CMC is difficult due to 
the marked clinical as well as morphological heterogeneity (Matos et al., 2012). 
The emphasis on highly sophisticated techniques in oncology and in the so-
called omics has led to an overlooking of tumor morphology, at least to some 
extent (Pinder et al., 1995). Still, it is consensual that the histopathological 
assessment of tumor features is somehow subjective and this can jeopardize 
the biological conclusions, namely in terms of prognosis, which can be retrieved 
from the study of CMC (Sørensen, 1992). Such subjectivity may be overcome 
by quantitative morphological parameters assessed by suitable morphometrical 
or stereological methods (Marcos et al., 2012). These methods are substantially 
different: while morphometry describes quantitatively what is seen in 
conventional sections [at the microscope or in two-dimensional (2D) images], 
using a caliper and sometimes benefiting from image-analysis software, 
stereology uses probes or test-systems in 2D images or virtual optical z-planes, 
aiming to obtain the three-dimensional (3D) information inherent of all biological 
tissues (Geuna, 2005; Marcos et al., 2012). Stereology can be used in 
histological sections of tumors, allowing objective and unbiased estimates (in 
relation to the 3D reality) of many parameters, such as absolute or relative 
volumes of the cells or their nuclei and numerical nuclear densities (Sørensen, 
1992; Ladekarl, 1998).   
Stereological studies have been performed in human breast cancer and 
estimates of nuclear volumes (volume and number-weighted mean nuclear 
volumes) and of numerical density (NV) of nuclei and mitotic figures have been 
correlated with prognosis (Sørensen, 1992; Ladekarl and Sørensen, 1993a; 
Artacho-Pérula and Roldán-Villalobos, 1997; Ladekarl, 1998). In CMC, the use 
of stereology is still very incipient (Casteleyn et al., 2014), but it already started 
to solve issues related with the subjective assessment of nuclear pleomorphism 
in grading of CMC (Santos et al., 2014). 
The relative proportion of neoplastic glandular structures, the so-called tubule 
formation is one parameter of the NHG, being scored 1, 2 or 3, respectively, 
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when more than 75, 10-75% or less than 10% of neoplastic cells are arranged 
in ductal structures, with an obvious lumen (Elston and Ellis, 1991). It has been 
suggested that highly cellular CMC, i.e., solid subtypes, are associated with a 
poorer prognosis comparing with tubulopapillary tumors (Misdorp, 2002; 
Sorenmo, 2003). However, cellularity assessed by pathologists tends to be 
purely qualitative (high versus low) and may be highly subjective. To the best of 
our knowledge, a quantitative evaluation of a cellularity parameter, such as the 
NV, has never been performed in CMC. Such an evaluation can be performed 
by the optical disector (Sterio, 1984; Geuna, 2005). Instead of counting nuclear 
cell profiles, which not only depend on the cell number but also on the size, 
shape, and spatial orientation and distribution of nuclei, the disector uses a 3D 
counting cube with inclusion and exclusion sides that allows counting nuclei in 
proportion to their real number (Marcos et al., 2012; Gundersen et al., 2013).  
The primary aims of this study were to estimate the NV (nuclei, tumor) in CMC 
and their relation with other clinicopathological parameters, namely tumor size, 
histological diagnosis, vascular/lymph node invasion and Nottingham 
histological grade (NHG) parameters (i.e., tubule formation, nuclear 
pleomorphism and mitotic count). Ultimately we intended to evaluate the 
prognostic utility of the NV (nuclei, tumor) in CMC.  
 
5.2 Material and methods 
5.2.1 Selection of cases and histological analysis  
Forty four spontaneous CMC treated at veterinary clinics of ICBAS-University of 
Porto were retrospectively selected, blinded to clinical and other pathological 
data. The animals were submitted to surgical resection of the tumors with the 
owner’s consent. Follow-up data were collected over two years following the 
protocol detailed in Santos et al. (2013) was available for twenty seven cases. 
The histological diagnosis and grading was reviewed by two pathologists (MS 
and PDP) using the criteria of the World Health Organization classification 
(Misdorp et al., 1999) and the NHG (Elston and Ellis, 1991). For this, routine 4-5 
µm thick sections resulting from the largest cross slab of the tumor (slab with on 
average 0.5 cm in thickness) were retrieved and screened. For every case, the 
tumor size and the histological evidence of vascular invasion and/or regional 
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lymph node metastases [lymph nodes were evaluated in routine slides and after 
immunolabelling with pancytokeratin AE1/AE3 and cytokeratin 14, as previously 
described by Matos et al. (2006)] were recorded. As to tumor size, it was 
categorized according to WHO criteria (T1< 3 cm, T2 = 3-5 cm and T3 > 5 cm). 
 
5.2.2 Sectioning and stereological analysis 
Of every case, a thick section (30 µm thick) from all the paraffin blocks was 
obtained. To avoid chatter, the surface of the paraffin block was warmed (by 
breathing on) immediately before cutting each section. After being picked from 
the water-bath, the sections were covered with a cotton cloth and gently 
pressed against the slide with a finger, for ensuring adhesion. The sections 
were mounted on precleaned slides primed with aminopropyltriethoxy-silane. 
Finally, sections were dried overnight at 37°C and then stained with 
hematoxylin-eosin.  
For the stereological analysis we used a workstation comprising: 1) a 
microscope (Olympus BX-50, Japan) equipped with a 100x oil-immersion lens 
(Olympus Uplan NA = 1.35) and a matching condenser; 2) a microcator 
(Heidenhain MT-12, Traumrent, Germany), to control the movements and 
position in the Z-direction (0.5 µm accuracy); 3) a motorized stage (Prior, United 
Kingdom) for stepwise displacement in the x–y directions (1 µm accuracy); 4) a 
CCD video camera (Sony, Tokyo, Japan) connected to a 17′′ PC monitor 
(Sony); and 5) a computer with a stereology software (CAST-Grid, version 1.5, 
Olympus, Denmark). At the monitor, a final magnification of 4750x allowed an 
accurate recognition of the nuclei of the neoplastic cells. The first field of vision 
was randomly selected by the software. Thereafter, fields were sampled 
systematically by stepwise movements of the stage in the x- and y-directions, 
so that a minimum of 40 fields were examined per tumor. Throughout the 
disector height — 16 µm, i.e., Z-distance used for counting within the 30 µm 
thick section — a software generated counting frame was superimposed, 
having a defined area of 253 µm2 and inclusion and forbidden lines (Fig. 1), to 
prevent the edge effect counting biases (Gundersen, 1977).  
Nuclei were counted when two conditions were met: (1) at the plane of focus, 
they were within the counting frame or touching the inclusion lines and not 
touching the forbidden lines or their extensions; (2) the rim of the nucleus was in 
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perfect focus at a plane below 4 µm and above or equal to 20 µm in the Z-axis 
(Fig. 1). The potential bias from lost caps was avoided by having upper and 
lower guard heights (of 4 and 10 µm, respectively) (Marcos et al., 2012). 
Spindle-shaped nuclei were excluded from the counts. 
The NV (nuclei, tumor) was estimated using the formula (Gundersen et al., 
1988): 
 
NV (nuclei, tumor) = ΣQ−/[h x a(frame) x ΣP] 
 
where ΣQ– corresponded to the total number of neoplastic cells counted in the 
sampled fields, and a(frame), h and ΣP were, respectively, the area of the 
counting frame, height of the disector and the total number total number 
sampled fields within the reference space. Since the reference space defined 
was the parenchyma of the tumor, fields that were empty, containing large 
vessels, stroma, or necrotic areas were excluded. The coefficient of error (CE) 
of the estimations of NV (nuclei, tumor) was determined using the formula 























where u and v stands for the number of nuclei counted (Q-) and total number 
sampled fields within the reference space (P), respectively. 
The CE of the NV estimations was then compared with the observed relative 
variance among cases, OCV2, according to the formula (Gundersen et al., 
2013): 
 
OCV2 = BCV2 + CE2(NV) 
where BCV2 is the inherent biological relative variance of the NV in tumors and 





Fig. 1 – Series of light micrographs from a thick section (30 µm) of a canine mammary 
carcinoma that form an optical disector (the depth of each optical plane is indicated in 
the upper left corner). Nuclei of neoplastic cells are counted if they are seen within the 
counting frame or touching the inclusion (green) lines, but not touching the exclusion 
(red) lines. In this illustrative field, 6 nuclei are counted (arrowheads); Bar 6 µm. 
 
5.2.3 Statistical analysis 
To test if the data followed a normal distribution the Shapiro-Wilk and 
Kolmogorov-Smirnov tests were used. For skewed data, a logarithmic 
transformation was applied. The associations between the NV (nuclei, tumor) 
and: 1) NHG grade (grade I, II and III); 2) grading parameters  tubule 
formation, nuclear pleomorphism and mitotic counts scores; 3) WHO size 
categories; 4) histological subtypes, were tested with one-way ANOVA, followed 
by Tukey post-hoc tests. The differences in NV (nuclei, tumor) in tumors 
presented or not vascular/lymph node invasion were assessed with the t-test for 
independent samples. Regarding the histological subtype, the tumors were also 
grouped and compared, as a) simple versus complex carcinomas and b) solid 
carcinomas versus all the other subtypes, using the t-test for independent 
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samples with F test for checking the homogeneity of variances. The association 
degree between the NV (nuclei, tumor) and the volume-weighted mean nuclear 
volume [previously assessed by point sampled intercepts (Santos et al., 2014)] 
was evaluated by Pearson correlation test. In all cases, a P value < 0.05 was 
considered significant. Statistical analyses were performed with the IBM SPSS 
Statistics, version 22 (IBM, New York, USA). 
 
5.3 Results  
Thirty out 44 tumors were diagnosed as simple carcinomas (11 tubulopapillary, 
16 solid, 2 squamous cell and 1 mucinous) and 14 were complex carcinomas. 
The tumor largest diameter ranged from 0.5 to 15 cm, being 7 cases T1, 25 
cases T2 and 12 cases T3. At the time of diagnosis, 12 cases (27%) presented 
vascular/regional lymph node invasion. Regarding NHG, 9 cases were grade I, 
15 were grade II and 20 were grade III. As to tubule formation, score 1, 2 and 3 
were present in seven, 20 and 17 tumors, respectively. Follow-up data was 
available for 27 female dogs, and during this period, 30% (8/27) of animals 
presented progression of the disease (defined as recurrence and/or metastases 
di novo). Of the remaining, 55% (15/27) were alive and clinically disease-free at 
24 months after the surgery, whilst 15% (4/27) were censored for being lost to 
follow-up or for non-malignancy-related death.  
Regarding the stereological estimation, an average of 259 nuclei was counted 
per tumor, (≈ 6 cells per disector); the mean section thickness was 28.9 µm 
(coefficient of variation = 0.1). The mean CE of the NV (nuclei, tumor) 
estimations was 0.07 (CE estimations varied from 0.04 to 0.11). This means 
that the estimation methodology was responsible for 5% of the total observed 
variance. Therefore, the biological variability was by far the most important 
component of the observed variability of the NV (nuclei, tumor) estimations. The 
mean (SD) and median NV (nuclei, tumor) were 1.6x106 nuclei mm-3 (0.5x106) 
and 1.4x106 nuclei mm-3, while the minimum and maximum values were 0.8x106 



















Fig. 2 – Histogram of the mean NV (nuclei, tumor) values in the 44 canine mammary 
carcinomas; lozenge-arrow: mean value; circle-arrow: median value. 
 
The NV (nuclei, tumor) was significantly higher in simple carcinomas 
[mean=1.7x106 (0.5x106 nuclei mm-3)] comparing to complex carcinomas 
[mean=1.3x106 (0.2x106 nuclei mm-3)] (t-test, P = 0.002), but no statistical 
difference existed when solid carcinomas were compared with the other 
subtypes (including when compared with the tubulopapillary carcinomas). The 
NV (nuclei, tumor) was 1.3x106, 1.7x106 and 1.6x106 nuclei mm-3 in grade I, II, III 
tumors, respectively; with no significant differences. Regarding the NHG 
parameters (tubule formation, nuclear pleomorphism and mitotic counts), the NV 
(nuclei, tumor) did not differ with the tubule formation scoring, but an 
association with nuclear pleomorphism was observed  tumors scored 3 for 
nuclear pleomorphism presented lower NV (nuclei, tumor) compared to tumors 
scored 2 (Tukey test, P = 0.02). Similarly, a significant increase in numeric 
nuclear density existed from tumors scored 1 or 2 to those scored 3 in mitosis 
counts (Tukey test, P = 0.006 score 1 versus score 3 and P = 0.013 score 2 
versus score 3). With respect to tumor size, no difference in NV (nuclei, tumor) 
was observed in tumors of each three WHO size categories. However, when 
tumors larger than 5 cm were compared with smaller ones, the former 
presented a significant higher NV (nuclei, tumor) (t-test, P = 0.03).  
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The NV (nuclei, tumor) was weak-to-moderate, negatively and linearly correlated 
(r = -0.34; P = 0.03) to the nuclear size pleomorphism, quantified herein as the 
volume-weighted mean nuclear volume  i.e., the NV (nuclei, tumor) tended to 
be lower in tumors presenting higher nuclear size pleomorphism.  
As to vascular/lymph node invasion status, the NV (nuclei, tumor) was similar in 
tumors with and without evidence of invasion. On the other hand, the eight 
cases that showed post-surgical disease progression during the follow-up 
period tended to have a lower NV (nuclei, tumor) (1.4x106 nuclei mm-3) when 
compared with cases without evidence of metastases and/or recurrence 
(1.8x106 nuclei mm-3) (t-test, P = 0.047).  
 
5.4 Discussion 
Studies over the last thirty years have built a consensus on the value of 
quantification for improving the prognostic value of morphological parameters in 
malignant tumors (Baak et al., 1985; van der Linden et al., 1986; Ladekarl and 
Sørensen, 1993a,b; Ladekarl, 1995; Ladekarl, 2004; Nedergaard et al., 2007). 
Stereological methods not only achieve such quantification, but have additional 
advantages of unbiasedness and reproducibility (Marcos et al., 2012). These 
have been applied for long in breast pathology (Ladekarl, 1998; Ladekarl, 
2004), but their use in the veterinary oncology is still incipient (Casteleyn et al., 
2014). 
In this study we used the optical disector to assess the NV (nuclei, tumor) in 
CMC. Notably, the mean value for CMC (1.6x106 nuclei mm-3) was higher (but 
in the same order of magnitude) than that reported for human breast cancer 
(0.4x106 nuclei mm-3) (Artacho-Pérula and Roldán-Villalobos, 1997). 
Interspecies differences may be at the basis of this discrepancy, along with 
eventual influences of technicalities, particularly variations in definition of the 
reference space (for example, we excluded stromal areas). Still, our data 
suggest that CMC present a higher density of nuclei than breast carcinomas. 
Despite the differences in figures between our and human studies, some 
observations in breast cancers were fairly mirrored in CMC. In both cases, there 
was no significant association between NV (nuclei, tumor) and histological 
grade, but a significant negative correlation was noted between the NV (nuclei, 
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tumor) and the volume-weighted mean nuclear volume  r= -0.34, -0.63 and -
0.31, respectively in our study and in two breast cancer studies (Artacho-Pérula 
and Roldán-Villalobos, 1997; Ladekarl, 2004). 
Another interesting finding in both dogs and humans is that cancers with worst 
survival outcomes had a lower NV (nuclei, tumor) (Artacho-Pérula and Roldán-
Villalobos, 1997). At a first glance, this is an unexpected observation that 
appears to contradict the traditional concept that highly cellular tumors are 
associated with poorer prognosis (Misdorp, 2002). However, it should be kept in 
mind that any numerical density is a relative parameter (i.e., a fraction) that can 
be influenced by the number of nuclei/cells or by changes in the reference 
space (i.e., decreases in numerator or increases in the denominator). A 
decrease in the NV (nuclei, tumor) can occur in different scenarios, namely 
when cells get larger, or more distant (e.g., due to an increase in extracellular 
matrix as it probably occurs in complex carcinomas, or due to the loss of 
epithelial adhesion), or when an increased nuclear/cellular pleomorphism exists 
(Fig. 3). The latter is more likely to occur in CMC, since we have previously 
described that the volume-weighted mean nuclear volume (which, we recall, 
estimates the nuclear size pleomorphism) was significantly higher in more 
aggressive tumors (Santos et al., 2014), and herein there is a negative 











Fig. 3 – Potential (theoretical) explanations for the changes in the NV (nuclei, tumor). 
For the sake of illustration consider a reference space (gray cube) holding particles that 
are counted through the optical disector (A). From B to D the NV (nuclei, tumor) 
decreases through different mechanisms. In (B) cells enlarge, thus few nuclei are 
counted, whereas in (C) cells are apart, due to extracellular matrix deposition or loss of 
intercellular adhesion. In (D) cells are highly pleomorphic, some cells are considerably 




Paraffin shrinkage during tissue processing can influence the reference space 
and, therefore, lead to overestimations of the NV (Mandarim-Lacerda, 2003; 
Marcos et al., 2012). Since the cases of this series were handled by the same 
surgical team, with similar fixation times and processing protocol, it would be 
reasonable to assume that the shrinkage in x-y would be alike in all cases. In 
fact, it should be stressed that the possibility of bias related to tissue handling 
when stereology is applied to routine diagnostic material (as in this study) 
should not cloud the advantages of stereology over traditional 2D techniques 
(Kamp et al., 2009). These latter are not only affected by shrinkage, but are also 
severely (uncontrolled) influenced by the shape, orientation and size of the 
particles (nuclei, cells) being counted (Wanke, 2002; Marcos et al., 2012; 
Gundersen et al., 2013). 
Herein, we observed that the NV (nuclei, tumor) was not associated with the 
qualitative assessment of tubule formation, which is integrated in the NHG. 
Indeed, we failed to observe differences between solid and tubulopapillary 
carcinomas regarding this stereological parameter. This supports that the 
presence of luminal structures in routine sections is not directly correlated with 
cellularity at 3D level. According to our present data, both solid and 
tubulopapillary carcinomas are heterogeneous regarding the 3D densities of 
nuclei; other studies of survival and immunohistochemistry status of solid and 
tubulopapillary tumors also pointed to the existence of heterogeneity in these 
groups of CMC (Santos et al., 2013; Yoshimura et al., 2014). Yet, this study 
evidenced that complex carcinomas have decreased NV (nuclei, tumor). A 
possible explanation for this could reside in the presence of small portions of 
myxoid matrix, typical of these tumors (Misdorp, 2002). When being surrounded 
by that extracellular matrix, cells tend to appear separated and thus fewer 
neoplastic cell nuclei would be counted in the disector (Fig. 3C).  
As a final methodological appraisal, in this first approach to the NV (nuclei, 
tumor) of CMC we obtained a small CE, much below the 0.1 threshold 
(Gundersen et al., 2013), and the error due to the methodology was also low. 
For future studies and for practical purposes this CE could be optimized, by 
counting fewer nuclei per tumor. In this vein, counting 20 fields per tumor would 
suffice and this would significantly reduce the time needed for the analysis (for 
forty fields, around 30 minutes were needed).  
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In conclusion, we showed that an objective and unbiased estimation of a 
cellularity-related parameter — expressed as NV (nuclei, tumor) — in CMC can 
be obtained by stereological methods. This study better characterizes CMC by 
offering new 3D-relevant data not influenced by the uncontrolled biases inherent 
to the simplistic 2D counts. The lower NV (nuclei, tumor) in cases that 
progressed seems to be a promising finding, but further follow-up studies with 
large series are needed to fully clarify the association between NV (nuclei, 
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SYSTEMATIC SAMPLED VERSUS SELECTIVE MITOTIC COUNTS  
















Mitotic activity has been proven to be a strong prognostic factor in human 
breast carcinomas, and different methodologies to counting mitosis have been 
scrutinized over the years. In malignant canine mammary tumors (CMT) the 
mitotic figures are considered a diagnostic and grading parameter. Mitotic 
counts performed in ten high-power fields with the highest (subjectively) 
perceived proliferative activity are included in the grading systems adapted to 
malignant CMT. The individual prognostic significance of this grading 
component has been scarcely studied in malignant CMT and conflicting results 
have been reported. In human pathology, selective mitotic counts have been 
criticized for supposed low reproducibility. Preliminary data indicated that this 
may also be true in malignant CMT. This study investigated the prognostic 
value of the mitotic count performed using the Nottingham grade method and 
whether the prognostic value could be improved by a systematic random 
sampling procedure, combined with a correction for the area of the epithelium 
present. Routine histological sections of fifty seven malignant CMT of different 
histological types were studied. For forty seven cases two years follow-up data 
was available. The selective versus systematic mitotic counts showed a weak 
positive correlation (r = 0.35, P = 0.03). The first estimation was higher in larger 
tumors and solid carcinomas, and no association between the systematic count 
and the clinicopathological parameters existed. Also, both types of mitotic 
counts did not provide prognostic information. In this vein, the inclusion of 
mitotic activity as a grading parameter in malignant CMT should be revised. 
Moreover, veterinary pathologists should explore alternative proliferation 
markers and, eventually, other quantification strategies for prognostic purposes 







The capability to sustain proliferative activity is considered one of the 
fundamental hallmarks of cancer (Hanahan and Weinberg, 2011). Ninety years 
ago, the first study addressing malignancy grading of human breast carcinoma, 
recognized the presence of mitoses as a key feature (Greenough, 1925). 
Afterwards, all the important grading systems developed for breast carcinomas 
contemplated mitotic figures as a relevant parameter (Patey and Scarff, 1928; 
Bloom and Richardson, 1957; Elston and Ellis, 1991). Initially, the mitotic and 
hyperchromatic nuclei were both considered in the grading systems, but after a 
modification was introduced, only unequivocal mitotic figures were counted and 
scored according to specific cut-offs based on the microscope field diameter 
(Elston and Ellis, 1991). Several reports favored mitotic count as the main 
prognostic component of the grade method of breast carcinomas, being 
especially important in the decision of adjuvant treatment for lymph node-
negative breast cancer patients (e.g., Meyer et al., 2005; Volpi et al., 2004; 
Skaland et al., 2008). 
Despite this, mitotic counting has been criticized due to its highly selective and 
subjective nature (Jannink et al., 1995). According to the grading 
recommendations, mitotic figures should be counted in the most proliferating 
part, which usually comprises the peripheral area of tumors (Elston and Ellis, 
1991). However, mitotic heterogeneity has been reported, and without sampling 
the whole tumor it is difficult to know where to begin (Jannink et al., 1996a,b; 
Tsuda et al., 2000; Meyer et al., 2005). Additionally, two other pitfalls regarding 
mitotic counting should be kept in mind. In one hand, the variability on the 
proportions of neoplastic cells in each high power field is not taken into account 
in the grading criteria, and, on the other hand, it is often difficult to distinguish a 
mitotic figure from apoptosis, pyknosis or even irregularities of nuclear staining 
(which can occur with routine staining) (Meyer et al., 2005).   
Several approaches have been recommended to overcome these limitations 
and to improve the reproducibility of mitotic count in human breast carcinomas. 
Some authors recommended a simplistic approach that consists in counting 
more than 10 high-power fields either in heterogeneous tumors or in those with 
low mitotic activity (O’Leary and Steffes, 1996; Elston and Ellis, 1998; Meyer et 
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al., 2005). Others researchers used morphometrical or stereological methods to 
objectivize the estimation of the mitotic count. Over 25 years ago, a method to 
standardize the counting of mitotic figures in tumors was developed, aiming to 
circumvent the problem associated with the varying amount of neoplastic tissue 
in each field (Haapasalo et al., 1989). This method included the simultaneous 
counting of the mitotic figures and estimation of the relative volume of 
neoplastic tissue, by a point-counting method in each field, thus generating the 
so-called volume corrected mitotic index (M/V index) (Haapasalo et al., 1989). 
The M/V index in breast carcinomas has been reported to be powerful in 
predicting survival (Lipponen et al., 1991; Aaltomaa et al., 1991, 1992; Jannink 
et al., 1995; Kronqvist et al., 1998). In one of these studies, the M/V index was 
also estimated by systematic random sampling (Jannink et al., 1995). The latter 
mitotic index gave an assessment of the mitotic activity throughout the whole 
tumor, presenting also prognostic value in breast carcinomas (Jannink et al., 
1995). Anyway, it seems that the different mitotic estimates (i.e., related to 
volume, area or number of nuclear profiles) in breast cancer tended to be highly 
correlated (Jannick et al., 1995; Ladekarl, 1998; 2004). 
In malignant canine mammary tumors (CMT), the number of mitosis is also 
used to assist in diagnosis and grading (Misdorp et al., 1999; Misdorp, 2002; 
Peña et al., 2013). The prognostic significance of mitosis estimations in CMT is 
scarcely studied and the existing reports are controversial, with two studies 
reporting no association with prognosis (Sarli et al., 2002; Santos et al., 2013), 
and a more recent study reporting the opposite (Mainenti et al., 2014). As far as 
we know, the use of systematic sampling for selecting the fields for mitotic 
counts has never been implemented in malignant CMT.   
Because the systematic sampling guarantees the generation of representative 
samples, when compared to schemes not grounded on probabilistic theories, 
like choosing fields of view by arbitrarily decisions of a pathologist, we 
hypothesized that using solid sampling schemes may improve the value of 
mitotic counts. Accordingly, the aims of the present study were to: 1) count 
mitotic figures in the whole tumor, using a systematic sampling approach and 
estimating the area of epithelial cells in each counting field; 2) compare mitotic 
counts per epithelial area with mitotic counts obtained by the histological grade 
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method criteria; 3) estimating the prognostic value of these mitotic figures 
estimations. 
 
6.2 Material and methods 
6.2.1 Selection of cases and histological study  
Fifty seven spontaneous malignant CMT surgically removed with curative 
intents in the veterinary clinics of the ICBAS-University of Porto were 
retrospectively selected from the Pathology laboratory archives. The selection 
of cases was blinded to clinical data. In the clinical archives, two years follow-up 
data was available for forty seven cases. The follow-up protocol was detailed 
elsewhere (Santos et al., 2013). Owners gave informed consent for both 
surgery and follow-up. 
The histological diagnosis and grade was performed by two observers (MS and 
PDP) using the WHO classification and the Nottingham grade method (Elston 
and Ellis, 1991; Misdorp et al., 1999; Karayannopoulou et al., 2005). Cases with 
score discrepancies in grading parameters were reviewed using a multi-head 
microscope, in order to obtain a consensual score. The tumor size (i.e., largest 
diameter measured with a caliper before surgery) and the histological evidence 
of vascular invasion (defined as the presence of tumor emboli within 
endothelial-lined spaces) and/or regional lymph node metastases [lymph nodes 
were evaluated in routine slides and after immunolabelling with pancytokeratin 
AE1/AE3 and cytokeratin 14, as previously described by Matos et al. (2006)] at 
the time of diagnosis were recorded. All the slides resulting from the largest 
cross section were screened. 
 
6.2.2 Assessment of mitotic activity 
Regarding selective mitotic count (sMC), the mitotic figures were counted in 10 
high-power fields (400x) and scored using the cut-offs defined by the field 
diameter of the microscope (field diameter of 0.55 mm; field area of 0.238 mm2) 
— score 1 (≤ 8 mitotic figures), score 2 (9 to 17 mitotic figures); score 3 (≥ 18 
mitotic figures) — thus assuring equivalence with assessments made by Elston 
and Ellis (Elston and Ellis, 1998; Karayannopoulou et al., 2005). The selection 
of the high-power fields for mitotic counting was performed in what the 
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observers judged to be the most mitotically active parts of the tumor, which 
generally corresponded to peripheral areas (Elston and Ellis, 1991). The mean 
value of the mitotic count performed by the two observers (MS and PDP) was 
obtained and used to estimate the number of mitotic figures per the total area of 
tumor.  
Systematic random mitotic counting (rMC) was performed by one observer (MS) 
in a workstation comprising: 1) a microscope (Olympus BX-50, Tokyo, Japan) 
equipped with a UPlan Apo 100x (1.25 NA) oil-immersion lens (Olympus); 2) a 
motorized stage (Prior, United Kingdom) for stepwise displacement in the x–y 
directions (1 µm accuracy); 3) a CCD video camera (Sony, Tokyo, Japan) 
connected to a 17′′ PC monitor (Sony); 4) a computer with a stereology software 
(Olympus Denmark, CAST-Grid, version 1.5). At the monitor, a final 
magnification of 4750x allowed an easy and accurate recognition of neoplastic 
cells and mitotic figures. In each tumor, a minimum of 40 fields of vision were 
sampled systematically random that, is, the selection of the first field was 
random and the subsequent fields were sampled systematically by stepwise 
movements of the stage in the x- and y-directions roughly proportional to the 
overall area of the tumor (Fig. 1). In each field, the area of the neoplastic 
epithelium was estimated using a probe of test points (points hitting the 
epithelial cells were counted). Simultaneously, the mitotic figures were counted 
in a frame with an area = 2533 µm2 (Fig. 2).  
For both sMC and rMC, only the unequivocal mitotic figures were considered, 






















Fig. 1 – Schematic representation of the systematic random sampling used for mitotic 
count. After outlining the tumor (hatched line) and setting the number of aimed fields, 
the software selects randomly the first field and the next ones are automatically equally 














Fig. 2 – Light microscopy image of a solid canine mammary carcinoma, with the test 
system used for counting the mitotic figures and assessing the area of neoplastic 
epithelium. It consists of a counting frame with inclusion lines (green), exclusion lines 
(red), and points (16 equidistantly spaced points). Mitotic figures were counted 
provided they are inside the counting frame or touch the green lines but not the red 
ones. For assessing the reference area, points hitting the neoplastic epithelium are 
counted. In this illustrative field, 2 mitotic figures and a total of 13 points hitting the 
neoplastic epithelium were counted. 
 
6.2.3 Statistical analysis  
The homogeneity of variances and normal distribution of the sMC, rMC and 
tumor size (in cm) values were verified using the Shapiro-Wilk and Kolmogorov-
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Smirnov tests, respectively. For skewed data, such as the sMC and rMC, a 
logarithmic transformation was applied.  
The correlation between the sMc and rMC was assessed using the Pearson 
correlation test. The same approach was used to evaluate the relation between 
the mitotic counts and the tumor size. The relation between each mitotic count 
and the WHO size categories was tested with one-way ANOVA, followed by the 
Tukey post-hoc tests. A similar approach was used to test the relation between 
each mitotic count and the histological subtypes of tumors. The differences in 
mitotic estimates in tumors < 2.9 cm and tumors ≥  2.9 cm (in the largest 
diameter), and in tumors with or without vascular/lymph node invasion, were 
assessed with the t-test for independent samples. Tumors were also grouped 
according to their histological subtypes (solid plus anaplastic carcinoma versus 
tubulopapillary plus complex) and compared using the t-test for independent 
samples.  
The differences in survival between tumors of the three NHG scores regarding 
mitotic count were graphically represented using the Kaplan-Meier curves, and 
compared by the log-rank test. A similar analysis was performed for the score of 
sMC and rMC defined by their tertiles thresholds values (sMC: score 1 ≤ 6; 
score 2: 7-12; score 3 ≥ 13 mitotic figures mm-2; rMC: score 1 ≤ 10, score 2 : 
11-24 mitotic figures mm-2; score 3 ≥ 25 mitotic figures mm-2). 
In all cases, a P value < 0.05 was considered statistically significant. Statistical 




In this series, 45 out 57 tumors were diagnosed as simple carcinomas (19 
tubulopapillary, 21 solid, 2 squamous cell and 3 mucinous carcinomas), 8 were 
complex carcinomas and 4 carcinosarcomas. The largest tumor diameter 
ranged from 0.5 to 15 cm, being more than 2.9 cm in 24 cases (42%). Nineteen 
cases (33%) presented vascular/regional lymph node invasion at the time of the 
diagnosis. Regarding histological grading, 9 cases were grade I, 24 were grade 
II and another 24 were grade III. As to sMC grading, score 1, 2 and 3 were 
present in 11, 15 and 31 tumors, respectively. Follow-up data was available for 
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47 female dogs; overall 36% developed recurrence and/or metastases and 24% 
died or were euthanized due to progressive disease.  
An average of 8 mitoses mm-2 and 15 mitoses mm-2 was determined in the sMC 
and rMC methods, respectively, being the range of values wider in rMC (Table 
1). In 21 out 57 the rMC was less than the sMC and, in 16 cases of those cases 
the rMC was less than 1 mitotic figure mm-2. In the other cases the rMC was 
higher than the respective sMC: in these cases, the correction to the area of the 
neoplastic epithelium increased the rMC values by ≈ 53%, on average. These 
two mitotic indexes were weakly but significantly correlated (r = 0.35; P = 0.03). 
The sMC, but not the rMC, was also positively correlated with tumor size (r = 
0.42; P = 0.001). Tumors with a size ≥ 2.9 cm presented a significantly higher 
sMC (t-test, P = 0.008). A similar result was obtained when the tumor size was 
categorized according to the WHO criteria: tumors with size larger than 3 cm 
presented high rMC compared to smaller tumors (Tukey test, P = 0.005), as 
well as tumors with more than 5 cm [higher sMC than tumors sized 3-5 cm 
(Tukey test, P = 0.001)].  
The sMC were significantly different in tubulopapillary compared to solid 
carcinomas (Tukey test, P = 0.003) (Table 1); but no differences were detected 
in rMC of tumors with different histological classification. When solid plus 
anaplastic carcinomas were compared with tubulopapillary plus complex tumors 
(excluding carcinosarcomas, squamous and mucinous carcinomas), the first 
ones presented a significantly higher sMC (14 versus 8 mitosis mm-2) (t-test, P 
= 0.001).  
No differences in sMC and rMC were observed in tumors with or without 
vascular/lymph node invasion. The log-rank test showed no significant 
association between the DFI or the tumor-related OS and the sMC values 
(scored either according to the NHG or by the tertiles of their distribution). A 
similar result was obtained when the rMC were scored according to tertiles. In 
fact, sMC and rMC were on average similar in tumors that showed post-surgical 
progression and those without progression (cases with a minimum follow-up of 






Table 1 – Median and mean ± standard deviation (SD) of selective mitotic count (sMC), 
expressed as number of mitoses per mm-2, and of systematic random mitotic count 
corrected for the area of the neoplastic epithelium (rMC), given as number of mitoses 
per mm-2.  
Tumor 
sMC rMC 
Median Mean ± SD Median Mean ± SD 
Simple carcinoma 8.5 11 ± 8 15 20 ± 20 
 Tubulopapillary 
carcinomas 
6  7 ± 5 15 16 ± 17 
 Solid carcinomas 13  13 ± 8 13  21 ± 22 
Complex carcinomas 6.5  9 ± 5 14.5 15 ± 15 
Carcinosarcomas 7  6 ± 2 14  17 ± 5 
All cases 8  10 ± 8 15  19 ± 19 
 
6.4 Discussion 
Mitotic counting is one of the oldest but also one of the most practical methods 
to assess proliferation in a tumor (van Diest et al., 2004). In malignant CMT, the 
role of mitotic count as a prognostic factor is sparsely studied and a profound 
discussion regarding the methodology of mitotic counting in these tumors is still 
missing. Sarli et al. (1999) introduced a correction of the mitotic counts for the 
area of the nuclei of the neoplastic epithelium presented in each field of vision, 
but their study did not include survival analysis. The same group established a 
mitotic index expressed as the number of mitoses per 1000 neoplastic cells, in 
10 high-power fields selected subjectively in the area with the highest mitotic 
activity. However, this index was not useful for prognostic purposes (Sarli et al., 
2002). Similarly, our group failed to detect significant associations between sMC 
and survival outcomes (Santos et al., 2013; Santos et al., 2015a in Chapter). 
However, a more recent study reported that mitotic count, defined by the 
threshold of 10 mitotic figures in 10 high-power fields, was an independent 
prognostic factor (Mainenti et al., 2014). We hypothesized that the low 
reproducibility of the counting method and/or high variation of cellularity in 
malignant CMT could contribute to the discrepancy regarding the prognostic 
significance of the mitotic count. Accordingly, we assessed the mitotic count in 
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malignant CMT by using the classic approach of counting 10 high-power fields 
in the peripheral area of the tumors and, for the first time, by a systematic 
random sampling of fields throughout the tumor, associated with a point-
counting method to estimate the area of the neoplastic epithelium. In 
approximately 30% of the cases, the rMC was less than 1 mitotic figure per 
mm2, while the sMC was higher. This indicates that in those cases the observer 
was able to select fields with increased mitotic activity for performing the sMC. 
The correction for the neoplastic epithelium area increased the rMC by 50%, on 
average, indicating that in those cases there was a high proportion of non-
epithelial tumoral elements, such as stroma or necrotic areas.  
In cases where the rMC was higher than the sMC, the possibility that the higher 
magnification used for the latter allowed a better identification of mitotic figures 
could not be excluded. Some mitotic figures, when observed with a smaller 
magnification, would not be differentiated from apoptotic nuclei and thus would 
not be counted. In human breast cancer, mitotic count perform in 10 randomly 
selected fields and corrected for the relative volume of neoplastic epithelium 
was generally lower that the sMC, even when the latter was also corrected for 
the relative volume of neoplastic cells (Jannink et al., 1995). 
Our results indicate the existence of a high variability regarding mitotic activity in 
malignant CMT. The heterogeneity in the mitotic activity within the tumor surely 
troubled the pathologist’s task of unambiguously identifying the most 
proliferative areas. This caveat would justify the interobserver variation in 
scoring sMC in malignant CMT (Santos et al., 2015b in Chapter 3), and backs 
the need for a consensus regarding the best methodology for assessing 
proliferative activity.  
In the studied series, the association between mitotic activity with other 
clinicopathological factors, such as histological type and tumor size, was only 
observed for the sMC. Nevertheless, both sMc and rMc were not associated 
with survival outcomes. The values obtained with both estimates were quite 
similar in the cases that showed progressive events (including fatal cases) 
during the follow-up and in those that did not. In this vein, no real advantage 
was shown by using the systematic random sampling protocol, even when a 
correction for the area of the neoplastic epithelium was simultaneously 
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performed. The absence of prognostic value of mitotic counts in malignant CMT 
contrasts with the existing evidence for breast cancer (Jannink et al., 1995; 
Baak et al., 2005). The canine mammary gland is well acknowledged for its 
profound cyclic proliferative and regressive changes that take place in each 
estrous cycle phase (Santos et al., 2010). Mitotic figures and high expression of 
proliferative markers (e.g., Ki-67) have been detected during the estrous cycle 
phases associated with raised progesterone (Santos et al., 2010). So, at this 
point, we cannot exclude the hypothesis that the normal cyclic hormonal 
influences in the canine mammary parenchyma could also affect the tumor 
cellularity and kinetics; viz. being partially responsible for the mitotic activity 
observed within the tumor. This would justify, to some extent, the heterogeneity 
of mitotic activity between cases and also the absence of prognostic value of 
mitotic counts in malignant CMT. As part of the mitotic activity would be a 
normal physiologic response, rather that an intrinsic aggressive neoplastic 
feature.   
Our results regarding sMC support previous evidences that solid carcinomas 
are associated with a high proliferative activity (Sarli et al., 1999; Yoshimura et 
al., 2014). However, variation in the amounts of neoplastic epithelium per each 
high-power field, between solid, tubulopapillary (presenting luminal and 
interpapillary spaces) and also complex tumors (presenting areas of myxoid 
matrix), could also contribute to that difference. Actually, in the solid carcinomas 
it is more likely to observe mitotic figures in each field, since it bears a larger 
area of neoplastic cells. Accordingly, Sarli et al. (1999) reported no differences 
between the solid and the other simple carcinomas by correcting the mitotic 
figures number per the area of the nuclei of the neoplastic epithelium counted in 
10 high-power fields selected in the zone with the high proliferative activity.  
The absence of prognostic significance of both types of mitotic counts supports 
a classical report by Owen (1979), where the author considered, in a comparative 
perspective, that the mitotic counts in dogs might not be as important as in 
women. Meanwhile, more recent studies also failed to demonstrate a prognostic 
role for mitotic figures estimates (Sarli et al., 2002; Santos et al., 2013).  
An important methodological issue related to mitotic counts is the reported lack 
of precision of the estimations in tumors with low proliferative activity (Ladekarl 
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et al., 1997); some tumors included in this study seemed to fit with this 
description. It was suggested that an increased precision of the proliferation 
measure would be achieved by using immunohistochemical staining against 
proteins expressed during different phases of the cell cycle, as for example 
PCNA and Ki-67 (Ladekarl et al., 1997). In malignant CMT high indexes of 
these proteins have been associated both with aggressive behavior and poor 
prognosis (Klopfleisch et al., 2011). Despite their proven prognostic value, these 
immunomarkers are still not included in the routine protocol for malignant CMT 
(Klopfleisch et al., 2011). 
Considering the state of the art of the methods used to assess mitotic counts, 
diverse refinements that can provide more realistic estimations of the number of 
mitosis could be performed. Despite practical in operational terms, the tested 
approaches inherently have a number of biases. In first place, the estimates 
were merely 2D and therefore depend on the size and orientation of the mitotic 
nuclei, as well as the section thickness. Modeling of the rMC values could be 
attempted to overcome the bias against smaller particles (in these case smaller 
mitotic nuclei) that occurred when using a thin histological section. Different 
model-based corrections such the proposed by Weibel and Gomez (1962) could 
be used to estimate the 3D number of mitoses. In order to apply such 
corrections, assumptions regarding the shape of the mitotic nuclei should be 
made and therefore, the estimations would still not be free of bias (Lemley et 
al., 2013). Additionally, to carry out this method an estimation of the volume 
fraction of the mitotic nuclear profiles would be needed. This will be tested in the 
near future; however, at this point, alternative proliferative markers, as 
previously stated, seem to be more rewarding tools for studying malignant CMT.  
In conclusion, at least with the currently tested methodologies, grading mitotic 
activity seems not to be important for prognosis definition of malignant CMT.  
Estimating mitotic figures over the whole tumor section and correcting the count 
for the amount of epithelium do not add prognostic significance. The results 
markedly contrast with that observed in human breast cancer, and raises further 
doubts on the adoption of 2D-based mitotic counts in the grading criteria for 
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SEARCHING FOR POTENTIAL GRADING PARAMETERS IN CANINE 












In recent years, the histological grade of malignant canine mammary tumors 
(CMT) has been assigned using the human Nottingham histological grade 
method as basis. When applied to CMT, the grade seemed to be useful for 
prognostic purposes; however the contribution of each grading parameter is 
unclear. Recently, it was reported that nuclear pleomorphism, when scored as a 
two-tier (score 1 plus 2 versus score 3) was the only grading parameter 
associated with survival. This finding incited the search for potential alternative 
morphological grading parameters. Herein, the association between eight 
morphological parameters and survival was investigated. Micropapillary 
structures, necrosis, squamous differentiation, nucleolar pattern, inflammatory 
infiltrates, scirrhous stroma, abnormal nuclei, and chromatin vesiculation were 
assessed. The parameters were evaluated qualitatively (presence versus 
absence) and semi-quantitatively (as a percentage) in 59 malignant CMT, for 
which two years follow-up data was available. The association between the 
parameters and the survival was investigated by univariable analyses. 
Additionally, multivariable Cox proportional hazards model was used to analyze 
the effect of different parameters on disease-free interval and overall survival. 
Nuclear pleomorphism (classified as two-tier system), vascular invasion and 
tumor size were also included as co-variables in Cox models. Necrosis, 
squamous metaplasia, abnormal nuclei were associated with short DFI and OS. 
Moreover, the predominance of a pattern of atypical nucleoli was a marker of 
increased odds for post-surgical progression, while the presence of scirrhous 
stroma was associated with tumor-related death. In the multivariable model, 
nuclear pleomorphism, vascular invasion and abnormal nuclei arise as 
independent factors for shorter DFI, while nuclear pleomorphism and necrosis 
emerged as independent prognostic factors for shorter OS. According to these 
results the pathologist should routinely report the nuclear pleomorphism score, 
the existence of vascular invasion, the percentage of necrosis and the 
proportion of cells with abnormal nuclei in all cases of malignant CMT, in order 







7.1 Introduction  
In recent years, the histological grading of malignant CMT has been performed 
following the standard method used for human breast cancer (e.g., 
Karayannopoulou et al., 2005; Clemente et al., 2010; Rasotto et al., 2012), 
namely by using the so-called Nottingham histological grade method (NHG) or 
the Elston and Ellis modification of Bloom and Richardson method. This system 
included the assessment of three parameters, being scored 1 to 3 and the 
overall grade determined by the final combined score, as detailed in Chapter 4 
(Elston and Ellis, 1991). Veterinary pathologists have been using the original 
method or a recent proposed modification (Peña et al., 2013). However, the 
prognostic role of histological grade is less established in dogs than in humans 
(Matos et al., 2012). Some issues related to histological grading, as the 
interobserver variation and the role of each grading parameter, remain fairly 
unknown in malignant CMT. Recently, the interobserver reproducibility in 
histological grading, as well as the individual prognostic value of each grading 
parameters were evaluated (Santos et al., 2015a; b in Chapters 3 and 4). For 
those studies a cohort of female dogs was used for which the two years follow-
up data was available. According to the results, the grade is prone to an 
interobserver variation similar to that observed in human breast cancer. Nuclear 
pleomorphism was the least consensual parameter among observers, followed 
by the mitotic counts. However, on a prognostic perspective the nuclear 
pleomorphism, classified as a two-tier system (score 1 plus 2 versus score 3) 
was also the only grading parameter associated with clinical outcomes (Santos 
et al., 2015b in Chapter 4). Neither tubule formation, nor mitotic count provided 
relevant prognostic information. A higher overall grade was associated with 
worst survival, especially when grade I plus II were compared to grade III 
(Santos et al., 2013; Santos et al., 2015b in Chapter 4). This evidence and 
similar ones provides raises questions regarding possible refinements of the 
method, eventually by adding or replacing some grading parameters. The 
search for morphological parameters, easily assessed by the pathologists in 
routine material, which can be associated with survival outcomes, represents a 
good investment in veterinary medicine (de las Mulas et al., 2005; Dagli, 2008). 
This is especially true when we consider that the more sophisticate diagnostic 
techniques are not affordable by most dog owners in many parts of the world. It 
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should be noted that the traditional factors, such as the grade or the 
pathological stage of the regional lymph nodes, still remain as cornerstones for 
prognosis definition in human breast cancer (Elston et al., 1999; Rakha et al., 
2010); even if the level of knowledge, regarding genetic and molecular markers, 
of human breast cancer is incomparably higher than in malignant CMT. 
This study aims to evaluate qualitatively and semi-quantitatively morphological 
parameters in malignant CMT, using histological routine sections and to 
disclose their prognostic value regarding DFI and OS in univariable and 
multivariable analyses.  
 
7.2 Material and methods 
7.2.1 Selection of cases and follow-up 
A cohort of fifty nine female dogs with spontaneous malignant CMT, treated at 
the veterinary clinic of ICBAS-University of Porto, was retrospectively selected. 
Dogs underwent surgery as the only treatment. Owners provided consents for 
surgery with curative intents, two years follow-up, and for the use of the material 
for research purposes. Of the female dogs, forty nine were selected based on 
the presence of a single malignant tumor. In the subgroup of 10 dogs with 
multiple malignant tumors, a reference lesion was assigned in accordance to 
published approaches for synchronous breast cancers and CMT (Beckmann et 
al., 2011; Santos et al., 2011; 2013; Schmid et al., 2011). This reference lesion 
was considered as the tumor presenting vascular invasion (primary criterion) or 
the one with largest diameter (secondary criterion). The selection of cases and 
their histological study were blinded to survival outcomes, thus following the 
recent guidelines in veterinary oncology (Webster et al., 2011). Dogs with 
distant metastases at the time of the diagnosis were excluded.  
The schedule and the protocol of clinical evaluations, before the surgery and 
during the follow-up period, were performed as previously described (Santos et 
al., 2013). The DFI was calculated from the date of surgery to the diagnosis of 
disease progression (recurrence or metastasis, with cytological or histological 
confirmation). As to the OS, it was calculated from the date of surgery to the 
date of animal´s death due to metastases. Animals that died or were euthanized 
for unrelated causes and those that were lost to follow-up were censored, 
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respectively, at the time of death and at the date of their last follow-up 
examination. Complete necropsies were performed in all dogs that died 
spontaneously or were euthanized, and suspected metastatic lesions were 
confirmed by histopathological examination.   
 
7.2.2 Assessment of morphological parameters 
Two observers reviewed the diagnosis, in a multi-headed microscope using the 
WHO classification of CMT (Misdorp et al., 1999) and considering all the slides 
resulting from the largest tumor cross section. The tumor size [in cm and 
categorized by the previously established cut-off (Santos et al., 2014)], vascular 
invasion [irrespective of the type and number of invaded vessels (Fig. 1A)], 
histological grade and scores of the grading parameters were retrieved from a 
previous study (Santos et al., 2015 in Chapter 4). The same observers 
assessed by consensus and, considering all the sectional area of the tumor 
presented in the slides, the following tumoral characteristics: 1) presence of 
micropapillary structures (Fig. 1B); 2) percentage of necrosis; 3) percentage of 
squamous differentiation; 4) nucleolar morphological pattern [pattern 1: 
indistinct nucleoli; pattern 2: small but prominent nucleoli; pattern 3: large, 
multiple or atypical nucleoli (Fig. 1C)]; 5) presence and type of inflammation; 6) 
presence of scirrhous stroma (either intra- or peritumoral); 7) percentage of 
abnormal nuclear forms [defined as relative number of nuclei not round or oval, 
that presented indentations, angularity or irregularities (Fig. 1D)]; 8) percentage 
of chromatin pallor or vesiculation. The definition criteria for the nucleolar 
pattern, abnormal nuclei and chromatin vesiculation followed a description for 
feline mammary carcinomas (Mills et al., 2015). A nucleolar pattern was 
assigned to a tumor when at least half of the cells presented that type of 
nucleoli. It is opportune to mention that the evaluation of the nuclear and 







Fig. 1 – A: vascular invasion corresponding to the presence of an obvious embolus 
within a endothelial-lined structure; B: micropapillary structures corresponding to small 
clusters of cells lacking a fibrovascular core within a duct; C: nucleolar morphology 
pattern 3, in which the majority of cells have large, multiple and atypical nucleoli; D: 
abnormal nuclei with irregular forms and with areas of pallor corresponding to 
chromatin vesiculation; Hematoxylin-eosin, bar 35 µm (A), 50 µm (B) and 20 µm (C,D).  
 
Categorization of the percentage of the morphological parameters was tested 
using different cut-offs, namely the median value, tertiles (or 3-quantiles, i.e., 
the two thresholds that divide the ordered distribution of percentage values into 
three parts) and quartile values for statistical purposes.  
 
7.2.3 Statistical analysis 
Disease-specific survivals were determined using Kaplan-Meier product-limit 
estimates, with log-rank (Mantel-Cox) test used to estimate differences in 
survival fractions according to the presence and the score of each 
morphological parameter. Univariable and multivariable analyses were done 
using Cox proportional hazards model to investigate the association between 
clinicopathological parameters and DFI and OS. The morphological parameters 
that proved to be significant in the univariable regression analysis (at a P lower 





collinearity the correlation between all independent variables was tested and 
when the correlation between two variables was strong, only one was allowed 
to enter the multivariable model. In this latter, backward stepwise selection was 
performed. Briefly, in this selection method, all the candidate variables are 
included in the first step. Then, in each following step the least significant 
variable was removed and the significance of the remaining variables 
rechecked. The deletion of variables was performed until no further 
improvement of the model was possible (achieving a P value lower than 0.05 for 
all variables in the model). Logistic regression coefficients were used to 
estimate the hazard of each independent variable of the model. The 95% 
confidence interval is given for all variables that figured in the final model. 
Statistical analyses were performed with R Development Core Team software, 




Fifty nine female dogs aged from 6 to 18 years (mean of 10.9 years) were 
included in this study. Of these, 38 animals presented simple carcinomas (18 
tubulopapillary, 17 solid, 1 anaplastic, 1 squamous cell and 1 mucinous 
carcinoma), 18 had complex carcinomas and 3 had carcinosarcomas. The 
largest diameter of the tumors ranged from 0.5 to 15 cm (mean 3.5 cm). At the 
time of diagnosis, 15 cases (25%) presented vascular invasion. Post-surgical 
progression was diagnosed in 17 cases (including 7 solid carcinomas, 5 
complex, 3 tubulopapillary, 1 anaplastic and 1 carcinosarcoma). During the 
follow-up, 14 dogs (24%) died due to progressive disease. 
The evaluation of the eight new morphological parameters was possible in all 
the tumors. The presence of micropapillary structures was not related to any 
survival time. On the other hand, the existence of necrotic areas within the 
tumors was marginally associated with short DFI (log-rank test, P = 0.06). When 
this parameter was scored using the median value (20%) as threshold, it 
allowed a good discrimination of tumors with significant differences in survival. 
Animals bearing tumors with less than 20% of necrosis necrosis had a DFI of 22 
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months and an OS of 23 months, while those cases where necrosisexceed  
20% had a 15 and 18 months of DFI and OS, respectively (Fig. 2).  
 
Fig. 2 – Kaplan-Meier plots comparing the disease-free interval (DFI) and overall 
survival (OS) according to the proportion of necrosis. Short DFI an OS was associated 
with the presence of necrosis ≥ 20% of the tumor area (log-rank test, P = 0.001 for DFI 
and P = 0.005 for OS). Censoring is indicated by vertical marks. 
 
Tumors presenting squamous differentiation were significantly associated with 
short OS (log-rank test, P = 0.02) and marginally associated with short DFI (log-
rank test, P = 0.05); the fourth quartile cut-off of 10% of squamous cells allowed 
a better identification of progressive and fatal cases (Fig. 3).  
Tumors with a predominance of nucleolar morphology pattern 3 (large, multiple 
and atypical nucleoli) were also associated with short DFI (log-rank test, P = 
0.04) (Fig. 4), but this parameter had no influence on the OS.  
The presence of inflammatory infiltrates of any kind, including 
lymphoplasmacytic ones, within and around the tumor, was not significantly 
related to DFI or OS.  
The presence of more than 25% (median value) of neoplastic cells with 
abnormal nuclear forms was associated with short DFI (P = 0.02). When the 
tertiles values were used for scoring this parameter, the first tertile value (15%) 
appeared as a better cut-off than the median value, showing the best separation 







Fig. 3 – Kaplan-Meier curves. Cases that presented 10% or more of squamous cells 
had significant shorter disease-free interval (DFI) and overall survival (OS) (log-rank 




Fig. 4 – Kaplan-Meier curves showing that cases with pattern 3 of nucleolar 
morphology (large, multiple and atypical) were associated with worst disease-free 






Fig. 5 – Kaplan-Meier plots of disease-free interval (DFI) and overall survival (OS) 
according to the percentage of abnormal nuclei: 15% or more nuclei with abnormal 
morphology was associated with poorer survival times (log-rank test, P = 0.001 for DFI 
and P < 0.001 for OS).  
 
The presence of neoplastic cells with chromatin vesiculation (even when 
different types of categorization were attempted) was not related to survival. On 
the other hand, the existence of dense collagenous/scirrhous stroma within or 
around the tumors was associated with short OS (log-rank test, P = 0.04) (Fig. 
6). 
 
Fig. 6 – Animals bearing malignant mammary tumors with a scirrhous stroma had 
shorter cancer-specific overall survival (OS) compared to those without that connective 




Results of univariable and multivariable Cox regression analysis are 
summarized in Tables 1 and 2. Considering DFI as dependent variable, the 
combined effect of necrosis (scored according to the median value of 20%), 
squamous differentiation (scored by the cut-off of 10%), nucleolar pattern 3 
(presence versus absence), scirrhous stroma (presence versus absence), 
abnormal nuclei (scored by the cut-off of 15%), tumor size (cm), vascular 
invasion (presence versus absence), and nuclear pleomorphism (evaluated 
according to the NHG criteria and classified as score1 plus 2 versus score 3) 
was evaluated by multivariable analysis. In the final multivariable model and, 
after the exclusion of non significant variables, the nuclear pleomorphism, 
vascular invasion and abnormal nuclei (≥ 15%) emerged as independent factors 
(P = 0.01, P = 0.007, P = 0.04, respectively) (Table 2). A similar approach was 
done for OS as a dependent variable with the same set of variables included in 
the multivariable model for DFI, except the abnormal nuclei that were scored by 
the median value (because with the cut-off 15% the model did not converged). 
In the final multivariable model nuclear pleomorphism and necrosis ≥ 20% 
emerged as independent factors for predicting OS (P = 0.002 and P = 0.02, 



















Table 1 – Univariable Cox regression analyses of disease-free interval (DFI) and 
overall survival (OS) as dependent variables in 59 cases of malignant canine mammary 
tumors. 
 Univariable analysis 
DFI OS 
Variables β SE P β SE P  
Micropapillae 1 0.1 0.53 ns 0.43 0.56 ns 
Necrosis 1 1.7 1.03 0.102 1.56 1.04 0.134 
Necrosis 2 1.8 0.64 0.004 1.64 0.65 0.012 
Squamous differentiation 1   0.9 0.50 0.057 1.22 0.56 0.030 
Squamous differentiation 3 1.1 0.51 0.028 1.63 0.55 0.003 
Inflammation 1  0.8 0.50 0.130 0.50 0.54 ns 
Scirrhous stroma 1  1.3 0.75 0.077 1.87 1.03 0.072 
Atypical nucleoli 1 1.2 0.64 0.054 1.10 0.65 0.091 
Abnormal nuclei 4  1.1 0.49 0.028 0.98 0.53 0.068 
Abnormal nuclei 5 2.6 1.03 0.010 nc nc nc 
Chromatin vesiculation 1  0.03 0.49 ns -0.36 0.54 ns 
Chromatin vesiculation 6 -0.3 0.36 ns -0.33 0.592 ns 
Vascular invasion 1  1.5 0.49 0.003 1.37 0.538 0.011 
Tumor size (cm) 0.1 0.06 0.058 0.09 0.069 ns 
Nuclear pleomorphism 7 2.1 0.58 <0.001 1.97 0.598 0.001 
Legend: 1 presence versus absence; 2 scored by median value of 20%, 3 scored by 4th quartile of 
10%; 4 scored by the median value of 25%; 5 scored by the 1st tertile value of 15%; 6 scored by 
the median value of 5%; 7 NHG score 1 plus 2 versus 3; β – beta coefficient; nc – model did not 







Table 2 – Multivariable survival analyses (Cox proportional hazards regression) of 
disease-free interval (DFI) and overall survival (OS) as dependent variables in 59 
cases of malignant canine mammary tumors. 
Dependent 
variable 
Independent variables β SE Hazard 
Ratio  
P  95% CI 
  DFI  Abnormal nuclei 1  2.14 1.06 8.46 0.04 1.06-67.5 
Vascular invasion 2 1.38 0.51 3.98 0.007 1.45-10.9 
Nuclear pleomorphism 3 1.48 0.60 4.39 0.01 1.36-14.1 
OS  Necrosis 4 1.45 0.66 4.29 0.02 1.18-15.6 
Nuclear pleomorphism 3 1.83 0.60 6.26 0.002 1.9-20.6 
Legend: 1scored by the 1st tertile value of 15%; 2presence versus absence; 3NHG score 1 plus 2 
versus 3; 4scored by median value of 20%, β – beta coefficient; CI – confidence interval; SE – 
standard error. 
 
7.4 Discussion  
Despite the promising value of more sophisticated techniques for studying 
malignant CMT, the most attractive prognostic factors remain those that can be 
assesed using easy, accessible and economic methods (de las Mulas et al., 
2005). Morphological parameters evaluated in routine sections of tumors 
certainly meet those criteria. Indeed, when examining malignant CMT 
pathologists frequently deal with the challenge of providing reliable prognostic 
data in their routine reports (Dagli, 2008). Assigning the grade to a tumor could 
be a simple way to achieve that goal (Betz et al., 2012).  
In the last decade, it was shown that grade of malignant CMT based on the 
NHG criteria (with or without some modifications) was associated with survival 
outcome (Karayannopoulou et al., 2005; Peña et al., 2013; Santos et al., 2013; 
Santos et al., 2015b in Chapter 4). However, the histological grade has less 
prognostic value than its parameter nuclear pleomorphism by itself, indicating 
that tubule formation and mitotic counts may dilute, rather than strengthen, the 
prognostic value of the histological grade (Santos et al., 2015b in Chapter 4). 
Based on these results, searching for alternative grading parameters in 
malignant CMT is warranted.   
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In this study, eight morphological parameters were evaluated qualitative and 
semi-quantitatively (by defining a percentages and, whenever possible, 
categorized by cut-offs) in 59 malignant CMT of different histological subtypes. 
Of those parameters, necrosis, squamous differentiation, nucleolar morphology 
pattern, presence of scirrhous stroma and presence of abnormal nuclei all 
showed a significant association with at least one survival time, in univariable 
analyses. In multivariable models the set of variables included nuclear 
pleomorphism, vascular invasion and tumor size, whose prognostic value has 
been previously highlighted (Santos et al., 2014; Santos et al., 2015b in Chapter 
4). Upon multivariable analysis, nuclear pleomorphism, vascular invasion and 
abnormal nuclei emerged as independent prognostic factors regarding DFI, 
whereas for OS, the independent prognostic factors were nuclear pleomorphism 
and necrosis (in more than 20% of the area of the tumor) (Table 2).  
In this series, the existence of a component of micropapillary structures (i.e., 
small clusters of cells lacking fibrovascular cores within a lumen) was not 
associated with prognosis. Micropapillary carcinoma is an aggressive variant of 
breast cancer, well known for its lymphotropism and poor prognosis (Zekioglu et 
al., 2004). Some evidence has been produced that this variant should also be 
considered in CMT (Gama et al., 2008; Gamba et al., 2013) and a recent 
classification scheme included this particular subtype of CMT (Goldshmidt et al., 
2011). In the present study, micropapillae were diagnosed in 17 tumors but no 
significant association with vascular invasion/lymph node metastases (data not 
shown) or with survival times were detected. We hypothesize that the prognosis 
of malignant CMT could be related to the level of micropapillary differentiation, 
rather than to the presence versus absence of those structures. Nevertheless, 
further studies are needed to completely elucidate this issue. The discrepancy 
of our results, and those previously reported (Gamba et al., 2013), could also be 
caused by different interpretation regarding the description of micropapillary 
structures.  
Necrosis has been regarded as a morphological marker of the growth rate of 
malignant tumors and its presence represents a sign of a discrepancy between 
tumor growth and blood supply (Leek et al., 1999). The prognostic significance 
of necrosis in malignant CMT was noted by other authors in univariable analysis 
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(e.g., de las Mulas et al., 2005). According to our findings, the score of 20% of 
necrosis seemed valuable for prognosis definition in malignant CMT. 
Occasionally, malignant CMT present components of non-glandular epithelial 
elements with squamous appearance, similarly to human breast cancer. In 
breast pathology their presence defined a metaplastic carcinoma, and has been 
considered an independent marker of worst prognosis (Rakha et al., 2015). 
Likewise, the squamous cell carcinoma of the mammary gland is considered a 
highly infiltrative and invasive tumor in female dogs (Misdorp et al., 1999). In the 
majority of cases in this series, the squamous elements were admixed with 
neoplastic glandular epithelium. Even if this mixed appearance (glandular / 
squamous) has been recognized for long (Hampe and Misdorp, 1974), the 
significance of the squamous component for the prognosis of malignant CMT 
has been less studied. In this study, the presence of squamous differentiation in 
a mixed pattern with other different neoplastic arrangements of the cells 
(tubular, papillary, solid) constituted a marker of short survival, especially when 
the squamous component accounted for more than 10% of the total of the cells. 
A similar threshold has been used by human pathologists to define metaplastic 
squamous carcinomas (Rakha et al., 2015). Previous studies were unable to 
correlate squamous metaplasia with malignancy and prognosis of malignant 
CMT (Monlux et al., 1977; Santos et al., 2013). In this vein, further studies are 
needed to confirm the association of squamous differentiation and a poor 
prognosis.  
Nucleoli are one of the parameters used to assist in the nuclear grading 
definition (Elston and Ellis, 1991). However, the individual role of the 
morphology of the nucleoli, when assessed in routine stained sections, as a 
prognostic marker in malignant CMT has never been detailed. According to our 
results, large, multiple and atypical nucleoli, when presented in at least half of 
the neoplastic cells, represented a morphological predictor for high recurrence 
and metastization rates. Previous studies in CMT reported conflicting results as 
to the prognostic value of nucleolar features. Two studies did not observe an 
association between tumor recurrence or metastization and the number of 
nucleoli and/or the counts of the nucleolar organizer regions (AgNOR) (Bratulic 
et al., 1996; Löhr et al., 1997). AgNOR correspond to nucleolar proteins 
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detected by a silver stain as discrete black dots, and their area is directly related 
to the total nucleolar area and to the level of transcriptional activity (Derenzini et 
al., 2009). In other study, AgNOR counts (area and number per cell) in 
malignant CMT were associated with cancer-free survival in univariable analysis 
(Sarli et al., 2002). Considering our results, and those focusing on AgNOR 
estimations, further analyze nucleoli as putative prognostic markers in 
malignant CMT is advisable and unbiased quantitative methods would be of 
interest in this context. The nucleolar volume and its variability, similarly to the 
nuclear size pleomorphism, could be estimated in routine sections of the tumors 
using the stereological method point sampled intercepts (PSI) (Sørensen, 
1992). This method has been successfully applied to estimate the nuclear size 
pleomorphism in both canine and human mammary carcinomas (Ladekarl et al., 
1998; Santos et al., 2014 in Chapter 2) and nucleolar size and its variation in 
human melanomas (Sørensen et al., 1993).  
According to our results the presence of intratumoral and/or peritumoral 
inflammation, including lymphoid infiltrates, was not of prognostic significance in 
malignant CMT. Still, the role of lymphoid infiltrates in the behavior of malignant 
CMT remains unclear (Kim et al., 2013). These infiltrates were either associated 
with lower recurrence rate (Kurzman and Gilbertson, 1986), or with the 
opposite, i.e., higher histological grade and lymphatic invasion and shorter OS 
(Carvalho et al., 2011; Kim et al., 2013). In human breast pathology, the 
prognostic significance of lymphoplasmacytic infiltration within and around 
invasive carcinomas has been, and continues to be a subject of intense debate 
(Hoda, 2014). An infiltrate rich in plasma cells is usually observed in medullary 
carcinomas (Ellis et al., 2003). The majority of non-medullary carcinomas with a 
prominent lymphocytic reaction tend to be poorly differentiated (Hoda, 2014). 
Some investigators have found that human breast carcinomas with a 
lymphoplasmacytic host response have a relatively favorable prognosis; while 
others found no difference or even a less favorable outcome (Ellis et al., 2003). 
In this study the observation of increased, fibrous and highly eosinophilic stroma 
around or forming septa within the tumor was associated with short OS. The 
scirrhous stroma, also known as desmoplastic reaction, has been regarded as a 
morphologic sign of a defense against invasive neoplastic cells in human breast 
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cancer (Parham et al., 1988). Interestingly, the amount of fibrous tissues 
produced has also been considered an indicator of the “age of the tumor”, with 
longstanding tumors presenting larger amounts of stroma (Parham et al., 1988). 
These two hypotheses (highly invasive and longstanding tumors) are both 
compatible with a short cancer-specific OS observed in this study.  
As regarding abnormal nuclei, they were defined as those with irregular shape 
and contour, following a similar description for feline mammary carcinomas 
(Mills et al., 2015). The individual prognostic value of abnormal nuclei in 
malignant CMT has never been reported, as far as we know. Using 
morphometrical methods on cytological smears of CMT of different subtypes, 
Simeonov and Simeonova (2007) reported a higher nuclear perimeter 
(expected in larger and irregular nuclei) in solid and anaplastic carcinomas 
comparing to benign tumors and tubulopapillary carcinomas. These authors 
also observed an increased nuclear morphometrical estimator (so called 
nuclear roundness) closely related to shape from benign to malignant tumors 
(Simeonov and Simeonova, 2006). However, none of these studies included 
follow-up data or survival analysis. Therefore the prognostic value of such 
cytological features could not be determined.  
Despite the auspicious findings regarding the prognostic value of some 
morphological parameters, this study has some limitations. One of the major 
disadvantages of using morphological parameters for prognostic assessment is 
the existence of high intratumoral heterogeneity regarding a specific parameter 
(Ladekarl, 1998; Meyer et al., 2005). In this vein, the prognostic value of the 
parameters should not only be validated in larger prospective cohorts, but also 
submitted to a rigorous evaluation regarding their reproducibility. In order to 
cope with this caveat, the assessments in this study were made by two 
pathologists in a discussion microscope. Still, the assessment of intra- and 
interobserver variation remains mandatory for validation of their prognostic 
value (Webster et al., 2011). Moreover, methodologies allowing an objective 
and unbiased assessment of morphological parameters should be tested in 
future studies. In this perspective, stereological methods should be evaluated, 
as a point-counting technique to estimate relative volumes of necrosis, 
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squamous cell differentiation or scirrhous stroma or the PSI method to estimate 
the mean nucleolar volume and its variability, as previously described.  
In conclusion, this study reinforced the independent prognostic value of nuclear 
pleomorphism and vascular invasion. The presence of necrotic areas in more 
than 20% of the tumor was also a marker of short OS. Regarding nuclei, not 
only the increased of the nuclear size and its variation seemed important for 
prognostic purposes, but also the presence of irregularities in their shape and 
outline. According to these results, the pathologist should routinely report the 
nuclear pleomorphism score, the existence of vascular invasion, the amount of 
necrosis and the proportion of cells with abnormal nuclei. Despite further 
prospective studies are needed to clarify their role for prognostic purposes, 
atypical nucleolar morphology, the existence of squamous cell differentiation 
and the presence of a desmoplastic reaction should also be described by the 
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Despite neoplastic mammary disease in female dogs represents a major health 
concern for owners and veterinarians, a step towards target and individualized 
therapy of the affected animals still has not been done. The growing knowledge 
regarding malignant canine mammary tumors (CMT) led to the view of CMT as 
a model for human breast cancer. However, the genetic basis of CMT and its 
homology with human breast cancer is still poorly characterized. In this study 
we performed high resolution oligonucleotide array comparative genomic 
hybridization (aCGH) to assess copy number changes in ten malignant CMT 
from seven female dogs. The series included synchronous multiple tumors from 
three female dogs. In eight tumors genomic imbalances were detected, with 
wider variation of losses, deletions and gains. The chromosomes CFA 9, 22, 27, 
34 and X were more frequently affected. In two tumors aberrations on the 
Xp21.3-p11.21 segment, which includes the PCDH11X gene also called 
protocadherin 11 X-linked were detected. Dissimilar aCGH ratio profiles were 
noted in synchronous tumors of the same animal and this provided preliminary 
evidence for a possible independent pathogenesis of multiple CMT. By 
analysing two samples of the different halves of two tumors, it was noticed that 
regional differences in the number of genomic imbalances could exist in larger 
tumors. Despite the small number of cases, this study already demonstrated 
that malignant CMT of different histological subtypes can displayed a wide 






Cancer represents the leading health concern among dogs and research on 
anticancer treatments is of utmost relevance for animal health (Morris Animal 
Foundation 2005). Mammary gland tumors are the most frequent neoplasia in 
female dogs in countries where the spaying is not routinely performed early in 
life (Sorenmo, 2003). Approximately half of the tumors are classified as 
malignant based on the histopathological examination (Lana et al., 2007). 
However the evidence of malignant morphological features does not always 
imply an aggressive biological behavior with development of distant 
metastases. The establishment of reliable markers for predicting malignant 
canine mammary tumors (CMT) metastatic capacity is an unresolved issue that 
limits the implementation of new therapeutic options (Matos et al., 2012). 
The heterogeneity both at the clinical and morphological level is an idiosyncratic 
characteristic of the CMT (Sorenmo et al., 2011). CMT can appear as a solitary 
nodule or, more frequently, as multiple synchronous nodules, with variable 
macroscopic and microscopic features (Perez-Alenza et al., 2000; Hellmén, 
2005; Sorenmo et al., 2009). Despite the common occurrence of synchronous 
multiple CMT, little is known about the interrelation between the lesions. The 
hypothesis that malignant CMT could arise from pre-existing benign tumors has 
been debated (Sorenmo et al., 2009). In human oncology, clarifying the relation 
between multiple breast nodules is considered of chief importance for 
establishing therapeutic strategies (Bendifallah et al., 2010). Genetic tests 
represent a suitable methodology to assess the relatedness of multiple 
synchronous tumors (Teixeira et al., 2002; 2004; Agelopoulos et al., 2003). For 
instance, radical surgical procedures would be recommended when 
intramammary spreading of neoplastic spreading cells seemed to be the 
mechanism responsible for the multiplicity of tumors (Bendifallah et al., 2010). 
At the microscopic level CMT are also high heterogeneous. Accordingly, tumors 
can be composed of luminal epithelial cells exclusively, or can have a biphasic 
and triphasic phenotype, with myoepithelial cells and metaplastic mesenchymal 
elements such as cartilage or bone tissue. Mammary tumors involving different 
morphological cell populations are more frequent in dogs than in humans 
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(Misdorp et al., 1999; Misdorp, 2002; Lakhani et al., 2012; Reis-Filho et al., 
2012).  
Human breast cancer is well characterized at the genomic level, primarily 
through classical cytogenetic and comparative genomic hybridization (CGH), 
techniques that provide a global picture of the whole genome organization 
(Teixeira et al., 2002; 2004). The latter is a method that detects unbalanced 
structural changes resulting in a physical change in copy number of a genomic 
region or in the whole chromosome (Reis-Filho et al., 2005). The resolution of 
CGH has been improved by the introduction of array based approaches (Costa 
et al., 2008; Tan and Reis-Filho, 2008). The usefulness of CGH technology in 
the classification, grading and prognosis assessment of human breast cancer is 
described in detail in several reviews (Reis-Filho et al., 2005; van Beeers and 
Nederlof, 2006; Climent et al., 2007). Moreover, CGH offers the opportunity to 
evaluate the degree of clonal association between multiple synchronous 
tumors, as well as the presence of intratumoral genetic heterogeneity 
(Agelopoulos et al., 2003; Teixeira et al., 2004; Wa et al., 2005; Torres et al., 
2007). 
To date only two studies described genomic aberrations in CMT (Beck et al., 
2013; Liu et al., 2014). Canine microarray-based CGH has been developed in 
the last years (Thomas et al., 2007; 2008; Breen and Thomas, 2012). A high 
resolution canine oligonucleotide array CGH (aCGH) platform is now available 
(Breen and Thomas, 2012), offering valuable opportunity to identify DNA copy 
number imbalances associated with carcinogenesis in different tissues. 
Additionally, the study of the type and nature of recurrent genomic DNA copy 
number aberrations (CNAs) in CMT should contribute to identify regions of 
canine genome containing genes associated with the mammary carcinogenesis 
process, as demonstrated for other canine malignancies (Thomas et al., 2007; 
Breen and Thomas, 2012) 
The aim of this study was to identify CNAs associated with malignant CMT 
using aCGH analysis. For this purpose a series of spontaneous malignant CMT 
of different histological type were chosen to reflect the usual heterogeneity 
observed in the diagnostic routine. In order to detect eventual different clonal 
populations within tumors, two paired samples were collected from the same 
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tumor whenever possible. Moreover, multiple synchronous CMT of the same 
female dog were also analyzed, aiming to evaluate their clonal relatedness. 
 
8.2 Material and methods 
8.2.1 Clinical cases, histologic and immunohistochemical study 
In this study ten spontaneous malignant CMT and one normal mammary 
parenchyma sample from seven female dogs that underwent surgical treatment 
in the UPvet, veterinary clinics of the University of Porto were included. From 
three of those female dogs, tissue samples from two macroscopically 
independent synchronous mammary tumors were analyzed. Additionally, for 
two tumoral lesions two paired samples from separate halves of the mass were 
studied. The owners provided informed consent and the study protocol was 
approved by the Ethics Committee of the ICBAS. Fresh frozen samples were 
stored at -80ºC until processed for DNA extraction by standard methods.  
The remaining tumoral specimens were routinely processed and slides stained 
with hematoxylin-eosin (H&E) were used for histopathological classification and 
grading. The histological diagnosis and grade was performed by two observers 
(MS and PDP) using the official classification and the Nottingham grade 
method, respectively (Elston and Ellis, 1991; Misdorp et al., 1999, 
Karayannopoulou et al., 2005). Immunostaining using a panel of epithelial, 
mesenchymal and myoepithelial cells markers was performed (Peña et al., 
2014) to confirm the histological diagnosis and assess cellular heterogeneity 
within the tumors (Table 1).  
 
8.2.2 Array comparative genomic hybridization  
Recurrent CNAs were assessed by analysis of extracted DNA using ~180,000-
feature microarray (design 025522, Agilent Technologies, Santa Clara, CA) 
comprising repeat-masked ~60-mer oligonucleotides distributed at 
approximately 13kb intervals throughout the dog genome sequence assembly 
(canFam version 2.0, May 2005) (Thomas et al., 2014). The reference DNA for 
each array comprised an equimolar mix of blood-derived DNA from six 
unrelated healthy dogs of the same gender and breed as the patient. Array 
image files were processed using Feature Extraction version 10.7 (Agilent 
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Technologies) and raw data were filtered to exclude probes exhibiting non-
uniform hybridization or signal saturation. Data were imported into Nexus Copy 
Number version 7 (Biodiscovery, El Segundo, CA) and recurrent CNAs within 
each tumor were defined using the FASST2 segmentation algorithm, based on 
a minimum of three consecutive probes with log2 tumor:reference values > 0.2 
(gain) or ≤ -0.2 (loss), resulting in an effective resolution of ~26kb (two intervals 
of ~13kb). High level gains and losses within individual tumors were defined 
using default log2 tumor: reference values of > 1.14 and ≤ -1.1, respectively. 
These data were narrowed using the ‘peaks only’ function to report the minimal 
regions within these segmented CNAs that show the highest penetrance within 
this series. Genes and uncharacterized coding sequences within regions of 
CNA were defined using the UCSC canine genome sequence browsers 
(www.genome.ucsc.edu/) and the Gene database (www.ncbi.nlm.gov/gene). 
 
Table 1 – Panel of antibodies used for immunohistochemical evaluation of canine 
malignant mammary tumors.  
Antibody Clone Dilutio
n 
Antigen retrievel / Incubation Source 
Pancytokeratin AE1-AE3  1:300 Water bath with Target Retrieval 
Solution (Dako) / Overnight 
Zymed 
CK 14 LL002 1:10 Water bath with Target Retrieval 
Solution (Dako) / Overnight 
Serotec 
α-Actin  HHF35 1:300 Water bath with Target Retrieval 
Solution (Dako) / Overnight 
Dako 
Vimentin V9 1:500 Water bath with Target Retrieval 




Pressure cooker with sodium citrate 




In this series, five complex carcinomas (CC), three simple carcinomas (SC) and 
two carcinosarcomas (CS) were included. The age and breed of the female 
dogs and macroscopic characteristics of the tumors are provided in Table 2. 
Relevant histopathological features of the tumors are summarized in Table 3. In 
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all the cases, tumor cells presented invasive features of the surrounding stroma. 
Simple carcinomas were characterized by a proliferation of luminal epithelial 
cells with some resting myoepithelial cells. In the complex tumors some degree 
of non-atypical myoepithelial proliferation, corresponding to p63 positive cells 
was observed. In the two carcinosarcomas, atypical, fusiform, vimentin positive, 
mesenchymal cells and/or foci of metaplastic immature cartilage (with 
endochondral ossification in one case) were observed. In all tumors, except two 
(MS3T2 and MS33T2) CK14 positive luminal epithelial cells were observed.  
 
Table 2 – Epidemiological and clinical characteristics of the seven female dogs with 
malignant mammary tumors.  
Case Age 
(years) 





I – MS10 13 Mixed-breed T1 M3 right 6 
II – MS27 10 Mixed-breed T1 M4 left 1.5 
T2 M4-M5 left 1.5 
III – MS3 11 Mixed-breed T2 M4 left 2.5 
IV – MS33 12 Retriever Labrador T2 M4 right 2 
T3 M5 left 4 
V – MS4 10 Siberian Husky T1 M5 right 1 
T2 M4 right  0.5 
VI – MS7 10 Mixed-breed T1 M4 right 6 





                                
Case Tumor Diagnosis Grade Nuclear 
grade 
Samples CNA’s 
I – MS10 T1 CC II 3 T1a Highly complex 26 + del of 11, 19 and 22 and gain of 24 in <25% of 
the cells. 
II – MS27 T1 CC II 2 T1a gain of 4, 9 and 13, also  starting to show loss of 12 and 27   
T1b gain of 4, 9 and 13, also  starting to show loss of 12 and 27 
T2 SC II 2 T2b Broad baseline  
III – MS3 T2 CC II 2 T2b del 22, gain 34 (with del) 
IV – MS33 T2 CC I 3 T2b del 22, gain 34 (with del) 
T3 CS II 2 T3c loss on Xp  
V – MS4 T1 CC II 2 T1a no major CNAs 
T2 SC II 2 T2a no major CNAs 
VI – MS7 T1 CS II 1 T1a loss 3, loss 5, del 6 dist, gain 9 (with del), gain 12 dist, loss 15, gain 
17, loss 18, gain 24, loss 27, gain on Xp  
T1b gain on Xp 
VII  –  MS5 T2 SC II 2 T2 Broad baseline, complex 15, 18, 23, 26 
 




High-resolution aCGH revealed that the DNA sample from the normal 
parenchyma (collected from MS7 animal) showed no CNAs. In all but two 
tumors genomic imbalances were detected (Table 3); on average three 
alterations per tumor sample were detected (range 0-11, excluding two samples 
with broad baseline and wider aberrations). Those aberrations were distributed 
throughout the karyotype and more commonly involving segments of different 
chromosomes. Most of the CNAs detected were whole chromosome aneuploidy 
with a mixed pattern of gains and losses identified in the majority of the 
samples; only two samples presented with a single chromosomal imbalance 
(Table 3). Losses/deletions (n=21) were more frequent that gains (n=13) and 
more complex changes (segmental aneuploidy) being even less common (n=8). 
The most common CNAs were detected on CFA22 (three tumors showed loss 
of segments), CFAX (MS7T1 showed gain in Xp21.3-p11.21 and MS33T3 
showed deletion of the same region; both showed gain in the Xq21.2), CFA27 
(two tumors showed loss), CFA34 (MS3T2 and MS33T2 exhibited similar 
complex pattern with gains and losses) and CFA9 (MS27T1 showing gain and 
MS7 showing gain with deletion). In four samples complex chromosome with 
simultaneous gains and deletions were detected (Table 3). 
Both tumors that exhibited aberrations in the Xp21.3-p11.21 and Xq21.2 were 
carcinosarcomas presenting chondroid elements with high cellularity and 
immature matrix (Fig. 1 and Fig. 2).  
A similar pattern of CNAs was detected in two complex carcinomas from 
different patients (MS3 and MS33) corresponding to deletion of CFA22 and gain 
with deletion on CFA34; these tumors had some level of phenotypical 
concordance, namely the presence of myxoid matrix, squamous metaplasia in 
some epithelial malignant cells and the absence of CK14 positive epithelial cells 
(Fig. 3).  
In two complex carcinomas (MS10 T1 and MS27T1) additional chromosome 
gains and losses were detected in less than 25% of the total cell population. 
The two synchronous contra-lateral tumors of case MS33 shared few 
morphologic similarities (different histological subtype, different histological 
grade and different nuclear pleomorphism grade) and did not share genomic 
imbalances. In case MS27, the T2 produced wider spreader of the data points 
suggestive of poor quality DNA sample, which jeopardized a reliable 
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interpretation. However, side-by-side inspection of the ideograms showed that 
the CNAs of T1 (gain of CFA 4, 9 and 13) were not precisely matched in T2. 
Both tumors of case MS4 had no detectable CNAs.  
The paired samples from the two halves of T1 from MS27 female dog revealed 
identical aCGH ratio profiles, while the paired samples of T1 from MS7 female 
dog shared only genomic gains on segments of CFAX (Xp21.3-p11.21 and 
Xq21.2), with one sample presenting a much larger number of chromosomes 
imbalances (Fig. 4). 
 
 
Fig. 1 – A and B – Carcinosarcoma (MS7 T1); A – mesenchymal fusiform cells are 
intermixed with foci of round tightly packed cells that resemble condroblasts; B – 
presence of immature cartilage with high cellularity and scarce basophilic matrix. C and 
D – Carcinosarcoma (MS33 T3); C – foci of immature cartilage and epithelial tubular 
structures; D – detail of a focus of pre-cartilaginous tissue showing continuity with 







               
 
Fig. 2 – aCGH profiles of chromosome CFAX in two canine mammary carcinomas. The same region of Xp 
(19.7Mb – 42Mb) was gained (blue) in both samples of tumor T1 from MS7 animal and was deleted (red) in the 


















Fig. 3 – Complex carcinomas from two female dogs (A – MS3T2; B – MS33T2) that 
completely shared copy number aberrations and some phenotype features, such as 
squamous metaplasia. C – aCGH profile along the length of the CFA34 in both tumors 
showing a similar pattern of gains (blue) and deletion (red). Hematoxylin-eosin; Bar 50 









                         
Fig. 4 – Whole genome aCGH profiles of the samples from the two halves of the tumor T1 from 
animal MS7. The log 2 ratio representing cut-offs of genomic gains and losses are indicated by the 
horizontal bars immediately above and below the midline black line, which represents normal copy 






Malignant CMT constitute a highly heterogeneous disease both in terms of 
morphology and biological behavior (Sleeckx et al., 2011), which certainly 
contributes to the challenge for prognostic stratification faced by veterinary 
oncologists and pathologists (Matos et al., 2012). Based on the similarity in 
some clinicopathologic and epidemiologic features, spontaneous CMT have 
been regarded as potential models for human breast cancer (Queiroga et al., 
2011). Molecular studies provided some evidence that some drivers of the 
mammary neoplastic process are shared by dogs and humans (Rivera and von 
Euler, 2011), however the amount of evidence supporting the dog as a model 
for human cancers, including breast cancer, is still limited (Breen, 2008; Rotroff 
et al., 2013).  
Few conventional cytogenetic studies in CMT have been published (Mellink et 
al., 1989; Mayr et al., 1990; 1993). Classic cytogenetic characterization of 
tumor-associated chromosomal abnormalities is challenging because of the 
large number of canine chromosome, their small size and acrocentic 
morphology (Tap et al., 1998; Thomas et al., 2008). Abnormalities in CFA 8 or 
11, 13 or 15, 37, 38 and X, including loss, formation of isochromosomes and 
centric fusion were reported by using fluorescence in situ hybridization 
technique (Tap et al., 1998). The development of cytogenetically-validated 
genome integrated bacterial artificial clones for each dog chromosome, allowing 
application of CGH techniques, which overcome the limitations of classic 
cytogenetic analyses (Thomas et al., 2007; 2008). CGH has been employed to 
elucidate the molecular events involved in the pathogenesis of different canine 
tumors, including lymphoma, osteosarcoma, venereal transmissible tumor, 
histiocytic sarcoma, among others (Breen and Thomas, 2012; Thomas et al., 
2014). Very few studies addressed the genomic-wide basis of the canine 
mammary carcinogenesis using modern and high-resolution techniques (Beck 
et al., 2013; Liu et al., 2014). In this study we used aCGH to perform a global 
analysis of DNA copy number changes in malignant CMT of different histologic 
subtypes. The aCGH analysis demonstrated a broad spectrum of chromosome 
losses and gains distributed throughout the genome. Even within each 
histologic subtype group a heterogeneous pattern of genomic aberrations was 
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identified. The high variation of genomic aberrations and the absence of 
commonalities in CNAs in CMT of the same histologic subtype has already 
been reported (Beck et al., 2014), suggesting that the clinical and morphologic 
variability of CMT may reflect heterogeneity at genomic level.  
Two of the ten cases in this study presented with no detectable CNAs. A similar 
finding was previously reported by two other research groups in five complex 
carcinomas and one simple carcinoma (Beck et al., 2013; Liu et al., 2014). 
However, it should be kept in mind that the absence of numerical chromosome 
changes in aCGH analysis does not exclude the possibility of structural 
genomic aberrations, which are undetected by CGH (van Beeers and Nederlof, 
2006; Climent et al., 2007). Moreover, epigenetic events such as methylation or 
histone modifications could also be involved in canine mammary carcinogenesis 
(Liu et al., 2014). We should also stress that the absence of CNAs in two 
tumors could be related to sampling bias (those tumors were the smaller ones 
of this series and were admixed and surrounded by a hyperplastic mammary 
parenchyma – data not shown). Factors such as contamination of the tumor 
sample with normal/hyperplastic surrounding cells or intratumoral stromal cells 
could be an explanation for the absence of major CNAs in those tumors. 
This is the first report of numerical aberrations in chromosomes 22 and 34. 
Corroborating previous findings, we also observed losses of CFA 3, 5, 18 and 
27, however the frequency of losses of CFA 27 in our series was lower (2/10 
cases) than that previously reported (Beck et al., 2013). Accordingly, our results 
did not support the hypothesis that malignant CMT are associated with a 
recurrent deletion of CFA 27 (Beck et al., 2013). Herein genomic imbalances 
were detected in all, except one complex carcinomas, including well (grade I) 
and intermediately (grade II) differentiated cases. In this vein, our results did not 
support a previous report where major CNAs were not observed in complex 
carcinomas (Liu et al., 2014). 
In human breast invasive carcinomas recurrent genomic alterations included 
gain of 1q, 8q, 20q, 17q and loss of 16q and 17p (Reis-Filho et al., 2005; Torres 
et al., 2007). Gains of 3q, 8q, 17q has been associated with poor prognosis, 
whereas loss of 16q correlated with a favorable prognosis (Reis-Filho et al., 
2005; Horlings et al., 2010). Interestingly, we observed gains in the canine 
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chromosomes homologues (CFA 9, 13, and 24) to the human chromosome 
segments 17q, 8q and 20q. Similarly, loss of CFA 5 that had homology with the 
human 16q and 17p segments was identified in a case included in our series 
(Breen et al., 1999).   
Particularly worthy of note was the detection of genomic imbalances (gains) in 
the Xq21.2 segment. This region including the PCDH11X gene also called 
protocadherin 11 X-linked. This gene belongs to the protocadherin gene family, 
a subfamily of the cadherin superfamily (Berx and van Roy, 2009). The encoded 
protein consists of an extracellular domain containing 7 cadherin repeats, a 
transmembrane domain and a cytoplasmic tail that differs from those of the 
classical cadherins (Yang et al., 2005). Protocadherin 11 X-linked is highly 
homologous to protocadherin 11 Y-linked, which is found exclusively in man 
(Berx and van Roy, 2009). Deletions involving different protocadherin genes 
(but not PCDH11X) have been reported in malignant CMT (Liu et al., 2014). 
The role of the protocadherin 11 X-linked in CMT, as well as in breast cancer is 
unknown, to the author’s knowledge. However there are evidences that 
PCDH11Y is up-regulated in human prostate cancer cell lines and could be a 
proto-oncogene (Berx and van Roy, 2009). In human prostate cancer cell lines, 
the expression of PCDH11Y was correlated with the occurrence of nuclear β-
catenin (Yang et al., 2005). Interestingly the aberrations of the segment 
containing the PCDH11X gene were detected in carcinosarcomas presenting 
p63 positive cells and foci of immature metaplastic cartilage. In the light of the 
human classification system these tumors would be considered as metaplastic 
carcinomas with mesenchymal elements or mixed metaplastic carcinomas 
(Reis-Filho et al., 2012; Brogi et al., 2014). Immunohistochemistry studies have 
demonstrated that a subgroup of human metaplastic carcinomas displayed 
nuclear β-catenin expression, which is indicative of Wnt pathway activation and 
of epithelial-to-mesenchymal activation (Lacroix-Triki et al., 2010; Geyer et al., 
2011). Moreover alterations in β-catenin expression and perturbation of Wnt 
pathway have also been reported in malignant CMT (Restucci et al., 2007; Uva 
et al., 2009).  
It is still not clear whether multiple CMT have an independent origin or represent 
multifocal clonal-related neoplastic lesions. More often the multiple CMT 
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present different clinical (e.g., size and consistency) and morphological 
features, including different histological classification (Sorenmo et al., 2009). 
Despite the fact that we have analyzed only three cases of multiple 
synchronous CMT, our morphologic data tended to support that observation. 
However, the independence or relatedness of multiple synchronous tumors 
should be confirmed at the genome level (Weiss et al., 2003). In this study, the 
synchronous tumors of two female dogs (excluding tumors of case MS4 that 
produced balanced profiles) revealed dissimilar aCGH ratio profiles and this 
provided preliminary evidence for a probable independent pathogenesis of 
multiple CMT. In human pathology the use of CGH (including array-based) has 
determined the clonal relationship between synchronous in situ and invasive 
breast carcinomas (Agelopoulos et al., 2003; Hwang et al., 2004; Teixeira et al., 
2004; Wa et al., 2005). The current evidence for women is that synchronous 
ipsilateral breast carcinomas seem to be clonally related, whereas bilateral 
multiple tumors represent clonally independent tumors (Agelopoulos et al., 
2003; Teixeira et al., 2004; Wa et al., 2005). Further genetic studies are 
warranted to fully ascertain the relation between multiple synchronous CMT. 
This issue would have major implications in treatment protocol and thus would 
be of great clinical importance. 
Although our analysis was limited to two cases, it preliminary demonstrated that 
related sub-clones could coexisted in some malignant CMT. Notably, in the 
larger (size > 5 cm) and highly heterogeneous tumor, the samples collected 
from the different halves of the mass shared only one CNA, while the two 
samples of the smaller (size < 3 cm) and less heterogonous tumor harbored a 
similar pattern of CNAs. At this point our results show that a single sample from 
large tumors may fail to detect all existing DNA copy number changes. 
Moreover, the hypothesis that clonal evolution in malignant CMT goes along 
with the increased of tumor size and increased phenotype heterogeneity 
deserves further investigation. It is important to recall that increased tumor size 
was associated with malignancy of CMT and it has been consistently 
considered a prognostic marker in malignant CMT (Sorenmo et al., 2009; 2011; 
Santos et al., 2014).   
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In conclusion, aCGH analysis of malignant CMT showed that the clinical and 
histological heterogeneity of this disease may reflect a wide variation of 
genomic changes. A large spectrum of genomic imbalances was observed in 
different histological subtypes of malignant CMT. Our results support that 
protocadherin 11 X-linked could be involved in canine mammary 
carcinogenesis, namely in the development of tumors with morphological 
evidence of mesenchymal differentiation.  
Despite the novelty of the majority of the findings of this study, some limitations 
can also be pointed. The number of analyzed tumors is limited and the number 
of non-tumor cells within samples was not controlled, which could have reduce 
the sensitivity for detecting CNAs (van Beers and Nederlof, 2006, Natrajan et 
al., 2010). For future studies, selection of tumoral areas enriched with 
neoplastic cells and free of stromal, inflammatory and normal surrounding 
parenchyma should be done by microdissection. Moreover, the aCGH findings 
deserve validation by independent cell-based method such as FISH or 
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9.1 Conclusions and future perspectives 
The expansion of knowledge in malignant canine mammary tumors (CMT) 
biology has still not been reflected on treatment changes of affected animals. 
Nevertheless, refinements in the management of female dogs with malignant 
CMT may be markedly influenced by the validation of prognostic factors (Matos 
et al., 2012). In human breast cancer, well defined and validated 
histopathological predictors, such as histological grade, are routinely used for 
assisting in prognosis definition and subsequent appropriate stratification of 
therapy (Rakha et al., 2010).  
Traditionally, the histological grading method for malignant CMT has followed 
human grading systems. Nonetheless, canine-specific morphological and 
clinical features should be taken into account when classifications systems 
originally designed to human breast cancer are adapted to malignant CMT 
(Sassi et al., 2010). While in human breast cancer carcinomas of no special 
type (previously known as ductal carcinoma) comprise the vast majority of 
cases (Ellis et al., 2012), in malignant CMT series the histological variability is 
much larger. For instance, the presence of myoepithelial proliferative cell 
population, whose biological role is still a matter of debate, is relatively common 
in malignant CMT, but a rare finding in human breast cancer (Misdorp 2002; 
Lakhani et al., 2012; Reis-Filho et al., 2012; Peña et al., 2014). 
In human medicine, the current trend is the early detection of sub-clinical breast 
cancer, reflecting the widely adoption of screening programs (Hoda et al., 
2014). On the other hand, in veterinary medicine we are still diagnosing very 
large and clinically advanced tumors, usually detected by the owner. In this 
vein, we hypothesized that the prognostic importance of the histological 
markers, including histological grade, will depend on its accuracy to address 
those morphological and biological specific features of malignant CMT.  
Current grading methods for malignant CMT were originally designed to human 
breast cancer, and were adopted more or less blindly, in the sense that a 
comprehensive evaluation of several aspects of the method was not performed 
before its adoption. In fact, such adoption to CMT requires a great deal of detail, 
particularly in the selection of relevant grading parameters, scoring criteria and 
in the evaluation of their reproducibility. Moreover, the clinical utility of 
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quantitative morphological features, estimated by using more objective 
techniques, such as stereology and morphometry, has never been tested in 
CMT. This markedly contrasts with human pathology, where quantitative 
estimations of histopathological parameters have prove to add objectiveness 
and augment the prognostic power of breast cancer grading (Ladekarl, 1998; 
Kronqvist et al., 2002). In fact, in human breast cancer, different quantitative 
measurement methods have been reported trying to objectivize the three 
grading parameters (tubule formation, nuclear pleomorphism and mitotic count) 
(Ladekarl and Sørensen, 1993a; b; Artacha-Pérula and Roldán-Villalobos, 
1997; Kronqvist et al., 1998; 2000; 2002). 
In the first study of this Thesis (Chapter 2), the value of ν	V for diagnosis and 
grading CMT was evaluated. The ν	V is considered one of the most robust 
estimates of nuclear 3D size and pleomorphism, being obtained from simple 
measurements carried out in 2D samples of the tumors, such as the sections 
used in the routine diagnostic setting (Sørensen, 1992; Ladekarl, 2004). The 
unbiasedness of the stereological method and the recognized value of ν	V as a 
prognosticator in breast cancer were the main reasons to pursue with its 
estimation in CMT. Our study demonstrated that ν	V estimations were 
significantly higher in malignant CMT comparing to benign tumors, with only a 
small proportion of overlapping ν	V values between the two types of tumors. This 
result supported the classification benign versus malignant made by the 
pathologists, as well as the eventual role of ν	V for grading purposes in case of 
malignancy. Accordingly, we also compared the ν	V in carcinomas of each 
nuclear pleomorphism score (performed following the NHG criteria). 
Carcinomas with nuclear score 1 or 2 presented similar values of ν	V, which 
were significantly lower than those obtained in tumors scored 3. This finding 
resulted in two remarks: firstly, the similarity in the 3D nuclear size and 
variability could contribute to low reproducibility in the subjective assignment of 
score 1 or 2 by pathologists; secondly, a simplified binary scoring of nuclear 
pleomorphism in CMT could be more accurate. The results also suggested that 
ν	V could be valuable for identify the most aggressive tumors (ν	V was 
significantly higher in cases that presented post-surgical progressive disease). 
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The study displayed in Chapter 2 was recognized as the first report on the use 
of stereology in veterinary oncology (Casteleyn et al., 2014), and the promising 
preliminary observations deserve further confirmation in large prospective 
survival studies. Hopefully, with this quantitative tool it will be possible to 
determine quantitative thresholds for allocating tumors with different nuclear 
grade and for predicting their clinical behavior. 
Interestingly, the ν	V values in epithelial cells of the normal mammary 
parenchyma during the different phase of the estrous cycle showed a 
particularly high variation. This finding reinforces previous evidences
 
that the 
normal canine mammary gland undergoes profound structural, cellular and 
subcellular changes during the estrous cycle (Rehm et al., 2007; Santos et al., 
2010). The pathologist awareness of this variation is important when evaluating 
and grading mammary lesions. The stereological study of nuclear size 
pleomorphism in the normal canine mammary gland will be extended, by the 
inclusion of a large sample of cases that have been previously characterized, 
both at the histological and immunohistochemical levels (Santos et al., 2010). 
The NHG criteria recommend the use of the normal surrounding parenchyma of 
a malignant CMT as a reference for scoring nuclear pleomorphism (Elston and 
Ellis, 1991; 1998). In this vein, it would be important to verify if the level of 
variability in nuclear volume and pleomorphism (as estimated by the ν	V) in the 
normal surrounding epithelial cells could be a contributing variable accounting 
for interobserver scoring discrepancy in nuclear pleomorphism.  
Still in Chapter 2, the previously reported evidence that tumor size and vascular 
/lymph node invasion represented relevant prognostic factors in CMT was 
reinforced. In this study, a ROC curve analysis was used, since this is the gold 
standard test for establishing reliable thresholds (Greiner et al., 2000). A tumor 
size of 2.9 cm was recognized as a valuable in order to assess early tumoral 
aggressiveness, as evidenced by vascular invasion or lymph node metastases 
at the time of the diagnosis. Hopefully, this cut-off could serve as guide for 
clinical treatment choices, warning clinicians for the need of a more rigorous 
and meticulous pre-surgical lymph node evaluation.  
Additionaly, the issue regarding the interobserver reproducibility in assigning a 
score to the grading parameters was introduced and the statistical analysis 
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revealed only a modest agreement in scoring nuclear pleomorphism. Based on 
that result, a more complete evaluation of the reproducibility of histological 
grading in malignant CMT was subsequently performed in Chapter 3. 
Grading reproducibility has been well discussed between human pathologists 
and there is unanimity that high variability in assessments would risk the clinical 
value of the histological grade (e.g., Dalton et al., 2000; Meyer et al., 2005; 
Longacre et al., 2006). Nevertheless, to the best of our knowledge, this issue 
had never been addressed among veterinary pathologists. For this first study of 
interobserver grading reproducibility of malignant CMT, included in Chapter 3, a 
panel of three observers of the same academic institution was recruited. The 
inclusion of an experienced medical pathologist permitted a critical judgment 
over the applicability of the “human-based” grading parameters to malignant 
CMT. Moreover, a comparison between veterinary and medical grading 
performances was possible. For these purposes, a series comprised only of 
simple luminal carcinomas was used, since they have been considered more 
similar to the common forms of invasive breast carcinomas (Liu et al., 2014).  
The kappa values were, on average, similar to that reported when NHG is 
applied to human breast cancer, representing moderate to good agreement. In 
addition, observers tended to cluster their opinions around two neighboring 
scores and grades, with discrepancy of more than one point being exceptional. 
Furthermore, the highest reproducibility was attained when scoring tubule 
formation, followed by mitotic counts and, finally, nuclear pleomorphism; this 
was also similar to the majority of human breast studies. The odds for variation 
in scoring augmented with the increased size of the tumors, but decreased 
when a consensus grade (performed by 2 observers) was compared with the 
grade assigned by a third observer. Therefore, a consensus grading should be 
pursued whenever possible, and particularly in large and heterogeneous 
tumors. Additionally, based on our data we proposed that the common practice 
of selecting a single slide (independently from the tumor size) can represent a 
bias in grading and this procedure should be discouraged.  
Certainly, this first report on interobserver reproducibility in grading CMT will 
encourage other research groups to evaluate this subject in larger studies, with 
different panel of observers and including all the spectrum of carcinomas. 
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Nowadays, with the advents of digital pathology imaging, high resolution digital 
microphotography and whole slide imaging large scale grading reproducibility 
studies can be designed. It is noteworthy that similar approaches have been 
used for assessing nuclear grading reproducibility in human breast cancer (e.g., 
Dunne and Going, 2001), as well as interobserver agreement in mitotic figures 
recognition (e.g.,Tsuda et al., 2000; Meyer et al., 2005; Al-Janabi et al., 2013). 
The scrutiny of the interobserver agreement level between pathologists from 
different parts of the world could be an important tool for training and discussion 
of the scoring criteria.  
While addressing the issue of reproducibility of histological grading, the 
prognostic value of each grading parameter of the NHG in malignant CMT was 
evaluated (Chapter 4). Such complete assessment has never been performed 
in veterinary pathology. Interestingly, only nuclear pleomorphism was predictive 
of survival in CMT, both in univariable and multivariable analysis. However, this 
occurred only when nuclear pleomorphism was classified as a two-tier system 
(i.e., score 1 and 2 compared against score 3), which was in line with the 
quantitative data of ν	V, presented in Chapter 2 (Santos et al., 2014). Although 
being subjective and less reproducible, the finding that nuclear pleomorphism 
has prognostic value reinforces the need for a strict nuclear grading 
assessment protocol in CMT. Meanwhile, the association of nuclear 
pleomorphism and prognosis advises for its inclusion in routine pathological 
reports of malignant CMT, besides the usually reported overall histological 
grade. 
Considering that the univariable analysis supported that NHG could be a 
prognostic factor to CMT, we tested, for the first time, its inclusion in a 
multifactorial prognostic index, based on the well-recognized NPI of human 
breast cancer. A modification from the original formula was performed in order 
to make it more suitable for the reality of surgical pathology of CMT. In 
veterinary oncology, the TNM system for malignant CMT does not consider the 
number of positive lymph nodes (Rutteman et al., 2001). Therefore, the 
quantitative lymph node stage (values from 1 to 3) of the original NPI does not 
make much sense in the veterinary scenario, and we opted to incorporate a 
histological surrogate of the metastatic capacity of the tumor, represented by 
 202 
 
the microscopic evidence of vascular invasion and/or the presence of lymph 
node metastases at the time of the primary diagnosis (Rasotto et al., 2012; 
2014). It should be noted that the evidence of vascular/lymph node invasion has 
been already used for prognostic staging purposes in malignant CMT 
(Gilbertson et al., 1983; Kurzman and Gilbertson, 1986; Papparella et al., 2002; 
Sarli et al., 2002), but this was the first time that it was included in a 
multifactorial prognostic index.  
Notably, the veterinary-adapted NPI, computed by the modified formula and, 
analyzed by a ROC curve test, appeared as a promising tool for predicting post-
surgical tumor progression. Moreover, in a prognostic perspective it seems 
valuable to include the NHG in a composite index with tumor size and with a 
variable related to the spread of the disease. Still, it is important to recall that 
after proposal of the NPI (Haybittle et al., 1982), its clinical value has been 
validated in a large cohort by that same group and by studies from other 
countries (e.g., Todd et al., 1984; Sidoni et al., 2004; Blamey et al., 2007). In 
this vein, further CMT studies including prospective cohorts are warranted to 
confirm the prognostic value of the veterinary-adapted NPI and, perhaps, to 
establish other modifications to the index.  
In Chapter 5, we tested a quantitative measurement method by which the level 
of tumor cellularity could be expressed in numerical terms. The unbiased 
stereological optical disector counting method was used to estimate the nuclei 
numerical densities [NV (nuclei, tumor)] in CMT. This cellularity-related 
parameter (Ladekarl, 2004) was not significantly associated with the subjective 
scoring of tubule formation, performed in routine sections of the same tumors. 
However, the NV (nuclei, tumor) was negatively correlated with the ν	V and was 
associated with post-surgical tumor progression. In this vein, the NV (nuclei, 
tumor) seems more important for prognostication than the subjective tubule 
formation evaluation. At the same time, it should be stressed that the use of the 
optical disector methodology is laborious and relatively time-consuming 
(Ladekarl, 2004). Accordingly, in a near future we intend to explore other 
quantitative unbiased cellularity-related variables, such as the volume fraction of 
neoplastic nuclei [VV (nuclei, tumor)], which can be estimated in thin histological 
sections. Moreover, we plan to evaluate the correlation between the different 
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quantitative variables and their individual role in scoring malignant CMT 
according to their biological behavior.  
As performed for the other grading parameters, a new quantitative approach for 
scoring mitotic figures in malignant CMT was developed and tested as 
prognostic factor in Chapter 6. It should be stressed that the reproducibility of 
mitotic count could be affected by the non-uniform criteria for mitotic recognition 
between observers or by the subjective selection of most mitotically active 
areas (Meyer et al., 2005; Baak et al., 2009). In that Chapter, mitotic figures 
were counted in a systematic sampling throughout the tumor, with an additional 
morphometrical estimation of the area of the neoplastic epithelium in each field 
of vision. Despite this approach obviated the subjective selection of the areas 
by the observer, and corrected the counts for the proportion of neoplastic 
epithelium, no significant improvement in the prognostic value of mitotic count 
was achieved. It should be noted that the used method was not completely 
devoided of counting bias. It is well known that 2D estimations of cells and 
nuclei are closely associated with sampling bias (Ladekarl, 2004). In this 
particular case, the probability of sampling the mitotic figures could be 
influenced by the section plane and the particle size (sampling / sectioning 
usually favors larger particles). Consequently, methodological refinements can 
be attempted, namely by using modeling of 2D estimates to correct for the 
sampling bias. Nevertheless, a low expectation exists regarding the prognostic 
value of mitotic counts in routine stained sections of malignant CMT. At this 
point, we anticipate that alternative proliferative markers, such as 
immunolabelling by Ki-67, could be more promising tools, particularly if 
combined with stereology.   
Some evidence has been provided in previous Chapters, as well as in other 
studies, that NHG has prognostic value in CMT. Nevertheless, at this point, it 
should be stressed that no efforts have been devised over the development of a 
new, reliable and canine-specific grading system, which would only include 
parameters that have proved independent prognostic value. Ideally, the ability 
to predict clinical outcome of that canine-specific grading system should be 
compared with that of the other grading system adapted to CMT, as it has been 
elegantly performed in feline mammary carcinomas (Mills et al., 2015). In order 
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to contribute to this ultimate goal, different morphological features were 
screened as potential grading parameters in routine sections of CMT, and their 
association with prognosis was evaluated in Chapter 7. Among the assessed 
parameters, necrosis (scored by the cut-off of 20%), squamous differentiation 
(scored by the cut-off of 10%), and abnormal shaped nuclei (scored by the cut-
off of 15%) arose as the most promising variables for predicting DFI. Although 
both DFI and OS were integrated as dependent variables in the regression 
statistical analyses of this Thesis, it was recognized that DFI is the most 
objective and more controlled end-point in prognostic studies of CMT (Matos et 
al., 2012).  
Using an approach similar to the one used to establish the human NPI 
(Haybittle et al., 1982), a multivariable Cox hazard proportional analysis was 
performed considering DFI as the dependent variable (Table 1), with the goal of 
settling the first advances over the design of a new canine-specific prognostic 
index (CPI). 
 
Table 1 – Multivariable survival analyses (Cox proportional hazards regression) of 




Independent variables β SE Hazard 
Ratio 
P  95% CI 
  DFI  Abnormal nuclei 1  2.09 1.08 8.09 0.05 0.98- 66.95 
Necrosis 2  0.94 0.72 2.55 0.19 0.63-10.38 
Squamous differentiation 3 -0.61 0.60 0.54 0.31 0.17-66.95 
Tumor size 4  0.37 0.54 1.44 0.50 0.50-4.18 
Vascular invasion 5 1.13 0.59 3.09 0.06 0.97-9.84 
Nuclear pleomorphism 6 1.52 0.66 4.58 0.02 1.26-16.61 
Legend: 1scored by the cut-off 15%; 2scored by the cut-off 20%; 3 scored by the cut-off 10%; 
4scored by the cut-off 2.9 cm; 5presence versus absence; 6NHG score 1 plus 2 versus 3; β – 
beta coefficient; CI – confidence interval; SE – standard error. 
 
Using the β coefficients of the first step of the multivariable analysis, with the 
influence of the tumor size, necrosis and squamous differentiation adjusted, and 
setting the significance level at P = 0.1 (considering the relatively small size of 
our sample), we arrived to the following formula: 
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CPI = 2 x Abnormal nuclei (1 if less than 15% and 2 if equal or more than 15%) 
+ 1.5 x Nuclear pleomorphism (1 for score 1 or 2 and 2 for score 3 according to 
NHG) + Vascular invasion (1 if absence and 2 if present) 
 
The values of CPI ranged from 4.5 to 9, being the higher values associated with 
worst prognosis. In order to establish reliable thresholds to assign each affected 
female dog to a well defined prognostic group, this formula must be apply 
prospectively to large cohorts of female dogs with malignant CMT. The 
validation process of the CPI would also warrant studies from other centers, as 
was performed with the human NPI (Lee and Ellis, 2008). As a final remark, 
regarding the findings of the Chapter 7, the scoring reproducibility of the 
pathologic variables and the role of quantitative estimates to objectivize such 
putative prognostic parameters will deserve further attention by our research 
group in the near future.  
At this point, it should be emphasized that for grading purposes all slides 
resulting from at least one largest cross section of the tumor should be used. 
Notwithstanding, this may represent an extra-effort in term of time, but obviates 
the possible bias due to the selection of the “most representative” slide in each 
tumor, which has became a relative common practice. This is probably the best 
strategy to account with the intrinsic heterogeneity of CMT. Since the tumor size 
can range from less than 1 cm to more than 10 cm, the selection of one slide 
per tumor would certainly misrepresent the morphological features of the largest 
tumors.  
Chapter 8 corresponds to one of the first approaches to the genomic profiles of 
malignant CMT. In this case we jointed our efforts with a research group 
headed by Professor Breen, well renowned for outstanding contributions in the 
the understanding of the genetic basis of different canine neoplasias (Alvarez, 
2014). This resulted in aCGH analysis of a series of ten malignant CMT. The 
results highlighted that the majority of malignant CMT of different histological 
subtypes are associated with chromosomal aberrations. Despite the small scale 
of the present study, the results pinpointed some chromosomes, such as CFA 
9, 22, 27, 34 and X, that may harbor genes potentially relevant for CMT 
development. In our series we included synchronous tumors from three female 
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dogs and in two cases the genomic profiles of the synchronous tumors were 
dissimilar (in the other case the tumors produced balanced profiles and no 
major DNA copy number aberrations). This preliminary data suggests the 
independency of synchronous CMT, at least in some instances.  
In human medicine, the identification of patterns of DNA copy number 
alterations harboring important genes for breast carcinogenesis has set the path 
for searching molecular markers of prognosis and exploring new target 
therapies (Andre et al., 2009). In veterinary medicine, such goals will be 
pursued, sooner or later, and the work presented in Chapter 8 can be viewed as 
one of the first steps.  
The potential use of aCGH for assessing the aggressiveness of the tumors and, 
in the cases of synchronous multiple tumors, determine their clonal relation, will 
certainly contribute to refine surgical treatment of CMT. This would be one of 
many uses of a high resolution and fast genetic screening technique, as has 
been demonstrated in human medicine (Weiss et al., 2003).  
In general, in female dogs with multiple tumors it is recommended to perform a 
radical mastectomy, instead of multiple nodulectomies or local mastectomies 
(Sleeckx et al., 2011). Proponents of radical mastectomy argue that this 
approach is faster and avoids the need of a second surgery, by reducing the 
risk of new tumors (Stratmann et al., 2008). Nevertheless, other authors claim 
that radical mastectomy is a very invasive procedure and may be considered an 
overtreatment, since approximately half of the cases will have a benign clinical 
course (Lana et al., 2007). Moreover, radical mastectomy does not control the 
eventual development of metastatic disease from established micrometastases, 
and no evidence exists that radical mastectomy effectively improves the survival 
of female dogs with malignant CMT (Misdorp, 2002; Chang et al., 2005). Some 
lessons can be drive from the history of human breast cancer surgery. From the 
radical mastectomy, proposed by Halsted in the late nineteen century and fairly 
undisputed for more than fifty years, a new era in surgical procedures and in 
research began to emerge in late 1950s (Cotlar et al., 2003). By that time, 
randomized studies with large number of patients showed that more 
conservative surgical approaches (lumpectomy and quadrantectomy) were 
equally effective, with much less morbidity (Cotlar et al., 2003). Moreover, it was 
then clear that the advances in mammography and the concomitant use of fine 
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needle aspiration and needle-core biopsy prompted surgeons to an early 
identification of malignancies (Cotlar et al., 2003; Schmitt et al., 2012).  
In human breast cancer, it was established that fine needle aspirations contain 
a high percentage of neoplastic cells and yielded sufficient DNA for aCGH 
analysis (Andre et al., 2009). The diagnostic value of aCGH in the preoperative 
evaluation of female dogs bearing mammary tumors will certainly be highest if 
the technique could be applied to cytological specimens. As a diagnostic 
method in CMT, cytology has been associated with low to moderate accuracy 
(Solano-Galeno, 2010). However, the association of cytology to ancillary 
techniques, such as stereology and aCGH could be valuable in pre-surgical 
clinical assessment of female dogs with CMT. It should be recalled that nuclear 
morphometric analysis in cytological smears of CMT already pointed to 
significant differences between benign and malignant cases (Simeonov and 
Simeonova, 2006; 2007).  
Gathering all the promising data from this Thesis, we will prospectively evaluate 
the diagnostic and the prognostic value of the stereological ν	V in cytological 
specimens of CMT, as well as the efficiency of DNA extraction from fine needle 
aspirations performed in the four quadrants of the lesion and its use in aCGH. 
Hopefully, with the information collected from all these approaches, the 
treatment of female dogs with mammary tumors may be tailored individually, as 
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